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Abstract
Biopharma industry currently works on shortening the time required to manufacture
drug candidates to support early preclinical testing, and reduces the failure rate by
early screening of the molecules with the best potential to reach the market later
on. This thesis focused on the development and integration of three aspects of
manufacturing to contribute in achieving these objectives. The first one looked
at the way to approach experimentation. The use of DOE was generalised to the
whole development and the creation of a library of statistical tools to develop an
algorithm for the analysis of the commonly used Central composite and Box-Behnken
designs. This algorithm proved to be as efficient as commercially available statistical
softwares but presents the advantage of automating the analysis of the DOE designs.
The second aspect consisted in developing viable manufacturing steps such as an
upstream PEI-mediated transfection process in CHO cells, capable of generating
100mg L-1 of product in less than 15 days, or a cation exchange purification platform
using a Quality by Design approach. The third aspect focused on the integration of
different processing steps to yield a whole integrated platform for the production,
then purification of one gram of a reporter antibody. This platform proved to be
a cost effective alternative to the development of a stable producing cell clone for
the production of recombinant product. In addition, this research reveals that the
adoption of a statistically driven approach to process development is as important
as the implementation of innovative technologies to address the challenges ahead.
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Chapter 1
Introduction
This Chapter first introduces the current challenges the pharmaceutical industry is
facing, and the future scenario for the manufacturing of biopharmaceuticals
through the use of mammalian expression systems, bio-manufacturing processes,
and experimentation methodologies.
One of the main goals of cell culture technology is to generate medical drugs as
treatments for cancer, infectious and autoimmune diseases. The development of a
new drug is a long and challenging process that lasts on average 10-12 years. It
is typically divided into three major steps: discovery, preclinical development and
clinical trial. From an economical point of view, preclinical phase is a screening step
of high importance. It is first aimed at determining the most accurate product effi-
cacy, stability and safety profiles. Based on these profiles, it evaluates if a molecule
has a reasonably good chance to hit the market in the near future, i.e. if a molecule
is worth the costly clinical trials that follow. Therefore, preclinical testing should
be a high throughput and cost-effective step. This is not the case. The transition
from preclinical development to the clinic is so challenging that it is often referred
to “the valley of death”(1–3) (Figure 1.1). If biopharma companies do not hesitate
to invest in drugs that make it to the clinical phase, potential investors hesitate to
support risky and costly preclinical development (4). One of the reasons is that the
industry still struggles to intensify their manufacturing capacity for early testing.
Indeed, biopharma industry mostly relies on costly and time consuming development
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of stable clones to generate the quantities required of drug candidates to support
preclinical testing. Moreover, the current process infrastructure for cell culture and
subsequent purification processes lacks flexibility, considerably increasing the costs
and time-lines of manufacture. This thesis focuses on adapting or developing op-
timization methods, statistical tools and processing technologies to allow the rapid
production of milligram to gram quantity of biopharmaceuticals to support preclin-
ical trials. The production platform will use an upstream transient gene expression
step, coupled with an adapted downstream train for efficient product purification.
The whole platform will consist of disposable/reusable integrated modules to provide
maximum flexibility, fast product production and turn over.
This introduction chapter provides a brief overview of the research context. First,
the current use of mammalian cells for the production of biopharmaceuticals is de-
scribed. Second, the current state and future of manufacturing platforms is pre-
sented. Finally, a brief overview on experimental methodology is described.
1.1 Mammalian expression systems for the production
of recombinant biopharmaceuticals
1.1.1 On the biopharmaceuticals
Biopharmaceuticals can be defined as clinical reagents, vaccines and drugs generated
by modern biotechnology. In contrast to traditional chemically synthesised drugs,
biopharmaceuticals show attractive properties for the treatment of cancer, infectious
and autoimmune diseases. Indeed, because they mimic the action of endogenous
proteins native to the human body, they theoretically present lower toxicity, higher
specificity and efficacy. The worldwide market for biopharmaceuticals has been, and
is expected to grow at a 15-18% rate annually, well above overall economic growth
rates including the pharmaceuticals market in general (6). The recombinant proteins
market alone is estimated at $100 billion.
Therapeutic monoclonal antibodies (mAb) boast one of the most active and
promising pipeline in the recombinant biopharmaceuticals industry. This is mainly
2
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Figure 1.1: From the research to the market: the development of a biopharma-
ceutical. The development of a new drug is a multi-stage process. The translation of a
molecule from early discovery and preclinical to clinical is particularly challenging. A way
to overcome this bottleneck would be to shorten and reduce the costs associated with this
translation process, encouraging potential investors to finance the testing of more molecules.
Adapted from (4, 5).
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due to the robust and flexible nature of the immunoglobulin molecule, as well as
advances in molecular biology. Indeed, since the approval of the first therapeutic
mAb Muromonab-CD3 in 1986, mAb formats have evolved from purely murine se-
quence, to “chimeric” and later, “humanised” forms containing human sequences.
New engineered mAbs present a generally reduced immunogenicity, increased sta-
bility and efficacy(7, 8). Recombinant DNA technology allows for the modification
of existing DNA sequence and production of an almost unlimited library of new
molecules (9, 10).
1.1.2 Mammalian cells as a choice of expression system
Over the past few years, cells from various origins have been used as hosts for the
production of biopharmaceuticals including bacteria, yeast, insect cells, plant and
mammalian cells (11). But in pharmaceutical industry, product quality represents
an overriding concern, and mammalian cells became the preferential host for the
production of biopharmaceuticals because of their capacity to perform protein fold-
ing, assembly and post-translational modifications similar to that found in humans
(12).
While several recombinant biopharmaceuticals have been expressed with baby
hamster kidney (BHK) (13), human embryo kidney (HEK) (14), NSO mouse myeloma
cells (15) or more recently the PerC6 or HKB11 cell-lines (16, 17), Chinese Ham-
ster Ovary (CHO) cell-line remains today the standard platform for several reasons.
Firstly, CHO cells are considered safe for the production of therapeutic proteins as
most human viruses are unable to replicate in these cells (18). Secondly, the his-
tory of approval of numerous recombinant proteins in CHO cells is an advantage in
the current stringent regulatory environment. Finally, in a context where biophar-
maceutical companies tend to minimise the development risks to a maximum, the
expertise and knowledge amassed over the past two decades ensure that CHO cells
will remain the industry’s workhorse for therapeutic recombinant production for the
foreseeable future.
For industrial purpose, suspension cell-culture processes are preferred to adher-
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ent cell culture because of the well-understood principles of scaling parameters, space
savings and the ease of process control in homogeneous systems (19). The media
in which the host cells will be cultivated is of primary concern. Biopharmaceuti-
cals must be expressed in animal-derived component free and if possible, chemically
defined media. The use of chemically defined media reduces the risks of virus con-
tamination, and results in greater consistency between batches, as well as easier to
implement downstream applications. Chemically-defined media is today a standard
for the production of clinical proteins (20).
At the moment, the quantities of product required to support early stage pre-
clinical studies are generated using stably expressing cell-lines. Practically, the de-
velopment of stably expressing cell clones consists of the transfection of the cells
with a gene of interest cloned into a plasmid vector, then the integration of the gene
of interest into the host cell genome, and finally the isolation and characterisation of
the clones. The major drawback of this method is that specific productivity of the
vast majority of the recovered stable cell clones is low. Hundreds to thousands of
clones need to be screened with respect to growth and productivity characteristics.
The process can be accelerated by selection, using a marker. In this case, the gene
of interest is flanked with a gene coding for a vital enzyme. A well-known example
is the dihydrofolate reductase (DHFR) system. DHFR catalyses the formation of
a precursor involved in the synthesis of purines, pyrimidines and glycine. DHFR
can be used in recessive selection for which a modified CHO cell-line lacking DHFR
activity is used. DHFR selection can also be applied to a normal CHO cell-line
cultivated in a depleted medium. The stably transfected cells will survive in culture
while the one lacking the enzyme activity will die. The glutamine synthetase (GS)
system is also commonly used. Most mammalian cells have naturally low levels of
endogenous GS and require exogenous glutamine to grow. The GS catalyses the
synthesis of glutamine from glutamate and ammonia. The co-transfection of the GS
gene therefore allows a glutamine independent growth. The two systems can also
speed-up the process of clone selection by imposing stringent conditions of survival.
Indeed, cultivating the cells with increasing concentration of the DHFR or GS en-
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zyme inhibitors, methotrexate or methionine sulphoxamine respectively, ensure to
select cell clones that can titrate the inhibitor, i.e. have several copies of the DHFR
or GS coding gene, and therefore several copies of the gene of interest (21–23). Even
if these methods, coupled with process automation, helped reduce the development
time-lines associated with clone selection (24), individual clones still need to be cul-
tivated for several months to exclude stability problems. Indeed, inherent instability
of CHO cell-lines at genetic and epigenetic levels, can result in progressive loss of
specific productivity over the generations (25). If at the moment, having a stable
clone available is a pre requisite for phase II and III of clinical trials, there is a
need for alternative technologies to speed-up the manufacture of milligrams to gram
quantities to support early preclinical phase.
1.1.3 Transient gene expression for the production of biopharma-
ceuticals
The introduction of foreign genetic material by transfection into mammalian cells
on a transient basis, i.e. without stable integration of the plasmid into the host cell
genome, has been used as routine procedure at small scale in research for decades.
However, its use as a method for production of recombinant proteins beyond the
laboratory scale is relatively recent (26). Transient gene expression (TGE) repre-
sents an interesting alternative to stable expression as this approach present several
advantages: a short time frame for the generation of product, applicability to a wide
range of host cell-lines, simple plasmid vector constructs and product consistency
as the production time-frame is relatively short. Early attempts to use this tech-
nique highlighted several challenges: low yields, a relatively high quantity of genetic
material required at transfection, and the short life-span of the transfected culture
(Figure 1.2).
Various transfection techniques exist. The advantages and disadvantages of the
main ones used are detailed in Table 1.1 and in the text below. Few physical means
have been successfully used to transfect mammalian cells. The majority of the meth-
ods (particle mediated gene transfer, needle injection, jet injection) present severe
6
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Figure 1.2: Comparison of stable and transient approach to recombinant protein
expression. Transient gene expression represents an interesting alternative to stable ex-
pression as this approach allows for the rapid generation of milligrams to gram quantities of
product, in days rather than months. In transient expression the foreign DNA is maintained
as an extra-chromosomal unit within the cell nucleus.
Adapted from (27).
drawbacks such as a limited transfection efficiency (number of cells transfected),
a relatively short duration of transgene expression and/or the complexity of the
method itself (28). The most efficient physical method is electroporation-mediated
gene delivery. Widely used at the millilitre scale, electroporation can only be per-
formed on a high concentrated pool of cells, previously washed and re-suspended
in a pulsing buffer, and is therefore difficult to apply at large scale (29). Cation
chloride salts, especially calcium phosphate salts, have been used for several decades
to transfect mammalian cells (30). This method is based on the co-precipitation
of the DNA with calcium phosphate (CaPi). This complex is then added to the
cell suspension. It has been shown that CaPi induces the endocytosis of the com-
7
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plex and protects the DNA from degradation by intracellular nucleases. However,
the time-sensitive nature of the transfection protocol makes the implementation at
large scale a challenge (31). Most recently, other salts have been successfully used
to transfect DNA in mammalian cells (32). However, the fact that the presence of
serum is still a pre requisite, makes the method unsuitable for the production of
clinical products (33–35).
Several types of viruses have been engineered for in vitro gene-delivery in mam-
malian cells (28). However, most of the systems have their own advantages and
disadvantages and are suited for specific cell types and/or applications, making
difficult the generalisation of one viral carrier for the production of recombinant
proteins. More importantly, the use of the majority of these viral vectors has not
been approved by the regulatory authorities due to their immunogenicity. Recently,
recombinant baculovirus vectors engineered to contain mammalian cell-active pro-
moter elements (known as the BacMam system from Invitrogen), have been used
successfully for transient gene delivery in a broad spectrum of mammalian cells
including CHO cell-lines (36). In contrast to other commonly used viral vectors,
baculoviruses have the unique property of replicating in insect cells, while being
incapable of initiating a replication cycle and producing infectious virus in mam-
malian cells. The viruses can be readily manipulated, accommodate large insertions
of foreign DNA, initiate little to no microscopically observable cytopathic effect in
mammalian cells and present a good biosafety profile. However, the production,
isolation and amplification of the vector still represents a lengthy, costly and chal-
lenging process, which limits its application for large scale production of recombinant
pharmaceuticals (37).
Cationic lipids and polymers are commonly used to transfect mammalian cells.
Although the transfection efficiency is significantly lower than for viral carriers,
cationic vehicles present several advantages including safety, low immunogenicity
and easy-to-use properties. The success of transfection relies on the capacity of
the carrier to encapsulate and/or condense the DNA and to transport it through
the natural barriers of the cell to the nucleus. Cationic lipids, and more precisely
8
Chapter 1. Introduction
synthetic amphiphiles, represent the most used carriers for small scale research ex-
periments. DNA is firstly mixed with the positively charged lipid carrier. The DNA
can be encapsulated or directly bound to the lipid. The complex will then inter-
act with the negatively charged cell membrane. The complex can be internalised
by endocytosis and the DNA released during the liposome trafficking, and/or the
DNA can be directly translocated into the cytoplasm after fusion of the lipid with
the cell membrane (38–40). However most of the cationic lipids present two main
drawbacks: a cell cytotoxicity at high concentration, and a high cost, minimizing
their use for large scale production.
Synthetic polycations proved to be an interesting alternative to other transfec-
tion vehicles as they are cheaper, relatively efficient, safe and ease to use, making
them suitable for large scale transfection. The most promising to date is the linear
polyethylenimine (PEI). Its properties are presented below.
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Table 1.1: Comparison of gene transfer methods
  Advantages Disadvantages 
Mechanical Means 
Electroporation 
Particle mediated 
Needle injection  
Jet injection  
Applicable to any cell type 
Efficient transfection 
 
High cell mortality rate  
Complex methods/protocols 
Not applicable at litre scale  
Co-Precipitation CaCl2  CaPi  
Inexpensive 
Applicable to any cell type 
Applicable at large scale 
Complex protocol 
 Need of serum 
 
Virus Carrier 
Baculovirus 
Parvovirus 
Adeno virus 
Herpes simplex virus 
Lentiv irus 
Retrovirus 
Alphavirus 
Broad host cell range 
Efficient transfection 
 
Strong immunogenicity (excepted 
baculovirus) 
Costly and time consuming 
production 
Limitation to small DNA inserts 
 
Cationic lipids  Liposomes Lipid part icles 
Safe, stable and biodegradable 
Efficient transfection 
Expensive  
Cytotoxic  
Cationic polymers Synthetic Polysaccharides 
Safe and stable 
Biodegradable (Polysaccharide only) 
Applicable at large scale 
Applicable to any cell type 
Inexpensive 
Medium to good transfection efficiency 
Relatively complex protocol 
Cytotoxic (Synthetic only) 
10
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1.1.4 PEI-mediated transient gene expression
The production of biopharmaceuticals at large scale requires a DNA carrier to be
GMP compatible, stable and cost-effective. Moreover, the carrier must efficiently
tranport the plasmid DNA through the natural barriers of the cell, protect it from
the cell’s natural desoxyribonucleases, and once within the cell nucleus, not interfere
with the DNA transcription process. PEI chemical is so far the most promising DNA
carrier as it presents all the characteristics cited above, and has been used in the
past at litre scale for the production of biopharmaceuticals (41–44).
1.1.4.1 Mechanism of transfection using PEI
Even if some discrepancies exist in literature with respect to the mechanisms involved
during cell transfection, there is no doubt that the relatively high efficiency of PEI
relies on its high cationic charged density potential (Figure 1.3).
N
H
n
Figure 1.3: Linear PEI structure. Linear PEI contains protonable secondary amino
groups every third atom.
PEI molecules are able to interact electrostatically with negatively charged DNA,
to condense it, and form stable particles called polyplexes. The mechanism of the
following internalisation of the complexes within the cell is subject to controversy.
Some studies proved the polyplexes could be internalised via clathrin and caveolae
mediated endocytosis (45, 46). Others showed that it could occur via interaction
with negatively charged heparan sulfate proteoglycans (HSPG) on the outer side of
the cell membrane. Using a proteoglycan-deficient CHO cell-line Payne et al. ob-
served a 3.6 times reduction in transfection efficiency compared to a normal CHO
cell-line (47). Kopatz et al. explored the mechanism further and found that. sub-
sequent to the interaction of polyplexes with the cell membrane, HSPGs diffuse
laterally to cluster in cholesterol rich rafts, and trigger an actin-mediated phagocy-
11
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tosis mechanism (48).
Plasmid DNA
Linear PEI
PEI/DNA complex
Heparan sulfate glycan
Rupture
DNA condensation
Actin-mediated
phagocytose
Actin
Active tracking
of polyplexes towards 
cell nucleusMicrotubule
H+
Cl-
H2O
Swelling
Dissociation
Figure 1.4: PEI/DNA polyplexes transfection and trafficking within mammalian
cells. PEI molecules are able to interact electrostatically with negatively charged DNA to
condense it, and form stable particles called polyplexes. Polyplexes are then internalised
following an heparan sulphate mediated endocytosis. Trapped in endosomes, polyplexes
migrate towards the cell nucleus via a protein driven transport on microtubules. Polyplexes
are then liberated in the cytoplasm, by rupture of the endosomes, due to an influx of water
caused by the the proton sponge effect of polyplexes.Following their translocation into the
cell nucleus, PEI molecules will exchange from plasmid DNA to surrounding chromatin.
Trapped in cellular endosomes, it is believed that DNA degradation is prevented
by its tight association with molecules of PEI (49). While the work of Suh et al.
shows that complexes are transported through the cell’s cytoplasm to the perinuclear
zone, within minutes, by a protein driven transport on microtubules (50), Payne et
al. contradicts this mechanism by showing that intact microtubules are not a pre
requisite to polyplexes trafficking to late endosomes, and that polyplexes trafficking
12
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could mostly be directed to late endosomes by their initial HSPG receptors (47).
Polyplexes are then liberated in the cytoplasm by a mechanism called the proton
sponge effect. PEI specificity over other polycations is a consequence of the high
number of protonable amino groups which results in a greater buffering effect in
endosomes. The pumping of protons, along with the concurrent influx of chloride
ions to maintain charge neutrality, increases ionic strength in the endosome. This
results in a swelling and a rupture of the endosome (51). Moreover, the proton
sponge effect would contribute to increase the endosomal pH and therefore inactivate
most of the endosomes nucleases. The relative proportion of PEI/DNA complexes
escaping the lysosomal trafficking pathway is relatively unknown and is cell-line
dependent. It seems that PEI/DNA complexes can be found in different forms in
the cytosol: captured in an endosome, bound to membrane fragments of a burst
endolysosome, or completely free within the cell cytoplasm (51). The mechanism of
DNA internalisation in the nucleus remains unclear. A controversy exists regarding
a potential cell competency for complex internalisation into the nucleus. Indeed,
according to some authors, the transition through mitosis, with the concomitant
transient loss of nuclear membrane integrity, is likely to be a prerequisite for nuclear
entry of endosomally derived complexes and expression of transgenes (52–54). On
the contrary, some studies showed that PEI/DNA complexes are translocated into
the nucleus without dependence on membrane integrity or cell mitosis (55–57). The
fact that post mitotic cells such as neurons could be transfected suggest that non-
mitosis dependent entry of plasmid into the nucleus is a reality. Pollard et al.
showed that PEI could promote transgene delivery to the nucleus via electrostatic
interactions with anionic lipids present at the nucleus surface (58). The presence on
the DNA plasmid of specific sequence, such as a SV40 promoter, showed to promote
DNA import via the nuclear localisation signal import machinery (59, 60). The
whole PEI/DNA complex is thought to enter in the nucleus. The polyplexes will
dissociate following an exchange of the PEI polymers with surrounding chromatin
and competitive interaction with naturally occurring nuclear polyamines (61). The
complete dissociation of DNA/PEI is not, however, necessarily a prerequisite prior
13
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to transcription (62). The principals mechanisms identified to date are summarised
in Figure 1.4.The several mechanistic discrepancies reported in the literature may
come from the fact that studies have been carried out using different mammalian
cell-lines. Indeed, Von Gersdorff, for example, described a cell-line specific preferred
route for polyplexes internalisation (46).
1.1.4.2 Optimisation in mammalian cells
Since Schlaeger and Christensen have demonstrated the usefulness of PEI for large
scale transfection, numerous studies focused on improving the method to increase
protein titres. Titres per litre now range in the milligrams to gram category whereas
a decade ago it was only possible to produce microgram to milligram quantities of
protein. Optimisation studies focused on different aspects of transient production:
(i) the transfection process and (ii) the modulation of the transgene expression
during the culture.
The success of PEI as a transfection vehicle lies in its ability to condense DNA
to form polyplexes. The mechanisms underpinning the formation of polyplexes have
been investigated in depth. It was found that the formation of polyplexes was a
kinetic reaction influenced by the size of the DNA vector, the molecular weight
and shape of the PEI molecule, the relative quantities of PEI and DNA, as well
as the medium in which the complexation occurs (63). Both the size and shape
of the polyplexes affect transfection efficiency (64). PEI molecules can be found in
linear or branched forms and in various molecular weights ranging from a few to
several thousands kilodaltons (kDa). The nature of PEI molecules is thought to
influence the rate of association and dissociation with DNA molecules as well as the
characteristics of PEI/DNA polyplexes. This is of primary importance as a weak
association will result in the degradation and/or loss of DNA molecules through
trafficking towards the cell nucleus, large polyplexes will struggle to be endocytosed,
and too strong an association will probably prevent the dissociation of PEI/DNA
polyplexes and limit the transcription of DNA within the cell nucleus.
So far, transfecting a cell culture using PEI can be done in two ways. The
14
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most common approach involves incubating the PEI and DNA molecules for a given
amount of time before adding them to the culture (65). However, Backliwal et al.
have shown that good transfection efficiency could be achieved by directly adding
PEI, then DNA, to a highly concentrated cell culture (66). Linear 25kDa PEI
molecules are so far judged as being the most efficient form of PEI. However, several
laboratories are modifying parental PEI molecules to further improve its efficacy as
a gene delivery vehicle. Commercially available jetPEI® (Polyplus) shows higher
transfection of small interfering RNA (67). Conjugated PEI with tween 85 or lipoic
acid showed to efficiently mediate non toxic gene delivery (68, 69). Indeed the main
drawback of PEI is its cytotoxicity. In the range of generally used concetrations,
PEI both induce cell membrane destabilisation and promote apoptosis via activation
of mitochondrially mediated apoptotic program. Free PEI molecules seem to be
more cytotoxic than when associated with DNA. Therefore, it is not surprising that
concentrations of PEI and DNA, the ratio PEI/DNA, and the cell concentration at
transfection are considered as the most critical factors for efficient transfection and
have been subject to numerous optimisation studies (34, 35, 53, 70–74). As shown
in Table 1.2, the optimal values of these critical factors significantly differ from one
study to another. It can be explained by the fact that PEI-mediated transfection
is a complex process in which a large number of factors are interacting. Except for
Thompson et al., all the studies presented have been carried out by optimizing one
factor at a time, meaning that factors interaction have been ignored. It is highly
probable that the identified optimal values for each factor depend on the order in
which factors have been optimised. As shown by Thompson et al., it seems that
the specific characteristics of the CHO cell-line may also play a large role in the
variations observed. On another level, Tait et al. increased transfection efficiency
and subsequent protein expression by synchronizing CHO cells in G2/M phase using
the microtubule polymerizing agent nocodazole. The proposed mechanism is that
during mitosis, more polyplexes could enter the cell nucleus thanks to the loss of
membrane integrity (53).
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Table 1.2: Summary of basal factors concentrations used or optimised for transfection in CHO cells using 25kDa linear PEI.
Cell line 
DNA:PEI 
Ratio 
(w/w) 
[PEI] 
(µg mL-1) 
[DNA] 
(µg mL-1) 
[Cell] 
(µg mL-1) 
Medium Reporter 
Protein 
Reference 
        
CHO K1SV 1:2.7 2.7 1 0.2 DMEM SEAP [77] 
CHO-S 1:1.35 1.35 1 0.2 CHO-SFM II Luciferase [53] 
CHO-S 1:3 3 1 1 Mix* GFP [71] 
CHO DG44 1:3 7.5 2.5 2 ProCHO5 mAb [74] 
CHO DG44 1:2 5 2.5 0.5 RPMI 1640 GFP [42] 
CHO DG44 1:2 7 3.5 2 CHOM SEAP [72] 
CHO DG44 1:5 12.5 2.5 2 ProCHO5 GFP [34] 
CHO L 1:2 22.6 11.2 2.1 CD-CHO SEAP [73] 
CHO M 1:1.1 13 11.4 1.6 CD-CHO SEAP [73] 
CHO-S 1:3 9 16.3 2.5 CD-CHO SEAP [73] 
CHO DG44 1:3 0.625 0.1875 4 ProCHO5 mAb [70] 
* Mix: 25% CD-CHO/ 75% DMEM
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An inherent limitation in TGE is the premature cell death caused by the stress
the cells undergo during the process. Indeed, transfection protocols generally involve
several dilutions and/or cell concentration steps, plus the addition of cytotoxic PEI
and exogenous DNA material. As a result, transient production processes tend to
be shorter than other culture processes. Moreover, the early cell death may decrease
the overall yield, while the lysis of cells may liberate cellular enzymes, such as gly-
cosidases, proteases or reductases, potentially affecting the product quality. A way
to overcome this problem is to maintain the viable cells for a longer period. Culture
process designs, such as fed-batch or perfusion cultures, limit by-product accumu-
lation and continuously supply the culture with nutrients to extend the lifespan of
the culture. These processes can be applied to transfected cultures. Using a per-
fusion mode, Sun et al. successfully extended the culture phase post transfection,
significantly improving protein titres compared to a normal batch culture (75).
Another approach is to modify the serum-free culture medium by supplementing
it with different amino acids, growth factors or peptones. Pham et al. reported a
two fold increase in secreted alkaline phosphatase transiently expressed in HEK 293
host cells after the addition of a casein peptone 24 hours post-transfection (76). This
effect was shown to be time, concentration and cell-line dependent. The addition
post transfection of some peptones promoted gene expression but resulted, in some
cases, in an enhancement of cell growth at the expense of protein expression. Stettler
successfully used a peptone supplementation method to enhance TGE in large scale
CHO cell culture (74). However, the detrimental effect that peptones on product
purity needs to be considered. Mild-hypothermia also proved to be a valid option
to maintain cell viability in culture by promoting the accumulation of cells in the
G1 phase of the cell cycle with an increased cell size, a reduced cellular metabolism,
a greater cell viability due to decreased accumulation of waste products, and a po-
tentially, partially inhibited PEI-mediated cytotoxicity (77, 78). Another limitation
to high yielding cultures is the degradation and dilution of the transgene during the
culture. It seems that mild-hypothermia also contributes to maintain high steady-
state levels of transgene mRNAs. On another level, in vivo and in vitro studies have
17
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demonstrated a rapid decrease in transcription from extra-chromosomal DNA prior
to the physical loss of the DNA from the nucleus, as the result of association with
histone deacetylases (79). Histone deacetylases promote DNA condensation within
the cell nucleus and therefore inhibit DNA transcription. Strategies have been de-
veloped to overcome these epigenetic pathways using specific histone deacetylase
inhibitors such as sodium butyrate or valproic acid (80). Valproic acid has been
approved by the FDA in the past and is relatively inexpensive. Therefore its use
can be extended to the production of biopharmaceuticals in large scale culture.
18
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1.2 The future of manufacturing processes
The biopharmaceutical industry has long been characterised by high research and
development costs. Until recently, companies managed to sustain high profit mar-
gins thanks to few blockbuster medicines. This is no longer the case. First the
“blockbuster” paradigm does not prevail anymore and we will more likely see, in the
future, more products with shorter life cycles. Second, numerous pressures including
governmental regulations, competition from generics, and shortening of blockbuster
patent protection times, incite biopharmaceutical companies to reduce the time,
costs and lack of flexibility of current manufacturing platforms, as well as the risks
of product failure during late clinical trials. So far several have been and are being
investigated:
• Limit unexpected, unforeseen issues during clinical trials by developing a good
knowledge of the product and the manufacturing process early on.
• develop/use tools for both high-throughput and better characterisation of can-
didates
• increase manufacturing flexibility for fast product turn-over
• streamline processing units for more straight-forward manufacturing
1.2.1 Product quality as a driver for faster process development
Ten years ago, the Food and Drug Administration (FDA) published a draft paper on
the good manufacturing practices for the 21st century (81). The document specified
that companies should build quality, safety and efficacy into their products as early
as possible. This concept became known as Quality by Design (QbD). A more
recent report (82) mentions that adopting a QbD approach to process development
could:
• Streamline product development
• Simplify regulatory compliance and increase flexibility
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• Fasten improvements to product manufacturing.
But how exactly? The easiest way to understand the advantages of QbD is to
look at the main reasons of a product development failure. Success or failure are
defined according to three dimensions: time, cost and product quality. In other
words, a project fails if the product fails at meeting initial expectations, and/ or if
the development takes too long or is too costly (83). Generally, time and costs are
overrun because the product fails at meeting all the expectations and induces man-
ufacturing process readjustments. The cost of failure is huge, not only financially,
but also from an ethical and reputation point of view. Prevention against failure lies
on the extent to which a product quality risk can be anticipated and managed early
on. Yet, the quality of a biological product depends to a large extent on the design
of the manufacturing process. Biopharmaceuticals, and especially antibodies, are
complex molecules, expressed in a complex environment. Therefore, compared to
chemically synthesised products, biopharmaceuticals are subject to numerous con-
taminants and, potentially, structural alterations. In the case of antibodies, protein
folding depends on low energy hydrogen bonds, and minor changes in the expression
environment may generate structural variants. Yet, the efficacy but also safety of
the molecule is conditioned by its structure. For example, changes in folding may
affect receptor binding and/or signaling. Abnormally folded proteins may impact
on immunogenicity through product aggregation or fragmentation. Natural post
translational modifications can also be altered (Figure 1.5). Those modifications,
as well as the presence of process-related impurities, may be critical with respect
to product pharmacokinetics, activity and, in some cases, safety. Typical quality
attributes for a monoclonal antibody are presented in Table 1.3.
QbD represents a systematic and rational approach to process development that
encompasses predefined objectives, and emphasises the link between product quality
and process design based on quality risk assessments (86). QbD innovation lies in
directly promoting and proving the quality of the product during the development,
by characterizing the product and the process early on, to avoid failure later on
(87, 88). QbD should be implemented wherever possible, from the development of a
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Figure 1.5: Antibodies structure is subject to potential structural modifications
in culture.
VL: variable region on light chain; CH: constant region on heavy chain. Adapted from (84).
single processing step to the whole manufacturing process. The QbD approach to the
development of one single processing unit is detailed in Figure 1.6. Each processing
unit’s objectives should be aimed at improving product quality while maintaining
good enough process performance. The first step is therefore to define the Criti-
cal Quality Attribute (CQA) of the product: the “physical, chemical, biological or
microbiological properties or characteristics that should be within an appropriate
limit, range or distribution to ensure desired product quality” (86). At first, a risk
assessment is aimed at establishing the potential interactions between the process
specific CQAs and the desirable process performance markers with the controllable
process parameters. In other words, this risk assessment serves to build a rational
experimental strategy. Process characterisation can therefore be conducted. The
experimental design evolves with the first experimental results until the process is
fully characterised. Finally a design space is chosen, i.e. critical operational param-
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Table 1.3: Typical quality attributes for a monoclonal antibody. From (85)
Products variants Process impurities Drug formulation attributes 
Aggregation Microbiological Foreign particles 
Conformat ion Virus Clarity 
C-terminal lysine DNA Color 
Deamided isoforms HCP Osmolality 
Disulfide bonds Protein A  pH 
Fragmentation Buffer components Concentration 
Glycation  Medium components Potency 
Glycosilat ion  Volume 
Oxydation   
Thioether link   
eter ranges where all CQAs are within an acceptable range. Because most of the
experiments are conducted using Design Of Experiments (DOE), it is necessary to
perform a validation step to control that predicted values are correct. QbD therefore
presents many advantages. Because of the extended amount of knowledge gained
early on in the development, the risk of introducing the “wrong” candidate into clin-
ical trials is reduced. Moreover, the fact that the quality risk assessment is based on
previous experience and data available within the literature can significantly speed
up the screening of candidates by ruling out the ones that will most probably fail
at a later date. Finally, QbD allows for the development of well characterised and
therefore flexible process platforms for which the impact of a change in process pa-
rameters on product quality is known and detailed. Still in its infancy, the evolution
of the number of recent publications highlights the importance this methodology is
gaining in our industry (Figure 1.7).
1.2.2 Current processing options for the manufacture of antibodies
Monoclonal antibodies represent a unique class of biopharmaceuticals. Their ho-
mologous structure, combined with the nearly universal use of mammalian cells
as expression hosts, make possible the harmonisation of manufacturing around base
platforms that can accommodate slight product variations. For these reasons, mAbs
represent really attractive products for biopharmaceutical companies as they are as-
sociated with rapid process development time-lines, and relatively cheap costs of
production. In fact, the relatively high price of this family of products on the mar-
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ket is justified by the high research and development costs that led to their release
on the market.
The last two decades have seen the emergence of generic production platforms
for the manufacturing of mAbs. Those are presented in Figure 1.8. Despite a rela-
tive uniformity with respect to the global processing chain, several steps are in fact
subject to a lot of variations between products and/or companies, upstream cell
culture probably being the step encompassing and leading to the greatest variety.
Indeed, numerous different culture medium, mammalian cell hosts, product type as
well as processing technology and process design, assure a great diversity of cell cul-
ture broth in terms of products and product contaminants. If the clarification step
is relatively unaffected by the nature of product expressed in the cell broth, a feed
containing a relatively high amount of contaminants can cause issues such as filtra-
tion membrane fouling or extended/complicated centrifugation protocol. Since no
single chromatography step can achieve the product purity required for biopharma-
ceuticals, a multi-step purification process scheme is required. Capture by Protein
A became a standard as the high specificity of Protein A for binding IgG makes it
a very robust process, relatively insensitive to variations in the feed composition.
The following intermediate and polishing steps are generally performed using ion-
exchange as the technique is highly effective at removing low concentrated products
such as DNA, aggregates and host cell proteins (HCP). The ICH Q5A guidance
document recommends the use of at least two orthogonal steps for viral clearance
(89). The first one is usually performed right after the Protein A binding step as
the product is eluted in a low pH buffer. Indeed, low pH treatment has shown to
successfully inactivate many enveloped viruses. The second step involves mechani-
cal separation by a filter. Finally the product is concentrated and formulated in a
buffer where the product will be stable e.g. a histidine buffer. The main techniques
involved in mAb processing are presented below, with the exception of upstream cell
culture processes as those have been described in previous sections.
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1.2.2.1 Clarification
The objective of clarification is to separate the product of interest from a solution
concentrated in cells, debris, particles and colloids. Centrifugation and microfil-
tration are the primary techniques used today in industry. While depth filtration
can be used as a harvest method it is more common to employ this technique as
an additional clarification step. For cell culture broths rich in nutrients, minimis-
ing the duration of the harvesting step to a few hours is of primary importance
to prevent bacterial growth during the process. Centrifuges accelerate the settling
that normally occurs during sedimentation by applying a centrifugal force. Cen-
trifugation can be used at every processing scale from millilitres to thousands of
litres. Most large scale applications (hundreds to thousands of litres) use disk-stack
centrifuges. Conventional lab centrifuges can effectively be used for scales up to
100 litres. The main drawback of a centrifuge is its inability to separate contami-
nants with a molecular weight close to that of the product of interest. As a result,
centrifugation processes are often followed by an additional depth filtration step.
Microfiltration becomes generally useful when litres of broth need to be clarified.
Compared to centrifugation, microfiltration generates a near particle-free harvest
stream that requires minimal additional filtration. Microfiltration uses membranes
with pore sizes ranging between 0.2 to 0.45µm. The choice of the pore size should
be dictated by the composition of the feed. Indeed, membrane filtration is generally
prone to fouling, with a progressive decline in membrane flux with time because
of the accumulation of retained material at the membrane surface. The flux also
decreases as the concentration of particulates/proteins in the feed increases. As the
fluid is forced through the pores, a concentration gradient in particulates is created
from the centre of the feed channel to the membrane. At high concentration, the
viscosity at the membrane surface increases and a gel layer can form. Fouling occurs
when the gel layer at the top of the membrane is no longer permeable. Fouling
is often characterised by chemical and physical adsorption of particulates either on
the membrane surface or within the pores. In other words, resistance to filtration
depends on the permeability of the gel layer and the size of the membrane pores.
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Figure 1.9: Comparison of different filtration modes. Membrane filtration is gener-
ally prone to fouling, with a progressive decline in membrane flux with time because of the
accumulation of retained material at the membrane surface. Fouling occurs when the gel
layer at the top of the membrane is no longer permeable. As opposed to normal flow filtra-
tion, tangential flow filtration consists of pumping the feed tangentially along the surface of
the membrane, causing the particles to be swept along and reducing the thickness of the gel
layer. Depth filtration differentiates by retaining particles throughout the width of a porous
filter rather than just on the surface of a filtration layer. Large particles are mainly trapped
in the membrane itself whereas small particles are retained by electrical and/or molecular
interaction with the media.
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As opposed to normal flow filtration, tangential flow filtration (TFF) consists of
pumping the feed tangentially along the surface of the membrane, causing the par-
ticles to be swept along and reducing the thickness of the gel layer (Figure 1.9, A
and B). Alternatives in flow configurations have been proposed to further mitigate
the effects of the polarisation layer. For example, the solids accumulated at the
membrane surface can be discharged back into the feed by using backflush systems,
where the flow is momentarily and periodically reversed. Other alternatives consist
in developing specific flow paths to initiate vortices that will sweep the membrane
efficiently. The formation of the gel layer is a well known mechanism and involves
two phases: a pressure dependent regime, where an increase in pressure results in
an increase in flux and a pressure independent phase in which increasing the pres-
sure will not increase the flux. Process efficiency can be significantly enhanced by
adjusting the transmembrane pressure at the maximal value that still allows control
of the flux. Therefore, and as opposed to centrifugation, the process often requires
a fine development prior to routine operation and complicates the introduction of
microfiltration as a multi-product platform.
Depth filtration differs from surface filtration in that particles are retained through-
out the width of a porous filter rather than just on the surface of a filtration layer
(Figure 1.9, C). Depth filtration operates on two different mechanisms: mechanical
sieving and adsorption. Large particles are mainly trapped in the membrane itself
whereas small particles are retained by electrical and/or molecular interaction with
the media. Most depth filters used in biopharmaceutical processes are made of filter
aids and cellulose fibre bound together by a polymeric sorbent that provides wet
strength and presents cationic surface charges that will help retain colloidal parti-
cles. Depth filters usually consist of an series of lenticular disks assembled into a
multi-stack housing. The different disks vary in terms of permeability and chemical
properties. These disks are usually laid out to form a gradient, the media becoming
progressively finer and denser along the passage of the solution.
Efficient and inexpensive clarification becomes more and more of a challenge
as high titre cell culture processes yield a greater amount of solids, of all sizes
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and density, that will foul the membrane, or even worse, escape coarse filtration
and damage chromatography sorbents. An inexpensive solution consists in adding
flocculants to the cell broth that will aggregate small particles and facilitate the
clarification. Association between flocculants and particles is based generally on
electrostatic interactions. By adding calcium chloride, then potassium phosphate
to a cell broth, Coffman et al. managed to trap cell debris, host cell proteins and
nucleic acid into large particles to yield a clear supernatant with the recovery of 95%
of the antibody (90).
1.2.2.2 Capture by Protein A
Protein A is a 54kDa protein originally found in the cell wall of the bacteria Staphy-
lococcus aureus. The molecule is structurally characterised by a linear series of
five homologous antibody binding domains. Immunoglobulin G binds to the indi-
vidual domains of Protein A via its Fc region at the junction between CH2 and
CH3 domains. The Protein A-IgG interaction consists of hydrophobic interactions
along with hydrogen bonding and salt bridges. The IgG class of antibody presents
a highly conserved histidyl residue that aligns face to face with a complementary
histidyl residue on Protein A. At physiological pH these residues are uncharged,
promoting the IgG-Protein A interaction. The interaction is reinforced by the hy-
drophobic character of the histidine imidazole side chain (91). At low pH however,
the residues are fully charged, hydrophobic and mutually repellent. Theoretically,
IgG can bind to any of the five domains of Protein A. However in reality, a binding
stoichiometry of 2 to 3.3 has been observed in a free solution (92). Capture by
Protein A is used in a bind and elute chromatography mode. Despite the costs,
Protein A high selectivity and capacity makes it the most used option for the cap-
ture of human immunoglobulin G1 and G2. Indeed, the Protein A capture step is a
very robust operation. This ligand can accommodate with a wide pH range (2-11)
and is able to refold after treatment with denaturing solutions. The random coil
sequences that link the domains of Protein A are, however, sensitive to proteolytic
cleavage and the Protein A itself can be denatured in alkaline conditions (93). It
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becomes therefore compulsory to remove any leached Protein A from the product of
interest to prevent any immunogenic reaction to the patient. The Protein A ligand
source varies with respect to the mode of production. Natural wild Protein A can be
obtained at high purity by lysostaphin digestion of the bacteria, followed by gel fil-
tration then affinity chromatography on IgG-agarose sorbent. However, recombinant
Protein A expression in Escherichia coli is now a preferred approach. Recombinant
variants can be expressed with different features to enable directional coupling of
the ligand to the solid phase sorbents. Regarding the latter, GE Healthcare has a
market advantage for Protein A sorbents with the MabSelect SureTM product that
can withstand strong alkaline conditions allowing the repeated use of 0.5M sodium
hydroxide for sanitisation. Protein A sorbents available on the market mainly vary
with respect to the solid phase matrix to which the Protein A is coupled. Matrix
composition but also bead and pore size, affect sorbents compressibility, chemical
resistance, mass transfer properties, capacity and selectivity (94). Agarose based
matrix is, for example, a highly porous material and is present in MabSelect Sure
and rProtein A SepharoseTM Fast Flow from GE Healthcare. Sorbents based on
rigid ceramic, such as HyperD® F from Pall Life Sciences, or porous glass, such
as ProSep®-A from Merck Millipore, can withstand high flow rates and pressures
during regeneration phases.
The cost of Protein A is a major concern as it contributes to a quarter of the
overall costs in mAb downstream processes. Protein A can therefore not be used as
a disposable component. However, Protein A can sustain a relatively high number
of cycles, and can be reused more than 200 times without noticeable loss in perfor-
mance. Purification platforms excluding the use of Protein A have successfully been
used in the past for purifying mAbs. However, such purification schemes require
extensive process development on a case by case basis and therefore cannot be used
for multi-product processing platforms.
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1.2.2.3 Ion exchange chromatography
Ion exchange chromatography encompasses two techniques: cation and anion ex-
change chromatography. These techniques are generally used as intermediate and
polishing purification platforms as, when combined, they allow effective clearance of
contaminants such as HCP, host cell DNA and product aggregates (95). Proteins are
molecules formed by polymerizing amino acids. Amino acids are structurally char-
acterised by at least one acidic carboxylic, and one basic amide functional group
(Figure 1.10). Each amino acid also possesses a side chain or R group, that can
exhibit acidic or basic properties with respect to the nature of the titratable groups
it contains. In fact, R group variability alone explains the difference in pKa between
amino acids. Proteins, which are built of numerous amino acids, therefore exhibit
numerous ionisable groups, and possess an overall net charge. The net charge varies
with respect to the pH of the solution, the charge’s density and distribution within,
and at the surface of the protein. When the pH of the solution is low, proteins will
tend to be positively charged and are called cations. At high pH, on the contrary,
negative charges will be predominant and the proteins will become anions. Because
the amino acid sequence and tri-dimensional structure are protein specific, at a given
pH, each protein has its own unique net charge. Ion exchange chromatography takes
advantages of these properties. The technique is based on the electrostatic inter-
actions between charged amino acids chains and the stationary surface charge of a
ion exchange sorbent. Electrostatic interaction strength depends on both the ionic
charge and ionic radius, which vary locally in proteins. Theoretically, cations of high
charge and small ionic radius have high electrostatic interaction strength, and are
more likely to interact strongly to a negatively charged sorbent surface than cations
of low charge and large radius. More importantly, proteins are “amphoteric”, i.e.
their net surface charge will change gradually as the pH of the environment changes.
In ion exchange chromatography, the mobile phase is a solution containing the
molecules to be separated. The solution is acid or basic in cation or anion exchange
mode respectively. The stationary phase usually consists of a sorbent coated with
an organic layer presenting positively charged molecules at its surface, in anion ex-
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Figure 1.10: Amino acid structure
change mode, or negatively charged molecules in a cation exchange mode. When
passed through the stationary phase, electrostatic interactions form between the
charged groups of the side chains of the molecules present in the mobile phase, and
the oppositely charged groups immobilised on the sorbent. This phenomenon of
adsorption is controllable by varying the mobile phase pH and ionic strength. For
example, in cation exchange mode, proteins exhibiting positives charges will adsorb
on the sorbent. A slight increase in pH will result in lower charged cations and
weaker electrostatic interaction energies and will promote the desorption of lightly
bound cations from the stationary phase. Desorption can also be promoted by in-
creasing the mobile phase ionic strength. By introducing counterions in the mobile
phase, competition for both the immobilised sorbent and cations charged sites result
in stoichiometric exchange with the bound charged groups of proteins (Figure 1.11).
Sodium ion is the most commonly used counterion in cation exchange chromatogra-
phy but other cations have been successfully used previously. Arginine, for example,
proved to help prevent protein aggregation that sometimes occurs during elution
(96). Guanidine, tetra-n-butylammonium, or calcium, have also shown to improve
the selectivity of the method (97, 98).
Since ion exchange chromatography is really selective, it is possible to isolate a
product of interest from relatively low quantities of contaminants. Therefore, even,
if IEX represents, in some cases, a viable alternative to Protein A for the capture of
mAb, the technique is often used for intermediate and polishing purification steps
where HCP, protein aggregates and DNA amounts need to be reduced to clinically
acceptable trace levels. In fact it is common to sequentially use a cation, then anion
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exchange chromatography (99).
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Figure 1.11: Cation exchange chromatography principle.Prior to loading, the sor-
bent is equilibrated with a buffer at relatively low pH and conductivity. During the loading,
the negatively/neutrally charged molecules are flowing through the sorbent. A buffer with
increasing ionic strength and sometimes pH is pumped through the sorbent allowing the
bound molecules to sequentially elute from the sorbent. By collecting separate fractions,
the product of interest can be isolated from some of its contaminants.
Ion exchange sorbents present interesting properties: sorbents are relatively
cheap, have a high loading capacity and separate proteins under near physiologi-
cal and non-denaturing conditions. Maximal dynamic binding capacity results from
a combination of fast mass transport, large binding surface to volume ratio and
quick and robust protein ligand binding. Sorbent design parameters include bead
and pores sizes, ligand density as well as the chemistries of the backbone, spacers
and ligand. In fact numerous sorbents are available on the market (99). Each option
presents several advantages and disadvantages. The paragraph below only describes
the most popular.
The nature of the sorbent backbone strongly depends on the manufacturer: Pall
Life Sciences provides Q and S HyperCelTM sorbents that are based on a rigid cel-
lulose matrix that generates low back pressures. GE Healthcare products include
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cross linked agarose backbones adsorbents. Polymethacrylate, used by Fractogel®
for example, presents greater selectivity for removal of aggregates due to non-specific
hydrophobic interactions with the backbone. Polystyrenedivinylbenzene is usually
present in Poros®from Life Technologies. Weak ion exchangers, that stay ionised
within a relatively narrow pH range, are usually reserved for specific applications and
are not suited for a multi-product platform. Strong anion ligands include quaternary
amino ethyl, triethylammonium ethyl, or quaternary aminoethyl immobilised to the
sorbent. Among strong cation exchangers, it seems that sulphopropyl, sulphoethyl
and sulphoisobutyl groups dominate the market (100). In order to improve per-
formance, traditional materials have recently been coupled with polymers such as
dextran to which the functional group is attached. This extended structure gener-
ally allows for better mass transfer and selectivity (101). Another modification is
the filling of the bead pores with a functional polyacrilamide gel to form the “gel-
in-a-shell” technology, available for both anion or cation exchange mode using the
Pall Life Sciences HyperD® F sorbents.
1.2.2.4 Tangential ultrafiltration/diafiltration (UF/DF)
Tangential ultrafiltration is widely used for product concentration. The principle
is the same as for microfiltration, previously detailed, except that the product of
interest is retained by the membrane, while volumes of buffer are gradually elimi-
nated from the feed, resulting in a concentration of the product. As opposed to the
concentration step, diafiltration, or buffer exchange, consists of adding the buffer of
the final desired composition to the retentate system at the same rate at which the
permeate is removed, thus maintaining a constant volume upstream of the mem-
brane. In mAb processing, UF/DF usually represents the last step before filling.
At this stage the feed is relatively pure of contaminants and requires little to no
optimisation. In fact, the process is mostly limited by the viscosity of the retentate.
Ultrafiltration membranes are made from different polymers including polysulphone,
polyethersulphone, polyvinylidene and regenerated cellulose. Cellulose membranes
are, however, mostly used in biopharmaceutical industry due to their low protein
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binding properties. Special care is, however, required as damage may occur when
using harsh cleaning methods (102).
1.2.2.5 Other processing options
A variety of other technologies are, or have been developed in the past to accommo-
date mAb processing requirements. Among them, the charged micro and ultrafiltra-
tion membranes as alternatives to sorbent bead chromatography, and mixed-mode
chromatography are particularly attractive.
The costs associated with the use of Protein A, the concern of immunogenic
leached Protein A in purified product, as well as the cumbersome “3-stages purifi-
cation scheme”paradigm have promoted the development of alternatives for more
efficient methods of purification. Mixed-mode chromatography combines different
mode for the separation of biomolecules. For example, MEP HyperCel sorbent from
Pall Life Sciences takes advantage of hydrophobic charge-induction chromatography.
The sorbent allows for the selective capture of mAbs by hydrophobic interaction un-
der near-physiological conditions, then desorption, by reducing the pH of the mobile
phase to promote charge repulsion between the ligand and the product. It is now
possible to use mixed mode chromatography as an alternative to Protein A for cap-
ture, and to develop an efficient two-step purification scheme (103).
The efficacy of sorbent bead chromatography is mainly limited by slow purifica-
tion flow-rates, due to the diffusion of the solutes into the pores of the beads. More-
over, sorbent bead chromatography requires high pressure, which necessitates robust
pumps, columns, connectors and other hardware that can withstand high pressure.
Chromatographic membranes are composed of porous polymer membranes. The
pores are significantly larger than the pores of sorbent beads. Therefore, convective
mass transfer is dominant over diffusion resulting in higher throughputs and shorter
processing time without compromising product recovery (Figure 1.12). Membranes
consist of polymeric substrate to which a functional ligand is chemically coupled.
The ligands used are generally identical to those used in resin chromatography. Re-
cent advances in membrane chromatography technology have yielded products suit-
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Figure 1.12: Comparison of the mass transfer mechanisms involved in resin
chromatography (A) and membrane chromatography (B). As opposed to resin chro-
matography, convective diffusion is dominant over diffusive diffusion, resulting generally in
relatively shorter processing time.
able for almost every kind of chromatographic operations including product capture,
intermediate purification and polishing. Membrane chromatography is now routinely
used as polishing step. At slightly basic pH and low conductivities contaminants
such as DNA, leached Protein A and host cell proteins will bind to the ligands while
the mAb will flow through the membrane matrix without being bound (104). Fu-
ture work on this technology should be conducted to overcome current drawbacks
including ligand breakthrough from membranes, low capacity and uniform flow dis-
tribution.
1.2.3 Novel manufacturing platforms
Biopharmaceutical companies face challenges to modify their manufacturing plat-
forms, especially for small to medium scale early productions of therapeutic can-
didates. There is a strong need for easy, cost effective production platforms that
would allow the production of milligram to gram quantities of biopharmaceuticals
with minimal to no process development. Conventional bioprocessing systems are
not adapted. Mostly made of stainless steel, they have been specifically designed
to support the production of only one to a few molecules. A quick turn-around of
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molecules requires flexibility and adaptable production platforms.
1.2.3.1 The adoption of disposable technologies in biopharma industries
The past decade has seen the emergence of single-use (SU) systems over more conven-
tional stainless steel systems. First reserved to sterile liquid handling, connections
and buffer preparation, disposables have successfully been implemented in complex
bioprocessing steps. The best examples are probably the success of the WAVE
Bioreactor® and WAVE BioreactorTM. In 1998, Wave Biotech was the first com-
pany to commercialise a completely disposable cell culture system (105). Wave bags
are today widely used for applications at scales of up to 500L and cell expansion
systems to feed stirred tank bioreactors (106). Wave bags are also used to carry
out complex culture processes such as perfusion (107). Compared to stainless steel
systems, SU options represent significant savings in costs, labour and time. SU also
allows for maximum flexibility as challenging and time consuming cleaning and val-
idation steps can be avoided. Therefore it is not surprising to have the SU market
growing annually at a steady 15-18% rate. The advantages of SU over stainless steel
are detailed in Table 1.4.
There is now a multitude of disposable bioreactors available on the market.
Cylindrical or cubic bioreactor bags mimic conventional bioreactors. They are de-
signed to fit in a stainless steel outer vessel including a heating jacket (108). Gas
transfer is promoted by disposable mixing systems while air is injected into the air
phase of the bag. Mechanical mixers are efficient but are a source of shear dam-
age for the cells. Other options involve moving platforms supporting a bag. Air is
sparged continuously into the headspace of the bag. The rocking motion of the plat-
form creates waves at the liquid-air interface enhancing the aeration of the medium.
Recently, two-dimensional wave motion resulted in high mass transfer capacities
which are able to support the oxygen demand of high density cell cultures. Orbital
shake bioreactors also represent an attractive alternative to other bioreactors as or-
bital mixing results in low sheer stress and the large surface of gas exchange allows
efficient oxygen transfer (109).
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Upstream technologies are way ahead of downstream technologies in terms of
disposable solutions. In fact, according to Langer, the expansion of the SU market
is slowed down by the lack of disposable options for the downstream bioprocessing of
biopharmaceuticals (110), cost and scalability being the main issues. For example,
the cost of Protein A sorbent, or chromatography membranes are not compatible
with a SU application. Future innovations rely on a plug-and-play approach towards
managing product design and innovation. This would help to provide a framework
to identify where and how disposable solutions will be of real benefit for easier and
cheaper processes. This could be driven by the development of processing platforms
for the processing of mAbs.
1.2.3.2 Process integration
A challenge for the next decade will be to develop processing solutions adapted to
the production of a multitude of products. Innovation will be driven by (i) a modu-
lar and “plug and play”approach to manufacturing and (ii) the development of well
characterised and flexible platforms. In fact, the modular approach to biomanufac-
turing already exists in some areas. At small scale, QIAGEN provides processing
disposable solutions for the purification of plasmid DNA or the preparation of ge-
nomic DNA. The solutions fit in a box that includes all the necessary components to
quickly and easily perform a sequential set of tasks (112). At large scale, and in the
area of protein production, Merck Millipore already offers its Mobius® FlexReady
solutions. Indeed, the main drawback of stainless steel installations is the rigidity of
the pipelines and connections between processing units as well as the impossibility to
switch between units if necessary. Mobius product’s innovation lies in the fact that
each processing unit is preassembled and features all the sterile tubing, connectors
and required handling systems on a moving cart (113). Therefore, units can easily
connect to each other in a modular way. These process options are, however, more
adapted to medium to large scale bioprocessing. In fact, there is currently a gap for
a completely integrated disposable solution for the flexible, cost effective and easy
production of milligram to gram of biopharmaceuticals. An approach here could be
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Table 1.4: Advantages/Disadvantages of single-use systems over stainless steel systems
(111).
Critical Factor Stainless Steel System 
Driver 
Direction 
and Strength 
Single-Use System 
Capital 
investment 
High >>>> Low 
Extractables/ 
leachables 
Low << High 
Area footprint High >> Small 
Sterilisation 
methods 
Steam, dry heat >>>> Gamma irradiation 
Utilities supply 
High use of water, 
steam and cleaning 
agent 
>>>> Low 
Chemical 
compatibility 
Good < 
Limitation due to 
plastic components 
Physical 
compatibility 
Good << 
Temperature and 
pressure constraints 
Solid waste 
diposal 
Low <<< High 
Liquid waste 
disposal 
High >>>> Low 
Energy use 
High for steam 
and WFI water 
>>> Low 
Labour 
requirements 
High >>> 
Pre-assembled and pre-
sterilised 
Scale-up Fully scalable << 
Limitations for some 
process units 
Process flexibility Low >>>> High 
Sterility assurance 
Assurance by SOPs, 
validation and system 
design 
>>>> 
Assurance with sealed 
and pre-sterilised 
systems 
Available 
technologies 
High <<<< 
Some components not 
fully developed 
39
Chapter 1. Introduction
to combine both the concept of “a process in a box” used by QIAGEN, and the
modular approach of bioprocessing, each box corresponding to one processing unit.
The whole boxed package would allow the realisation of all the steps resulting in the
production and purification of biopharmaceuticals “on the bench”. For the concept
to succeed, each processing unit should be a platform, i.e. able to accommodate
many biopharmaceuticals. Each platform should also be interfaceable with each
other not only from a physical , but also biological point of view.
Platform development and process integration are complex tasks, especially with
interdependent, multi-stage processes involved with the production of biopharma-
ceuticals. Process integration methodology typically involves different activities that
have been described in the literature (114).
The first one is called “Task Identification” which aims to explicitly express the
goal to achieve, and describes it as an actionable task. For example: speed-up the
production of therapeutic candidates to support pre-clinical tests. This could be
achieved by developing an integrated platform for the production of therapeutic
proteins using disposable processing technologies. The second, called “Targeting”,
refers to the identification of performance benchmarks ahead of detailed design. In
this project the overall objective is to produce a quantity of 1g of a purified reporter
protein using a transient upstream expression system coupled with a specifically de-
veloped purification platform. Targeting is a structure-independent step. However,
within each stage of the process, targets can be identified and used in the following
stages. For example, in a two stage protein purification process with an overall tar-
get of 99% of purity, the targeting of 95% purity to achieve in the first stage would
lead the scientist to identify the second stage targeting as the removal of 80% of the
contaminants. The third one consists in “Generating Alternatives” or covering the
range of possible solutions to reach the target. For example, reusing Protein A sor-
bent can be an alternative to decreasing the amount of sorbent needed to purify 1g
of mAb. This activity is also aimed to identify the integer and continuous variables:
integer variables correspond to the existence or absence of certain technologies and
pieces of equipment in the solution. Continuous variables correspond to non discrete
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design and operating factors such as flowrates, pressures, units sizes and assembling.
The fourth activity is aimed at selecting the best alternatives, extracting the opti-
mum and/or the most promising solution(s). Finally, the selected alternatives are
tested and analysed by experimentation. Every activity in the methodology goes
through a process of questioning. Some are reported in Table 1.5.
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Table 1.5: Process of questioning in process integration. Adapted from (115).
1. Goal    What solution to achieve the goal? 
2.Targeting Inputs What are the inputs?   
    What standards must they meet? 
  Outputs What are the outputs?  
    What standards must they meet? 
3. Generate  Inputs How is their adequacy assessed? 
Alternatives    Do they need to be stocked, formulated? 
  Outputs How is their adequacy assessed? 
    Do they need to be stocked, formulated? 
  Operations What operations to converts  inputs in outputs? 
    
What tools, equipment and resources are needed to 
complete  
those operations? 
    What resources are generated? 
    What initiates the operation? 
    What terminates it?   
  Connections 
What kind of connections to connect operations between 
each other? 
    
What tools, equipment are needed to connect operations 
between each other? 
  Operator Who or what is the operator? 
    What capabilit ies does the operator require? 
  Controller Who or what serves as a controller?  
    What tools, equipment are needed to control the operations? 
    
What tools, equipment control the informat ion about Inputs and 
outputs? 
4. Select  Inputs Do they fulfil the standards?   
Alternatives  Outputs Do they fulfil the standards?   
  Operations 
What are the best tools, equipment to complete the necessary 
operations?  
    Are they available?   
    Can the operations be integrated? 
    What are the advantages of each operation in terms of : 
     
cost? 
 
     
processing time?  
     
robustness? 
 
   
output's nature and quality? 
      complexity?    
  Controllers Can the number of controllers be min imised?   
5. Analyse of  Operations Can the selected operations reach the target(s)? 
the alternatives   Do the operations need optimisation? 
  Controllers Is the information accurate? 
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1.3 Process development using design of experiment ap-
proach
Experimentation is at the core of any process development. With respect to the
new challenges that biopharmaceutical companies are facing, there is a considerable
need to maximize the benefits of experimentation i.e., increase the amount of mean-
ingful data and perform more thorough process characterisation while minimizing
the number of experiments for quick and cost effective development.
1.3.1 DOE methodology
Any process can be visualised as a black box in which inputs are transformed into
outputs. Input variables, or factors, regroup discrete or continuous controllable,
uncontrollable and unknown variables. The interaction of factors with the process
results in the formation of outputs, also called responses. Some of these responses
are quantifiable and can be used to develop a process.
Process Responses
Inputs:
Unknown variables
Inputs:
Controllable
variables
Inputs:
Uncontrollable variables
Figure 1.13: The process box. Unknown variables regroup both controllable and un-
controllable variables that may affect the process response independently, or via interaction
with the known input variables.
Compared to chemical processes, biotechnology processes are significantly more
complex, involving numerous reactions inside a host cell, most of them being un-
known. This has two consequences: first, product and processes are highly interde-
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pendent and only a slight variation in input variables may significantly affect process
responses. The second is the difficulty of characterising intermediates and narrowing
down the evolution of one response to one particular reaction. In this context, pro-
cess development represents a critical step prior to transfer at manufacturing scale.
The main difficulty being the numerous inputs variables, known or unknown, that
may affect process responses in some way and complexify the characterisation and
optimisation of the process. With regards to this complexity, experimentation should
rely on an organised scientific approach, from the planning through conduction and
analysis of experiments. Moreover, due to the cost and practical concerns, most
experiments are generally conducted at small scale, laboratory experiments being a
small scale representation of what the future manufacturing process could be. Be-
cause the environment greatly differs from the early research experimentation phases
in the laboratory and the manufacturing environment (different experimenter, dif-
ferent lots of chemicals, different equipment, ...) it is critical to assess the robustness
of the process before the transfer to larger scale. It is also of primary importance to
screen for factors that, not varied at small scale, could potentially affect the process
at large scale. These reasons support the idea that experimentation should rely on
an organised scientific approach, from the planning, throughout the conduction and
analysis of experiments.
The full benefits of DOE appear when the comparison is made with one factor
at a time (OFAT) methodology. Conventional experimentation consists in varying
one factor at a time while keeping the others constant and observes the impact on
one or several responses. This operation is repeated for all factors. As described by
Anderson and Whitcomb , this approach presents several disadvantages (116) :
• OFAT fails at estimating the effect of interactions of factors on the response(s).
• OFAT fails at identifying the true optimal conditions (Figure 1.14).
• OFAT requires a large number of experiments to get to conclusions, especially
when continuous factors are involved.
• Process optimisation with OFAT becomes difficult when multiple responses
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evolve differently with a change in factors.
To this list could be added that OFAT does not allow the scientist to know exactly
to what extent the process is robust, as well as how the process responses evolve
from a given distance from the optimum.
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Figure 1.14: OFAT fails at identifying optimal condition. While keeping the factor
X1 constant, five experiments varying factor X2 are performed. Then starting from the
best condition (the centre point in this figure), factor X1 is maintained constant while
another set of five experiments varying factor X2 is carried out. This OFAT approach
leads to the identification of an optimum that is not the true optimum as factor X1 and
X2 are interdependent (Contour plot was generated from a DOE-optimised PEI transient
transfection process in CHO M cells (73)).
DOE mainly differs from OFAT in that all factors studied are varied simultane-
ously, following a previously constructed plan of experiments. Data is statistically
analysed afterwards, thus allowing the scientist to get more information from fewer
experiments. The DOE approach to process development is a multi-stage process.
Firstly, the objective of the experiment dictates the type of DOE design to use. Fol-
lowing this choice, the experimenter identifies the factors and responses that needs
investigating and accordingly sets up an experimental plan. DOE general methods
also apply to experimentation with three basic principles for later meaningful statis-
tical analysis: randomisation, blocking and replication (117). Indeed randomisation
of experiments is a prerequisite to any DOE analysis involving the estimation of fac-
tors significance. Randomisation eliminates the lurking effect of unknown variables
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e.g. time. Blocking, on the other hand, consists of grouping experiments in different
blocks relative to a known influential variable, which the experimenter does not want
to take into account during the analysis of data. In other words, blocking minimises
the variation between experiments that are not accountable to the factors under
study. Finally, replication consists in repeating the full experiments to estimate the
experimental error but also obtain a more precise estimate of a factor effect.
An ANOVA test is then performed to reveal factors and factor interactions that
significantly affect the process response. As opposed to OFAT method, which tends
to gets closer from the optimum by experimentation only, the identification of the
optimum is based on the generation of a mathematical model from the data collected,
and the use of this model to statistically “map” a predicted response across the
design space. This empirical model links process factors (X1, X2, ...,Xn) to one
process response (Y). The same empirical model can be further analysed to map and
identify the extent of process robustness. An infinite number of empirical models
can be generated. But only a few are useful, the rest being misleading. Model
validation is critical for meaningful analysis and often overlooked by experimenters
due to its relative complexity. This will be detailed further in this chapter.
1.3.2 The DOE designs involved in process development
Several types of DOE design exist, each one being tailored for a specific purpose.
Below are presented the designs that are most generally used in process development
i.e. factorial and response surface designs.
Factorial designs are used for screening the factors affecting the process re-
sponses. In this type of design, each factor is balanced at two or more levels, the
experimental values taking the possible combination of levels across the range of
factors screened. When all the possible combinations of factor levels are experimen-
tally tested the design is called a full factorial design. The number of experiments
to perform is relative to the number of factors, as well as the number of levels for
each factor. Factorial designs are effective tools for screening of factors, especially
when the factors are balanced only at two levels. Indeed, with more than two levels
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per factor, the number of experiments to perform become excessive with respect
to the amount of knowledge gained. A viable approach consists of performing sev-
eral 2-levels factorial designs. A large number of factors to screen also leads to an
excessive number of experiments. In this case a viable option is to go for a frac-
tional factorial design in which only a fraction of the full factorial design will be
experimentally tested. The fraction is chosen in the manner that high-order inter-
actions (large number of factors interacting altogether to affect a process response)
are aliased with low-order interactions. The viability of this design relies on the
principle that the effect of high order interactions on process responses is negligible
and that only effects due to main factors or low-order interactions are significant
(118; 119) (Figure 1.15). The number of experiments is as follows:
Number of experiments = levelsfactors−p (1.1)
in which p is a real number as a
1
2p
fraction of the factorial design actually exper-
imentally tested. The effects of different input variables on a process response can
only be assessed and compared if these variables are transformed into normal, di-
mensionless, coded variables. To do so the upper and lower levels of factors are coded
+1 and -1 respectively. Factorial designs are then really useful for the screening of
input process variables, assuming the non-existence of high order-interactions.
Increasing p results, therefore, in smaller experimental design to the expense of
aliasing lower order interactions with main effects. Every experimental design can
be defined by a resolution number that varies according to the number of factors
screened and the number of experiments to perform. The resolution of a design
defines the alias relations between factors and their interactions (Table 1.6). Res-
olution II designs are useless as the effect of main factors are aliased with each
other. Resolution V designs are generally considered safe for most screening steps
as the effect of main factors and low order factor interactions are aliased with high
order factors interactions only (120). The resolution R of the design is sometimes
included in the design notation as an indication. For example a 25−1V is a 2 levels
fractional factorial experimental design of resolution V, including 5 factors and 16
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Figure 1.15: Types of factorial designs. In the example of a 23 full factorial design,
each of the three factors screened is balanced at two levels, bringing the total of the possible
experiments to 8. Reliable information about the process can still be obtained by performing
only a fraction of the total possible combinations. However, the experiments to perform
must be chosen carefully and the effect of some interactions of factors on the response not
identifiable.
Table 1.6: Alias structures associated with different design resolution
Resolution Alias structure 
II Main factors are aliased with each other 
III Main factors are aliased with two factors interaction 
IV Main factors are aliased with three factors interactions. Two factors 
interaction are aliased with each other 
V Main factors are aliased with four factors interactions. Two factors 
interaction are aliased with three factors interactions 
experiments.
Once the few vital factors as well as their interactions have been identified, the
process can be further optimised by looking at optimal combination of factors as
well as their optimal levels that enhance one or several responses in a desired way.
Response surface methods are useful for that matter. During experimentation and
for practical reasons, it is likely that the scientist will not test the exact combination
of factors levels that will lead to the discovery of the true response optimum. Re-
sponse surface methods (RSM) are specific DOE methods aimed at mapping process
responses across a given range of levels of factors. They can provide the scientist with
three and two-dimensional representations of process responses as well as the possi-
bility to predict the response at a given, but not experimentally tested, co-ordinate
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of the characterisation space. This is at the core of experimentation in QbD. As the
experimenter gets closer from the response peak, two level factorial designs do not
provide enough information to adequately model the response. Indeed, close from
the optimum the likelihood to encounter a curvature in the response is relatively
high. To adequately estimate this curvature, more complex designs, such as CCD or
Box-Behnken designs, involving more experimental points are required (121). The
most practical feature of CCD is their ability to be built blocks by blocks. In fact
CCD are augmented factorial designs, with a centre point and several axial points.
The centre point provides information for the estimation of curvature and, when
replicated, for estimation of experimental error. Axial points allow for the accurate
modelling of the process response. (Figure 1.16). The distance of axial points from
the centre point can be varied by the experimenter under four constraints: rota-
bility, orthogonality blocking, operational constraint and the number of factors. A
design is rotatable if the variance of the predicted response at any point depends
only on the distance of the point from the centre point. In other words, the stan-
dard error of all the points at the same distance from the centre point is equal. A
design should also be orthogonally blocked, which means that there is no correlation
among the factors included in the model (122). This property is important for good
estimation of quadratic terms of a model. In general rotability and orthogonality
can both be satisfied by positioning the axial points outside the initial design space
(circumscribed CCD) or by positioning the factorial points inside the design space,
the axial points being at the extreme of the design space (inscribed CCD). The latter
becomes useful when the values that a factor can take are constrained within the
range of the possibility that can physically be investigated. In some cases however, it
is impossible to test the process with factors taking values outside the design space,
whereas accuracy of the model estimates at the extremes of the design space is still
required. In this case, the axial points can be positioned at the extreme of the design
space instead of outside to form a cubic type of design called a face-centred CCD,
or CCF. With a CCF, however, the distance of the axial points and the factorial
points from the centre differ. The design is therefore not rotatable and estimation
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of the quadratic terms of the model is relatively poor (123).
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Figure 1.16: The construction of a central composite design (CCD) starts with
a 23 factorial design. CCD are augmented factorial design with the presence of a centre
point, that provides for the estimation of curvature and pure error and axial points, that
allow accurate modelling of the process response. The distance of the axial points from the
centre point can vary and specify the nature of the CCD used.
Despite increasing popularity, the use of DOE in our industry is not fully adopted
due to several reasons. Firstly, “pure” biologists are not well familiarised with the
technique. Secondly, DOE methodology involves complex statistics which, without
the help of statistical packages, is not practical to adopt. Finally, DOE methodology
reveals its true power when the whole process, from early parameter screening to final
identification of an optimum in response, is developed using a rationally integrated
set of DOE tools. To our knowledge, only one study, published recently, describes a
global integrated DOE approach towards drug and process development (124).
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1.4 Thesis outline
The work presented in this thesis describes the development of a platform for the
production of milligrams to gram of recombinant protein. The platform should
accommodate with the flexibility required by the quick and cost effective production
of multi-products. Innovative technologies such as transient expression, and the use
of statistically driven tools and methods were developed to achieve this objective.
Chapter 2 details the development of statistical tools for the creation of a com-
putational algorithm to considerably simplify, secure and speed up the analysis of
DOE-generated response surface experimental designs. In addition to the algo-
rithm’s unique properties, its performances were compared to three commercially
available statistical packages.
Chapter 3 presents the development of a method for the optimisation of multi-
variate transient gene expression processes in CHO cells. Recombinant mAb titres
could be enhanced 200 fold while maintaining cells viable using non specifically
designed DNA vector, cell-line and culture medium.
The subsequent two chapters elaborates on the development of a purification
train for a reporter mAb protein, and the integration of the processing units. The
main aim was to achieve a reduction of the protein’s contaminants to an acceptable
level for preclinical studies, while maintaining its native conformation. Purification
relies on an integrated three stage chromatography. In Chapter 4, a cation ex-
change resin chromatography step was characterised and developed using a Quality
by Design approach to make it a mAb robust intermediate purification platform.
In Chapter 5, this step was finally integrated with a pre-existing Protein A based
capture step, as well as a developed anion membrane chromatography step as a final
polishing chromatography step. The whole platform was then scaled-up to allow the
production, then purification of 1g of antibody. This Chapter also introduces the
economical aspect of the developed production platform.
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Development of an algorithm
for the automated analysis of
DOE-Response Surface
Methods designs
This work attempts to address the difficulties associated with the building of
empirical regression models for DOE-RSM designs. After presenting the theory
behind the construction of regression models, the Chapter focus on the development
of statistical tools, then an algorithm. Finally, the performances of the algorithm
were compared to those of available statistical softwares through a case-study.
2.1 Introduction
Response surface modelling (RSM) is part of DOE methodology and regroups sev-
eral mathematical and statistical techniques for empirical model building. Empirical
models can be used to estimate the evolution of a process response across a continu-
ous design space, and identify a set of process parameters leading to a minimum or
maximum in response. RSM is, therefore, extensively used in process development
and is systematically used in QbD methodology. RSM is a sequential methodology
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that consists in (Figure 2.1):
1. Formulating the objective of the experiment
2. Choosing the appropriate RSM design
3. Identifying a suitable design space
4. Designing a plan of experiment
5. Performing the experiments
6. Modeling data
7. Analyzing the model
8. Drawing conclusions
Recent reports showed that the FDA strongly encourages biopharmaceutical com-
panies to adopt a Design of experiment (DOE) driven methodology towards process
development. Whilst it is possible to conduct DOE with general statistical softwares,
a recent survey showed that considerable progress still has to be made. Indeed, 29%
of the respondents judged that DOE software packages can lead to “illogical bio-
logical recommendations”, whereas 26% of them found the packages not being user
friendly and 21% too complex (125). This study clearly points out that DOE soft-
wares should eliminate the need for statistical expertise on the part of the user. If
currently available softwares now guide the user through the DOE driven experimen-
tation by performing all the calculations, none to our knowledge tackled the problem
of empirical model selection. Yet, model selection represents the biggest challenge in
RSM. Indeed, the success of a RSM design can be judged by its ability to generate
a model that properly fits experimental data and makes accurate predictions across
the operational space. Generating a model is relatively easy thanks to the avail-
able statistical softwares. However, model validation, prerequisite to the use of the
model, is so far a non-automated task and is the responsibility of the experimenter.
Moreover, several assumptions relative to the model analysis, as well as model char-
acteristics need to be validated or checked prior to using the model. A large number
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Figure 2.1: DOE-RSM approach to experimentation. RSM is a sequential method-
ology aims at modelling experimental data to estimate with confidence a process response
on a continuous scale, as well as identifying a set of process parameters that optimise the
response while minimizing the amount of experiments required to do so.
of models can be generated: 64 for a 3 factors Central Composite Design (CCD) or
a Box-Behnken Design (BBD), 1024 for a 4 factors CCD, and this by limiting the
construction to linear and quadratic models and ignoring three factors and higher
order factors interactions. Selecting the right model trough all these possibilities is
a challenging and time consuming task. Algorithms are frequently used in economy
and medicine to automatically construct empirical regression model. However, as
described by Babyak, they tend to produce overfitted models leading to spurious
conclusions (126). They have also not yet been integrated with DOE methodology.
Moreover, in an industry where development times and costs need to be reduced, it
becomes critical to select, then work, with the most accurate model. In this context,
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the development of statistical tools for the automation of model selection would be
of real value.
In this study we describe the development of an algorithm in Mathematica soft-
ware for the automated selection then analysis of the most accurate model(s) for a
DOE-RSM (BBD, CCD, CCF or CCI with 2,3 or 4 factors) generated set of data.
The algorithm integrates several independent statistical modules to test all the po-
tential models (instead of constructing it step by step) and gradually rules out the
inappropriate ones.
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2.2 Theory
2.2.1 Data modelling
RSM is a specific DOE methodology that produces visual representation of a pro-
cess response based on an empirical model. All empirical models present the same
properties (127):
• The process response, usually noted y
• The mathematical function noted f(~x; ~β)
• The error ,  ∈ R
The mathematical function regroups two coordinate vectors. The dimension of
the vector ~x is equal to the number of model variables (sometimes called regressors),
and varies from one model to another. For example the list of variables of a three
factors full quadratic model will contain the process factors (x1, x2, x3) , but also the
full list of factors interaction (x1.x2, x1.x3, x2.x3) and quadratic terms (x
2
1, x
2
2, x
2
3).
The coordinates of the vector ~β are the regression coefficients or equation parame-
ters. The term  stands for an observation error i.e. the sources of variability not
accounted for in the model, such as measurement error on the response, background
noise, or the effect of other factors than the one studied. The general form of the
model is generally written:
y = f(~x; ~β) +  (2.1)
In DOE, the model is a multiple linear regression model. Low order polynomial
models, such as linear models, are adapted to approximate process responses in a
relatively small design space, or when a curvature of response is not expected across
the design space. In other cases, second order polynomial approximations must be
used. Third or higher order polynomials are, however, generally not needed if the
experimental plan is appropriately chosen at the start (128), i.e. not too wide.
Moreover, the relatively low number of experiments of the two most commonly used
RSM designs, CCD and BBD, do not allow for third-order response approximations
56
Chapter 2. Development of an algorithm for the automated analysis of
DOE-Response Surface Methods designs
without aliasing. For a series of k process variables (x1, x2, .....xk) the model equation
can be written:
y = β0 +
k∑
i=1
βixi +
k∑
i=1
βix
2
i +
∑
i<j
k∑
j=2
βijxixj +  (2.2)
Generally the structure of the relationship between the process response and the
model variables is unknown. In other words, the exact model equation is unknown.
The first step in RSM is, therefore, to find a suitable approximation of the true
relationship. This is done by estimating the coordinates of the vector
~ˆ
β whose
coordinates (βˆ1, βˆ2, ...βˆk) are the estimates of (β1, β2, ...βk), and choosing the right
vector ~x. The estimated regression equation, or fitted model, taking the form:
yˆ = βˆ0 +
k∑
i=1
βˆixi +
k∑
i=1
βˆix
2
i +
∑
i<j
k∑
j=2
βˆijxixj (2.3)
The difference between the observation yi and the model fitted value yˆi is the
residual ei = yi − yˆi. In other words the residuals are the estimation of the errors.
The method of least squares regression used for the construction of linear regression
models consists in finding the coordinates of the vector
~ˆ
β that minimises the sum of
squares of the residuals:
SSE =
k∑
i=1
ei
2 (2.4)
The fitted model can be used to graphically map the predicted response across
the design space as well as identifying the values of the process factors that maximise
or minimise the response. However, before proceeding, a critical step in DOE is to
validate the model.
2.2.2 Model validation
Once the model has been constructed it is critical to verify that (i) the model
accurately fits experimental data, and (ii) is an accurate representation of the studied
process response across the design space.
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2.2.2.1 Quantifying the model ability to fit experimental data
With the computational power of today’s available statistical packages, constructing
complex model is relatively easy. However, complex does not mean appropriate. An
overly complex model will describe noise instead of the actual relationship between
process parameters and process response. This phenomenon, called overfitting, re-
sults in models that overestimate the variations due to experimental error, in other
words, explain error that exists in sample data but do not really exists in the pop-
ulation, and hence will not replicate. The number of model variables is too high in
overfitted models. In other words, overfitted models include one or several variables
that do not contribute to explain true variation in a set of data. Several statistical
tools can be used to screen for overfitted models. The first one is called analysis of
variance (ANOVA). ANOVA consists of simultaneous hypothesis tests to determine
if any of the effects attributed to the model variables is significant or not. ANOVA
relies on computing several statistics:
• Sum of Squares (SS): sum of all the squared effects
• Degrees of freedom (df): number of free units of information
• Mean square (MS): SS divided by df. Computed only for the model and the
model variables.
• F-statistic: MS divided by MS of pure error.
These statistics were calculated for the model, each model variable, the model resid-
ual and the pure error from experiment replicates. In ANOVA, the difference is
made between the Model Sum of Squares and the Error Sum of Squares. The Model
Sum of Squares represents the variability explained by independent variables. The
Error Sum of Squares represents the variability not explained by the Model. These
values are used to calculate the F-statistic. The F-statistic allows for the estimation
of the significance, generally at 95%, of the model and the model variables. As a
general rule, Type III ANOVA are used in RSM because compared to Type I/II
ANOVA, it provides estimates that are not a function of the number of observations
in a group.
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Another statistical approach to assess if a model is overfitted consists in calcu-
lating then comparing two statistics: the R2 and the R2adjusted. The R
2 measures the
amount of variation around the mean explained by the model and can be defined
as:
R2 = 1− SSresiduals
SSresiduals + SSmodel
(2.5)
Usually, the better the regression model, the higher the R2. However, R2 counteracts
the tendency for overfitting data when doing regression. However, as more variables
come into the model, the R2 cannot decrease, whether or not the effect of added
variables is significant. As a result, the R2 cannot be used to discriminate overfitted
models. The R2adjusted statistic, however, takes into account the number of variables
in the model and will decrease with the addition of model variables that do not add
value to the model.
R2adjusted = 1−
SSresiduals
SSresiduals + SSmodel
× dfresidual
dfresidual + dfmodel
(2.6)
As a result, the R2adjusted is always inferior or equal to the R
2. If R2adjusted falls far
below R2, there is a good chance to have non significant terms in the model. This
difference can be used to rule out the models presenting too much overfitting.
2.2.2.2 Quantifying the accuracy of model predictions
The purpose of data modeling is not only to accurately fit experimental data, but also
use the constructed model to make predictions within the range of the experimental
combinations tested. It is therefore critical to validate the ability of a model to
make accurate predictions. The R2predicted measures the amount of variation in new
data explained by the model. This statistic measures the ability of the model to
accurately predict a response from a given factors combination. The computation
of this statistics is based on the calculation of the predicted residual error sum of
squares (PRESS) (129).
PRESS =
n∑
i=1
(
ei
1− hii
)2
(2.7)
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where hii represents the position ii in the diagonal of the hat matrix.
R2predicted = 1−
PRESS
SSresiduals + SSmodel
(2.8)
The closer the R2predicted will be from the R
2
adjusted, the more accurate the model will
be on average. The difference between those two statistics can be used to rule out
the models with poor prediction power. As a rule of thumb, a difference inferior to
0.2 is considered acceptable.
Prediction interval also represents a valid solution to assess the ability of a model
to make accurate predictions. A prediction interval is an estimate of an interval in
which future observations will fall with a certain probability. Boundaries from the
prediction interval can be calculated using:
yˆ ± t1−α/2,ν σˆp (2.9)
where yˆ denotes the estimated value of the regression function, t1−α/2,ν is the 1−α/2
critical value from the student-t distribution with ν degrees of freedom and
σˆp =
√
σˆ2 + σˆ2f (2.10)
where σˆ2 is the estimate of the residual standard deviation and σˆ2f the estimate of
the standard deviation of the predicted response for the experimental data.
Available softwares usually provide the user with an interval of confidence around
the optimum in response. If this confidence interval is useful, it would also be of
importance to know the confidence intervals around the factors value leading to this
optimum. To our knowledge, commercial softwares only identify the set of factors
values leading to an optimum in response, but do not calculate their associated
confidence intervals. A way to calculate those intervals is to use the fact that,
theoretically, an infinity of models with same fitting and prediction power can be
constructed by varying only the model parameters values. Those models, however,
will predict different response optimum and factors combinations. By assuming that
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each model parameter follow a normal distribution, each parameter value can take a
different value within a given confidence interval. Moreover, model parameters are
correlated. Indeed, in order to yield a model with the same fitting and prediction
power a change of value of one or several model parameter implies a change in other
model parameters to adjust the new model to similar model characteristics. Using
a general mathematical software, it is possible to use a multinormal distribution
to generate as many models with same fitting and prediction power as wanted.
From this list of models it is therefore possible to calculate a standard deviation
around the studied process factors optimum leading to an optimum in response.
Due to their relative complexity, and the fact that most mathematical software
include multinormal distributions function, the detail of the calculations will not be
presented in this chapter, but can be found in the code presented in appendix.
2.2.2.3 Least square assumptions verification
The use of least square regression is conditioned by fundamental assumptions be-
tween the studied process parameters and the process response. As described in
(130), “Knowledge and understanding of the situations when violations of assump-
tions lead to serious biases, and when they are of little consequence, are essential to
meaningful data analysis”. From a practical point of view it is more convenient to
check model assumptions by diagnosing the residual’s population for:
• normal distribution (i)
• independence of residuals (ii)
• constant variance (homoscedasticity) (iii)
• zero mean (iv)
Generally these assumptions are checked using studentised residuals rather than
raw residuals. Indeed, it is not unusual to have great variation in residual stan-
dard deviation, especially when measured observations vary by several orders of
magnitude. Studentised residuals are raw residuals divided by their estimated stan-
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dard deviation. Because residuals do not all have the same variance, studentising is
helpful when it comes to compare residuals (131).
(i) Regression assumes normal distribution of model residuals. Non-normality
may affect the Fisher test of significance used in ANOVA. There are several ways to
check for normality of a population. The Shapiro-Wilk test tests the null hypothesis
that a population is normally distributed. It is proved to be more efficient than
numerous other tests such as the Kolmogorov-Smirnov test (132, 133). The test is
based on the calculation of a statistic W .
W =
(
∑n
i=1 ai(x(n−i+1) − x(i))2∑n
i=1 (xi − x¯)2
(2.11)
with x(i) being the i
th sample value, n the sample size, x¯ the sample mean and ai are
constants generated from the means, variances and covariances of the order statistics
(available in tables). The W statistic is then compared to a p-value. If the p-value
is inferior to the chosen alpha level (0.05 or 0.01) the null hypothesis is rejected (at
95 or 99% respectively) and the sample distribution is considered normal.
Non-normality of a population can also be visually detected using normal proba-
bility plots. As described by Filiben et al., a normal probability plot can be generated
by plotting the quantiles of the observed sample as a function corresponding to the
normal N(0,1) order statistics medians (134). A linear function can also be fitted to
the studentised residuals to help assess the normality of the distribution, the further
the residuals being from the line, the greater the departures from normality (Fig-
ure 2.2). However, the Fisher significance test is “quite” robust to small departures
from normality. Therefore the experimenter should not worry if a slight non linear
points pattern is visible (116). In case of significant departures from normality, data
can be transformed using a Log, Inverse, Inverse Log, Square root or inverse square
root transformation which can in some cases normalise the residual distribution.
(ii) Residuals should be independent from the tested factors’ levels. In other
words, plots showing residual distribution versus factors levels should present a
random pattern. Experimenters should especially look for conical or curved patterns
which indicate that a high order term is missing from the model equation or that
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Figure 2.2: Normal probability plot. This type of representation is often used to
visually assess the normality of the residual distribution. Several statistical tests are also
available for this purpose like the Shapiro-Wilk test for example. In this example, points
deviate from a straight line, so the normality assumption may not be satisfied.
data need a square root/inverse square root transformation (119).
(iii) and (iv) Homoscedasticity and residual zero mean can be checked at the same
time. More importantly, by plotting the residuals versus the model fitted values,
and looking at the distribution pattern, it is possible to assess which assumption
is broken. The assumptions are validated if the residuals are distributed in a non-
patterned fashion around 0. A curved pattern indicates that a quadratic term is
missing from the model equation. A conical pattern (variation in residuals increasing
or decreasing with an increase of fitted values) proves that the constant variance
assumption is violated. Potential outliers, which usually have a much larger residual
than the rest of the observations, can also be detected using this plot.
2.2.2.4 What to do if violation of assumptions occur? The Box-Cox
transformation
In situations where one or several least square assumptions are violated, a power
transformation can be applied to the data. The benefits from it depend entirely
on the set of data but can include an improvement in the normality of the residual
distribution and more stable variance. Power transformations are merely trans-
formations that raise numbers to an exponent. Therefore, an infinity of different
transformations can theoretically be applied to a set of data. However, the most
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common includes adding a constant, or a conversion to square root
(
y0.5
)
, inverse(
y−1
)
or logarithmic (log(y)) scales. With the computational power available to-
day, the difficulty does not lie in applying the transformation, but in identifying the
transformation to apply. In 1964, Box and Cox solved this problem by publishing
a method allowing to identify the power transformation λ that will minimise the
residual sum of squares (135). For normal distribution of residuals, the Box-Cox
distribution is written:
yλ =
yλ − 1
λ× y¯λ−1 for λ 6= 0
yλ = y¯ln(y) for λ = 0 (2.12)
where y¯ is the geometric mean of the data with n observations:
y¯ = Exp
(∑n
i=1 ln(yi)
n
)
(2.13)
Myers et al. went further by including a confidence interval for λ that can be found
by computing (136) :
SS∗ = SSR(λ)
(
1 +
t2α/2,ν
ν
)
(2.14)
and by locating the two coordinates where SS∗ intercepts the curve SSR(λ) (Fig-
ure 2.3). If the confidence interval contains 1, there is no need for transformation.
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Figure 2.3: The Box-Cox procedure applied to a central composite design set of
data In this example the optimal λ = 0.12 and the 95% confidence interval includes 0 and
excludes 1. The use of a log transformation is therefore indicated.
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2.3 Algorithm development
Because model selection and validation are relatively complex due to the multiple
and interdependent statistics that need to be checked, it was decided to design a
computational algorithm that will automatically perform these tasks for the exper-
imenter. The algorithm was written in Mathematica (Wolfram Research, Cham-
paign, IL) and is structured around a “mother file” that calls different “modules”
in a given sequence to (i) generate all the possible models with respect to the type
of DOE design and (ii) gradually rule out the models that do not satisfy a good
data fitting and good prediction power. The first step of this work was to create a
library of the necessary modules to write the algorithm. This library is presented in
Table 2.1. The modules call for one or two inputs and generate an output. Under
this format, the modules can easily be integrated in any order desired to provide
the experimenter with a maximum of flexibility with respect to the development of
an algorithm. Each module codes for a specific operation i.e. a Shapiro Wilk test,
a Box-Cox transformation, the generation of a list of models from a set of data, etc.
The presence of a model variable in the model equation is conditioned by a test
of significance, usually based on an ANOVA type III. ANOVA type III are generally
used in DOE because of the treatment of unbalanced set of data and the potential
significance of factors interactions. Algorithms for model construction have been
developed in the past. They are based on a “forward” or “backward” procedure
whether the model variables are sequentially added or removed from the model
equation. This method is flawed as in type III ANOVA, the calculated results at-
tributed to one model variable are correlated to the variation attributable to the
effect after correcting for any other effects in the model. In other words, the signif-
icance of an effect of a model variable may depend on the presence or absence of
other model variables in the model. Moreover, some developed algorithms took into
consideration the overall model significance as only statistics to validate the model
selection. However, with a type III ANOVA, the test for model significance can be
positive while the effect of some model variables was not significant. This results is
the selection of an overfitted model.
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Table 2.1: Library of created modules.
Module name Purpose Input Output 
ModelsGenerator 
Generate a list of all the regression models 
equation that can apply to a set of data, without 
aliased variables. 
Data set List of models equations 
ModelsEqGenerator 
Generates a list of all the regression models 
formal equation that can apply to a set of data, 
without aliased variables. 
Data set List of formal models equations 
ShapiroWilkTest 
Performs a Shapiro-Wilk test of normality and 
answer the question: is the residual distribution 
not normal? 
Fitted model "Yes" or "No" 
BoxCoxTransformation Performs a Box Cox transformation i.e. check if a data transformation is recommended. 
Fitted model, 
Formal fitted 
model equation 
A grid with the recommended power 
transformation, Lambda and lambda 
confidence interval limits. 
DataTransformation Generates a new data set applying a power transformation to the studied/observed data. 
Data set, Power 
transformation A new data set. 
ModelSignificance Test the model significance at 95% using an ANOVA. Fitted Model "Yes" or "No" 
ModelOverfitting Test if the model is overfitted Fitted Model "Overfitted" or "Not overfitted" 
ModelStatistics Calculates the model associated principal statistics: R-sq, Adj-R-sq, Pred-R-sq Fitted model 
A grod with the model associated principal 
statistics: R-sq, Adj-R-sq, Pred-R-sq 
ModelOptimums 
Generates a grid with the optimal predicted 
studied response as well as the factors leading to 
it and their associated confidence intervals 
Formal model, 
Fitted model 
A grid with the optimal predicted response, 
the optimal factors leading to it, and their 
associated confidence intervals. 
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ModelResAnalysis 
Perform the model residual analysis 
(independence vs factors, linearity and 
homoscedasticity. 
Fitted model A table with the charts needed for the validation of the model residuals behavior. 
ModelContourPlots Generates contourplots associated with a model. Fitted model 
Generates contourplots associated with a 
model. The number of contourpolots 
depends on the nature of the design. 
Each module performs simple operations and requires one or several inputs to generate one output. The code behind each module can be visualised in
Appendix.
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The algorithm developed in this study was based on the construction of all possi-
ble models with respect to any CCD (2,3,4 factors) and BBD generated set of data.
The first step performed by the algorithm was to import the experimenter data from
an excel file. The algorithm then constructs all the possible models: simple linear
to full quadratic with all the intermediates. The algorithm then performed several
loops in sequence aimed at testing a specific criteria, one model after the other. The
first loop included a Shapiro-Wilk test that tested for the model’s residual’s normal
distribution. If the distribution was estimated normal, the model was saved into the
list “TableResNormalModels”. If not, a Box-Cox- transformation was applied. If a
power transformation other than 1 was indicated by the Box-Cox transformation,
the data was transformed and a new model with the same variables was fitted to
the data. Whether or not the distribution of the residuals of the new model was
normal, the model was saved into the list “TableResNormalModels” (Figure 2.4).
For each model in “TableResNormalModels”, a type III ANOVA was then per-
formed. Significant models were saved into a newlist: “TableSignificantModels”.
For each model in this list, if the p-value associated to at least one model variable
was superior to 0.1, the model was rejected. This step ensured to reject all the
overfitted models. If the p-values associated to the model variables were inferior or
equal to 0.1, the model was compiled into the list “GoodFittingModels”. For each
model of this list, if the difference between the R2adjusted and R
2
predicted was superior
to 0.2, the model was compiled into the list “Potential Models”. This step ensured
to select only the models that presented a good prediction power (Figure 2.5).
Finally, for each model in the “PotentialModels” list, a full analysis was per-
formed. Because, the validation of homoscedasticity and independence assumptions
on residuals can only be checked visually, the algorithm provided the user with the
necessary plots to select the most appropriate model. At this stage generally, only
a few models (less than 10) are present in the list. Therefore, this visual check can
be performed quickly.
At the different steps of the algorithm, if any list was found empty, the user was
warned of the presence of one or several outliers in the data provided.
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Import data
Models generation into a list:
“C andidates”
Models equation generation
into the list: “ModelE qs”
ModelsGenerator
ModelsEqGenerator
Select Model i
Residual
distribution not
normal?
Box-Cox
Transformation
Recommended
power
transformation
≠1 ?
Data
transformation
Generation of a
new model
Residual
distribution not
normal?
Compile into the list:
“TableR esNormalModels”
Yes
Yes
Yes
No
No
ShapiroWilkTest
No
BoxCoxTransformation
DataTransformation
ShapiroWilkTest
Select Model i+1
Model i last
model in
“C andidates”?
No
Yes
End
Figure 2.4: First algorithm loop: ruling out the models that present a non
normal model’s residuals distribution. Several modules were used in this algorithm
loop. They are indicated in italic.
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“TableR esNormalModels”
Model
Significant?
Compile into the list:
“TableS ignificantModels”
Yes
No
ModelSignificance
Select Model i
Select Model i+1
Last model in
“C andidates”?
Yes
“TableS ignifican
tModels”
Empty?
Warn the userYes
No
Model
overfitted?
No
Select model i in:
“TableS ignificantModels”
Compile into the list:
“GoodF ittingModels” Select Model i+1
Last model in
“GoodF ittingMo
dels”?
Yes
No
Yes
“GoodF ittingMo
dels”
Empty?
Warn the userYes END
No
END
ModelOverfitting
70
Chapter 2. Development of an algorithm for the automated analysis of
DOE-Response Surface Methods designs
Select model i in:
“GoodF ittingModels”
Accurate
predictions?No
ModelStatistics
Compile into the list:
“PotentialModels” Select Model i+1
Last model in
“GoodF ittingMod
els”?
Yes
No
Yes
“PotentialModels”
Empty?
Warn the user
Yes
Model analysis
ModelOptimums
ModelStatistics
ModelResAnalysis
ModelContourPlots
Select model i in:
“PotentialModels”
Compile into Output Select Model i+1
Last model in
“GoodF ittingMod
els”?
Yes
No
Show Output
No
END
Figure 2.5: Algorithm for model selection. The modules used in the algorithm are
indicated in italic on the figure.
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2.4 A case-study: the optimisation of a PEI mediated
transfection process in CHO cells
The algorithm was validated using twenty four DOE generated set of data including
BBD (six designs), two, three and four factors CCD (three, twelve and three designs
tested respectively). Data sets were found in books or generated from experiments in
house (116, 121, 136). The algorithm output was compared to the ouputs of other
statistical packages including Design-Expert® 7.0 (Stat-ease, Minneapolis, MN),
Minitab® 16 (MinitabState, State College, PA) and JMP® (SAS Institute Inc.,
Cary, NC). A case study is presented below, in which a PEI-mediated transfection
process was optimised using a three factors CCF, then a BBD.
2.4.1 Experimental method
The aim of the experiment was to optimise a PEI-mediated transfection process in
CHO cells. More specifically, identify a combination of PEI, DNA and cell concen-
trations at transfection that would maximise protein titres 5 days post transfection.
CHO-S cells were routinely cultured in vented 250mL shake flasks in a 5% CO2
orbital shaker (125rpm, OT of 25mm) in CD-CHO (Life Technologies, Paisley, UK)
supplemented with 8mM of glutamine (Lonza, Slough, UK) and passaged when the
the culture reached mid exponential phase. Prior to transfection, cells were diluted
to the desired concentrations in 50mL CultiFlasks (Sartorius AG, Goettingen, Ger-
many) in CD-CHO supplemented with 8mM of glutamine in a total volume of 5mL.
The reporter plasmid used in this study coded for the secreted alkaline phosphatase
protein (SEAP). The plasmid construction details can be found in (73). PEI chemi-
cal (25 kDa linear, Polysciences, Warrington, USA) was dissolved into water at 1mg
mL-1 and stored at -20°C. On the day of transfection, in separate micro-centrifuge
tubes, the desired quantities of PEI and DNA were diluted with an equal volume
of NaCl 300mM. PEI and DNA were then mixed together and allowed to complex
for 1min in a total volume of 333µL made up with 150mM NaCl. The PEI/DNA
solution was then added to the cells. CultiFlasks were immediately orbitally shaken
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by hand and directly placed in an incubator at 37°C in 5% CO2 with orbital shak-
ing at 170rpm and an orbital throw of 50mm. Cultures were harvested after 5
days. Cell concentration and viability were assessed using trypan blue exclusion
method on a Vi-Cell (Beckman-Coulter, High Wycombe, UK). Samples were taken
and stored at -20°C for SEAP quantification using the SensoLyte® pNPP Secreted
Alkaline Phosphatase colorimetric reporter gene assay kit (Cambridge Biosciences,
Cambridge, UK) according to manufacturers instructions.
First experiments were performed following a three factors CCF design. PEI
concentrations were varied from 7.5 to 20µg mL-1, DNA from 1 to 10µg mL-1 and
cells from 0.50E+06 to 2.50E+06 cells mL-1. Then the process was re-optimised
using a BBD design for which PEI concentrations ranging from 11 to 19µg mL-1,
DNA from 7 to 11µg mL-1 and cell counts from 1.75E+06 to 2.75E+06cells mL-1.
2.4.2 Algorithm performance for the CCF
The algorithm output consisted of a list of two models. Out of the 64 models initially
generated, nine did not meet the requirements of normal model’s residuals distribu-
tion. Out of the 55 remaining, nine were found not significant at 95%. Among the 46
remaining a vast majority (40) were overfitted. In the end, four of the good fitting
models were not making accurate predictions and were discarded and the algorithm
output consisted of a list of two models. For both models, the data was transformed
using a 0.5 power transformation. The models did not present any violations of
residual homoscedasticity or independence. The predicted optimal concentrations
of DNA, PEI and cell at transfection were very similar for both models. How-
ever one model presented better statistics in terms of fitting power (higher R2adjusted
and low difference between R2 and R2adjusted) as well as prediction power (higher
R2predicted and low difference between R
2
adjusted and R
2
predicted) (Figure 2.6). Model 2
was therefore selected and used to identify the combination of DNA, PEI and cell
concentration for which an optimum in reporter protein yield could be achieved.
In the available statistical softwares, the experimenter can generally enter exper-
imental data and automatically generate a model constructed with a list of model
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variables of their choice (linear, linear with interactions, quadratic, etc). Using the
same list of model variables of the model selected by the algorithm, models were
constructed in Design Expert, Minitab and JMP, and analyzed. Model statistics
were then compared (Table 2.2). The model fitting and prediction statistics (R2,
R2adjusted and R
2
predicted) were similar across the different platforms. However, the
algorithm is the only one to integrate the use of a Shapiro-Wilk test to check the
normality of the model’s residuals distribution. Indeed, a Shapiro-Wilk test can be
performed using Minitab and JMP but requires the experimenter to first create the
model, then isolate the residuals as a list and independently perform the test in a
new data table. Shapiro-Wilk statistics were calculated in both Minitab, JMP and
GraphPad Prism® (GraphPad, San Diego, CA) and shown to be equal to the one
calculated by the algorithm (data not shown), proving that the test was executed
correctly by the ”ShapiroWilk” module.
All programs are able to perform a Box-Cox transformation. However, slight
differences in the lambda values, as well as confidence intervals, could be observed.
As Design Expert and the algorithm use the same calculations and Box-Cox trans-
formation, the differences between the algorithm and Design Expert were due to
calculation approximations within both programs (137). The differences observed
with Minitab and JMP are probably due to a different Box-Cox transformation used.
2.4.3 Algorithm performances for the BBD
The algorithm output consisted of a list with 6 models. Out of the 64 models initially
generated, 14 did not meet the requirements of normal model’s residuals distribu-
tion. The total 50 remaining were significant at 95% according to the ANOVA
tests. However, 43 of them were overfitted. Out of the seven remaining, only one
was found not acceptable with a R2adjusted − R2predicted equal to 0.2136. None of the
six remaining models (”potential models”) were constructed from a transformed set
of data, mainly because transforming the data did not lead to significantly lower
SSresiduals. Out of the six models proposed four presented significant violation of
residual assumptions of independence and/or homoscedasticity. Therefore, from this
74
Chapter 2. Development of an algorithm for the automated analysis of
DOE-Response Surface Methods designs
Model 1
Model Optimums
Model Statistics
Model Equation
Box Cox results
Model 2
Model Optimums
Model Statistics
Model Equation
Box Cox results
Response x 1 x 2 x 3
Optimum 5.66981 15.561 10. 2.03444
95 C. I . 0.37474 0.780103 0. 0.327252
RSq Adjusted RSq Pred RSq Adj RSq Pred RSq
0.846127 0.775109 0.590735 0.184375
9.62451 1.61866 x 1 0.0646789 x 1
2 0.395096 x 2 0.035414 x 1 x 2 4.06443 x 3 1.03278 x 3
2
RecommendedTransformation Lambda LowCI HighCI
0.5 0.3 0.0792183 0.429972
RSq Adjusted RSq Pred RSq Adj RSq Pred RSq
0.867163 0.819721 0.708302 0.11142
2.67171 0.683537 x 1 0.0284922 x 1
2 0.22055 x 2 0.018839 x 1 x 2 0.353207 x 3
RecommendedTransformation Lambda LowCI HighCI
0.5 0.3 0.107699 0.659343
Response x 1 x 2 x 3
Optimum 6.77584 15.2928 9.8234 2.5
95 C. I . 0.1031 0.5217 0.1895 0.
Figure 2.6: The algorithm output for the CCF design included two models.
Out of the 64 models constructed, only two models were selected by the algorithm. The
model 2 presented better data fitting (higher R2adjusted and low difference between R
2 and
R2adjusted) and ability to make accurate predictions (higher R
2
predicted and low difference
between R2adjusted and R
2
predicted).
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Table 2.2: The exactitude of the calculations performed by the algorithm, was
validated by comparing the calculated model statistics between the algorithm,
and other commercial statistical softwares.
 Design 
Expert Minitab JMP Algorithm 
R2 0.8672 0.8672 0.8672 0.8672 
Adjusted R2 0.8197 0.8197 0.8197 0.8197 
Predicted R2 0.7083 0.7083 - 0.7083 
          
Shapiro Wilk statistic -  -*  -* 0.8769 
     
 
        BoxCox 
    Box Cox LowCI 0.04 0.41 - 0.12 
BoxCox HighCI 0.68 1.09 - 0.65 
Lambda 0.36 0.72 0.6 0.3 
RecommendedTransformation 0.5 0.5 - 0.5 
 
        
Optimums 
    Optimum predicted response 6.7454 7.1637 7.1639 6.7758 
Response Confidence interval 0.1296 0.1520 0.1031 
Optimum factor x1 14.9126 15.3153 15.3011 15.2928 
Factor x1 confidence interval - - - 0.5217 
Optimum factor x2 9.6395 10.0000 9.8234 
Factor x2 confidence interval - - - 0.1895 
Optimum factor x3 2.3491 2.5000 >2.5 
Factor x3 confidence interval - - - - 
- 
10.0000 
2.5000 
For a CCD, using the same model variables of the model identified using the algorithm, new
models were constructed in Design Expert, Minitab and JMP. Models statistics, as well as
the combination of DNA, PEI and cell concentration leading to a maximum in response,
were then compared. The model statistics across all the platforms are comparable. The
developed algorithm however offers the advantage of computing confidence interval for the
optimal factors value.
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Table 2.3: Comparison of the calculated model statistics within different pro-
grams for the Box-Behnken design.
 Design Expert Minitab JMP Algorithm 
R2 0.9753 0.9753 0.9753  0.9753 
Adjusted R2 0.9560 0.9560 0.9660  0.9560 
Predicted R2 0.8790 0.8790 - 0.8790 
  
             Shapiro Wilk statistic -  -*  -* 0.9634 
         
BoxCox 
    Box Cox LowCI 0 -1.62 - 0.2984 
BoxCox HighCI 3.49 2.92 - 3.2570 
Lambda 1.85 0.43 1.8 1.9000 
RecommendedTransformation None 0.5 - None 
 
    Optimums 
    Optimum predicted response 7.3467 7.3469 7.3467 7.4172 
Response Confidence interval 0.1509 - 0.3415 0.1324 
Optimum factor x1 17.3506 17.3623 17.3609 17.6141 
Factor x1 confidence interval - - - 0.5014 
Optimum factor x2 9.0039 9.0136 9.0064 9.0490 
Factor x2 confidence interval - - - 0.0439 
Optimum factor x3 2.7500 2.75 2.7500 >2.75 
Factor x3 confidence interval     
analysis, only two models only showed to be appropriate for use. The one presented
in Figure 2.7 presented a lower difference between the R2adjusted and the R
2
predicted
(0.076991 for the first one, 0.152971 for the second). A comparison of the calculated
model statistics and factors optimal concentrations across the different statistical
softwares and the algorithm did not reveal any significant differences (Table 2.3).
Major differences were observed for the Box-Cox transformation associated calcula-
tions, most probably because of the different way the transformation is coded and
applied within the softwares and the algorithm.
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Model 1
Model Optimums
Response x1 x2 x3
Optimum 7.43934 17.8049 9.03267 2.75
95 C.I. 0.0866722 0.669199 0.0598217 0.
Model Statistics
RSq Adjusted RSq Pred RSq Adj RSq Pred RSq
0.975257 0.956013 0.879022 0.0769908
Model Equation
0.0399074 x12 0.344391 x3 x1 0.438185 x1 0.173612 x22 1.5607 x32 3.12724 x2 9.86448 x3 3.43254
Box Cox results
RecommendedTransformation Lambda LowCI HighCI
1 1.9 0.603976 3.00348
- + +
-
- + + - -
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Points in the charts above should distribute around the 0 line in a random pattern.
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Points in the graph above should distribute randomly around the 0 line
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Figure 2.7: The algorithm output for the Box-Behnken design. The output pro-
vides the user with the analysed models that can be used. Here, only one model is shown.
The output generates a report that includes the model optimums, equation and other fitting
and prediction powers statistics, graphs to check for residual independence and homoscedas-
ticity and two dynamic contour plots.
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2.4.4 Summary
The algorithm and the statistical softwares were able to provide the user with a
predicted maximum in response (protein titres) as well as the concentrations of
PEI, DNA and cell leading to it (those optimal values are explicitly reported in
Chapter 3). The optimal concentrations slightly varied with respect to the program
used. However, the confidence intervals provided by the algorithm suggested that
these differences were not significant and therefore most probably due to different
combination of model parameters. Indeed, theoretically, an infinity of models with
same fitting and prediction power can be constructed by varying only the model
parameters values. The algorithm took advantage of this property to generate hun-
dred of models and calculate the confidence intervals around the predicted optimal
concentrations.
79
Chapter 2. Development of an algorithm for the automated analysis of
DOE-Response Surface Methods designs
2.5 Discussion
The developed algorithm fills a gap left by commercial statistical softwares: the auto-
mated selection of an empirical model that both satisfies good fitting and prediction
properties as well as the assumptions associated with linear regression (Table 2.4).
The algorithm also proposes an accurate and more detailed model analysis with
the calculation of confidence intervals around all predicted optimums (response and
studied factors). Moreover, experimenters do not need to possess a broad knowl-
edge of statistics to draw reliable conclusions from their set of data. Indeed, the only
input required from the experimenter is an Excel file containing the experimental
data. As a result, the use of algorithm considerably mitigates the risk of making
mistakes during the model selection and analysis.
The main drawback is the need for the experimenter to possess the Mathematica
software. The algorithm execution takes less than a minute for a three factors CCD
and less than two on average for a four factors CCD. The algorithm presents another
significant advantage over commercial statistical softwares: flexibility. Indeed, the
algorithm is constructed in a modular way. Each module being independent they can
be rearranged to create new algorithms. More importantly, recent surveys showed
that DOE methodology implementation in industry suffers from the risks of misusing
the methods, or available softwares. The risks of making mistakes during model
selection and analysis is thought to be particularly high when using JMP or Minitab.
Indeed, in these softwares the model selection and analysis fall to the experimenter.
Moreover, the tools to assess the suitability of a model are either not present, or
difficult to access without a strong statistical knowledge. JMP and Minitab main
advantage remains in the user interface, made of icons on which the user can ”point
and click”. Design Expert is thought to be more intuitive, providing the user with the
tools and graphical representations to select an appropriate model. However, in this
case as well, the model selection falls to the experimenter. This algorithm attempts
to address these concerns as the automation of the model selection significantly
mitigates those risks.
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Table 2.4: Comparison of software and algorithm functionalities.
 Design Expert Minitab JMP Algorithm 
Purpose 
Plan of experiment 
Model construction 
and analysis 
Plan of experiment 
Model construction and 
analysis 
Plan of experiment 
Model construction and 
analysis 
Model construction, model 
selection and analysis. 
Residual analysis     
    Residual type Native/ Studentized 
Native/ 
Standardized 
Native/ 
Studentized Studentized 
    Normal distribution check Half normal plot (visual) 
Half normal plot (visual)/ 
Various normality tests 
Half normal plot 
(visual)/ Various 
normality tests 
Shapiro-Wilk test 
    Independence, 
Homoscedasticity, Linearity 
 
Distribution pattern 
(visual) 
Distribution pattern 
(visual) 
Distribution pattern 
(visual) Distribution pattern (visual) 
Integrated Box-
Cox transformation
 Yes No  
 
No
 
Yes 
Model selection 
(Automated - Manual) 
 
  Manual  Manual  Manual  Automated 
Risk of error in model selection 
(None-High-Very high) High Very high Very high None 
Amount of knowledge required 
(None-Low-High) Low High High None 
Flexibility 
(None-Low-High-Very high) Low High High 
 
Very high via 
the library of modules. 
While the algorithm is limited to the data analysis only, the algorithm is fully automatic which prevents the source of error, check the assumptions
relative to the construction of empirical model, and ensure that the empirical model selected is the most appropriate
81
Chapter 3
Multivariate optimisation of
transient production processes
using an integrated set of
”Design Of Experiment” tools
This Chapter presents a holistic approach to the development of transient
transfection processes. The aim was to validate that, using an integrated set of
DOE tools, it was possible to characterise, then optimise a process in a more
efficient manner than by using a traditional one-factor-at-a-time experimental
approach.
3.1 Introduction
Transient gene expression (TGE) allows for the quick conversion of a recombinant
gene into protein product, without the need of long and labour intensive screen-
ing and amplification methodologies that underpin the development of a stable cell
line. Among the basal process variables involved in transient gene expression pro-
cesses, the concentrations of DNA, DNA vehicle and cells at transfection are almost
systematically subject to optimisation in the studies attempting to develop a TGE
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process. However, a comparative analysis of the results published highlights that
the optimal combination of these variables is case-specific (Table 1.2). This sug-
gests that numerous other factors such as the transfection protocol, the cell line or
the culture medium, may critically influence the process efficiency as well. More-
over, if an efficient transfection is a prerequisite to a high yielding process, the
expression of the transgene also represents a major obstacle. Isolated studies report
the introduction of isolated process design innovations such as mild-hypothermia
which consists in lowering the temperature of cultivation, or the addition of histone
deacetylase inhibitors such as valproic acid or sodium butyrate, could significantly
enhance transgene expression by preventing the condensation of transgene DNA.
In other words, despite its apparent simplicity, TGE is a complex process whose
efficiency is underpinned by numerous interdependent factors. In this context, a
rational approach such as the one presented in Figure 3.1 for a holistic development
of a TGE process, combined with the use of design tools to reduce the complexity
and time taken to explore and generate a viable production process would be of real
value.
Under the acronym DOE lies a set of statistical and mathematical techniques
that present a preferable alternative to the one-factor-at-a-time approach to exper-
imentation. Firstly, DOE is a rational method that focuses on characterizing the
process by identifying the major influencing process variables, then optimising these
variables simultaneously to develop a high yielding process. In other words, DOE
takes into account the potential effect of process variable’s interactions on a process
response. Secondly, DOE derived plan of experimentation are constructed in such
a way that, combined with a thorough statistical analysis, meaningful information
can be obtained in a minimum amount of time and experiments. In a recent study, a
PEI-mediated TGE process was successfully optimised using a DOE approach (73).
However this study limited itself to the optimisation of the basal variables involved
in a PEI-mediated transfection process. Here we describe a rational and integrated
method for the flexible, holistic and rapid development of a transient gene expression
platform in CHO cells. Using this approach it was possible to enhance the titres of
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Culture strategy, Vessel
Screening
Characterization
Optimisation
Screening
2. Secondary Variables
3. Process Design
DNA vector, Cell line, Vehicle, 
Transfection protocol, 
Culture medium
[DNA]º, [Vehicle]º, [Cell]º
Continuous
Discrete
Transfection enhancer
rDNA expression enhancer
Cell maintenance
Experimenter requirements:
Material 
Product quality, quantity
Characterization
Optimisation
1. Basal Variables
Figure 3.1: Rational and holistic development of a transient expression process.
The variables underpinning a transient gene expression process can be classified in three
categories. The basal known variables, without which the process does not exist, regroup
both discrete and continuous variables. The nature of the combination of basal variables is
chosen according to the experimenter needs. The second category regroups all the variables
aimed at improving either the transfection or the protein expression efficiency. The effect of
most of these variables is case specific and unknown prior to experimentation. As a result,
a screening step is generally necessary to keep the vital few over the trivial many variables.
The last category regroups the process design variables such as the mode of culture or the
bioreactor type.
a recombinant mAb by more than 200 fold in 45 days.
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3.2 Material and methods
Cell culture: CHO-S cells (Life Technologies, Paisley, UK) were routinely cul-
tured in vented Erlenmeyer shake flasks (Corning, Surrey, UK) in CD-CHO medium
(Life Technologies, Paisley, UK) supplemented with L-glutamine (Sigma-Aldrich, St.
Louis, USA) at a concentration of 8mM, at 37°C in 5% (v/v) CO2 with orbital shak-
ing at 140 rpm. Cells were re-suspended in fresh medium every 3-4 days at a con-
centration of 2.00E+05 cells mL-1. Cell concentration and viability were routinely
measured by an automated Trypan Blue exclusion assay using a Vi-CELL® counter
(Beckman-Coulter, High Wycombe, UK) according to manufacturer’s instructions.
Reporter plasmids: Two different plasmids were used in this study. The first one,
available in-house, was based on pSEAP2-Control (Clontech, Mountain View, CA)
backbone. The SV40 enhancer of pSEAP2-Control was deleted by partial diges-
tion with HpaI and BamHI. After blunting the ends with Klenow enzyme (Roche,
Penzberg, Germany), the DNA was self-ligated. CMV promoter was amplified by
PCR from pcDNA3.1/V5-His-TOPO/lacZ (Life Technologies) with primers: CMV-
a, 5-GATCA GATC TCGA TGTA CGGG CCAG ATAT ACG-3 and CMV-bN,
5-GATC GAAT TCGA TCTG ACGG TTCA CTAA ACCA GCTC TGCT TATA
TAGA CCTC CCAC-3 and cloned into the BglII and EcoRI sites of pSEAP2-
Control. The sequence of the construct was finally verified by PCR (The synthesis of
this vector had been performed by Andrew Tait). The second plasmid encoding the
recombinant chimeric IgG4 mAb cB72.3 was provided by Lonza Biologics (Slough,
UK). Plasmids DNA were purified using plasmid maxi purification kits (QIAGEN,
Crawley, UK), re-suspended in a 10mM Tris-HCl buffer, pH 8.5 and stored at -20°C.
Transfection of CHO cells: CHO-S cells were cultured in shake flask to mid
exponential phase prior to transfection. One hour prior to transfection, cells were
diluted to the desired concentrations in 50mL CultiFlasks (Sartorius AG, Goettin-
gen, Germany) in CD-CHO supplemented with 8mM of glutamine in a total volume
of 5 mL. For PEI mediated transfections, in separate micro-centrifuge tubes, the
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desired quantities of 25kD linear PEI (Polysciences, Warrington, USA) and DNA
were diluted with an equal volume of 300mM NaCl. PEI and DNA were then mixed
together and allow to complex for 1 min in a total volume of 333µL made up with
150mM NaCl. The PEI/DNA solution was then added to the cells. This procedure
was noted CF in the text. When specified in the text, cell culture were spined down
(200g, 5min), the conditioned media was discarded and cells resuspended in fresh
media (CD-CHO supplemented with 8mM of glutamine, total volume of 5mL) to
the desired cell concentration. Finally, DNA and PEI were directly added to the
cells. This procedure was noted DA in the text. When specified in the text or the
figures, cells post transfection were cultured in various culture media including Pro-
CHO 4 and ProCHO 5 (Life Technologies). When specified in the text, cells were
transfected with the FreeStyleTM Reagent (Life Technologies). The procedure was
carried out according to manufacturer’s instructions. CultiFlasks were immediately
orbitally shaken by hand and directly placed in an incubator at 37°C in 5% CO2 with
orbital shaking at 170rpm and an orbital throw of 50mm. Cultures were harvested
after 5 days. Cell concentration and viability were assessed 5 days post transfection.
Samples in separate micro-centrifuge tubes were stored at -20°C for reporter pro-
tein quantification. When specified in the text, the cultures were supplemented one
hour post transfection with various chemicals: valproic acid, DMSO, LR3IGF and
EDTA (all four chemicals were supplied by Sigma-Aldrich) and/or placed at 32°C
in 5% CO2 with orbital shaking at 170rpm and an orbital throw of 50mm. When
specified in the text, cultures were fed at different days with FeedA and/or FeedB
(Life Technologies).
Reporter protein quantification: SEAP was quantified using the SensoLyte
pNPP Secreted Alkaline Phosphatase colorimetric reporter gene assay kit (Cam-
bridge Biosciences, Cambridge, UK) according to manufacturer’s instructions. IgG
was quantified using the FastELYSA® Human IgG quantification Kit (R&D Biotech,
Besancon, France).
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3.3 Results
3.3.1 The effect of basal TGE variables on culture viability and IgG
titres was response specific
Initially an augmented factorial design was constructed to study the effect of three
factors, DNA, PEI and cell concentrations, on two process responses: cell culture
viability and IgG titres, 5 days post transfection. This type of design is characterised
by a relatively low number of experiments and the presence of a centre point (Fig-
ure 3.2). Each combination of factor levels is experimentally performed once, with
the exception of the “centre point” located at the mid-level of each factor which is
replicated four times. Replicating the centre point allows for an estimation of exper-
imental error but also for a curvature test. This test investigates whether a linear
model can accurately represent the process response. A significant curvature indi-
cates that a linear model is not adapted, and that the design should be augmented
to a CCD by the addition of other experiments before making any conclusions on
the evolution of the response. However, if no curvature is detected, the linear model
generated can be used to describe the evolution of the process response. The design
space i.e. the ranges of factors to test were chosen following the method described
by Thomson et al.: DNA concentration was varied from 1 to 10µg mL-1, PEI from
1.5 to 20µg mL-1 and viable cell counts from 1.50E+06 to 2.50E+06 cells mL-1 (73).
The extreme points of the concentration ranges were chosen as low and high fac-
tor levels to construct the design.For each response, a linear model was generated
and analysed using the algorithm described in Chapter 2. A test for curvature was
performed using Mathematica. Curvature was estimated significant when the p-
value associated to the ratio of the mean square was associated to the centre point
replicates, and the mean square of the model error was inferior or equal to 0.05.
With respect to culture viability response, the test for curvature came back
negative at 95% confidence (p − value = 0.0646). The results from the centre
point are represented in Figure 3.2, A and are located between the two lines, which
is in accordance with the fact than an increase in PEI linearly affected cell culture
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viability. However, using the model equation an intercept of 80.2 could be calculated
when all the factors were at their mid-range level. Centre points results fell slightly
below this value.
Ln(Cultureviability) =
4.61545
−3.45182E − 003 ∗ [PEI]
−0074201 ∗ [DNA]
+2.29659E − 003 ∗ [PEI] ∗ [DNA]
(3.1)
Therefore, a slight curvature in response may have been present, but did not sig-
nificantly affect the model accuracy. As a result, the linear model presented here
could be confidently used to analyse experimental culture viability data, and make
predictions across the design space. The effect of cell concentration at transfection
on culture viability was not found significant (p− value = 0.12). However, PEI and
DNA concentrations, as well as their interaction, were found to significantly affect
this response. High concentrations of PEI resulted in lower culture viability after 5
days. The effect of DNA, however, varied with respect to the concentration of PEI in
culture. Indeed, at high PEI concentrations, variations in DNA concentrations did
not influence the response. At low PEI concentrations, a high DNA concentration
resulted in higher culture viabilities. This suggests that PEI was less cytotoxic when
complexed with DNA than in its free form. The evolution of culture viability re-
sponse with respect to DNA and PEI concentrations is represented in Figure 3.2, B.
If a linear model was acceptable to describe the culture viability response, it clearly
was not adapted to the IgG titre response. Indeed, IgG titre response exhibited a
significant curvature (p − value < 0.001). It is therefore not surprising to observe
the centre point results falling well above the predicted response lines in Figure 3.2,
C.
While the design space construction method used by Thompson et al. (73) was
valid when PEI was used as a DNA carrier, it did not hold true when it was adapted
to the FreeStyle reagent. Indeed, the reagent was much less cytotoxic than PEI
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Figure 3.2: Augmented factorial design revealed curvature in IgG titre response
but not in culture viability. This type of design is characterised by a relatively low
number of experiment and the presence of a centre point. Each combination of factors levels
is experimentally performed once, with the exception of the “centre point”, located at the
mid-level of each factor, which is replicated four times. The interaction plots display the
mean in response (A: culture viability, B: IgG titres) for the different combination of the
PEI and DNA factor levels tested. The centre point replicates can also be visualised on the
plots. The presence of curvature in the response can be generally detected by the ex-centred
location of the centre point replicates. When curvature is not detected in the response,
contour plots can be used to estimate the evolution of the response across the design space
(C), without requiring further experimentation.
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with culture viability 5 days post transfection superior to 80% in all cases. In that
case, despite a highly significant and good fitting linear model, the initial operating
factors range tested was not adapted as a maximum in response was located outside
the design space. It was however possible to “move” gradually towards the response
maximum by adjusting the design space.
3.3.2 Augmenting the factorial design to a central composite design
led to the identification of a combination of basal continuous
factors that maximised protein titres with minimal experi-
mental effort.
The previous augmented factorial design was augmented to a face-centred composite
design (CCF) by adding axial points. The new axial combinations of factors were
tested once, while the centre point was replicated twice. Compared to the previous
augmented factorial design, the increased number of experiments allowed for the
estimation of quadratic factors, and therefore, accurate estimation of the curvature
in the response. Data in Figure 3.3, shows that the quadratic model identified was
accurate at modelling the response curvature. Indeed, the intercept of the generated
mathematical model equation at the centre point equalled 4.9mg L-1. This value
was reasonably close from the experimental values collected for the centre points
replicates (5.34, 5.44, 4.52, 5.52, 5.16, 5.22 mg L-1). The interaction plot pointed
out the significance of the effect of the interaction of DNA and PEI on the IgG
titres. The fact that protein yields declined when both factors were set at the same
level revealed an antagonistic interaction. In fact, a simple maximum in response
prediction could be identified within the design space for a given combination of
basal continuous factors (Figure 3.3,B). Cell concentration at transfection proved
to significantly affect IgG titres. Indeed, in the range of concentrations tested, the
higher the concentration, the higher were the titres. An optimum of 6.7 mg L-1
could be achieved which represent a 550% increase compared to the titres obtained
using the protocol described in (77).
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Figure 3.3: A central composite design led to the identification of a combina-
tion of basal continuous factors that maximised IgG titres. The previous augmented
factorial design was augmented to a face-centred composite design (CCF) by adding axial
points. The new axial combinations of factors were tested once, while the centre point was
replicated twice. Compared to the previous augmented factorial design, the increased num-
ber of experiments allowed for the estimation of quadratic factors, and therefore, accurate
estimation of the curvature in the response (A). As a result, the empirical model can now
be used to graphically represent the evolution of the response across the design space.
Legend: : Low PEI concentration; : High PEI concentration
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3.3.3 The optimal combination of basal continuous variables de-
pended on the early choice of discrete basal variables.
The experimental strategy described above was then reproduced for different combi-
nations of basal discrete variables. The concentrations of basal continuous variables
that maximised protein titres are reported in Table 3.1. For those conditions the
culture viability at the time the cultures were stopped (5 days post transfection)
was also reported. Results showed that the optimal concentration of the continuous
factors greatly varied with respect to the discrete combination of factors chosen.
Optimal combination of basal continuous factors differed with respect to the media
utilised. While being similar for cultures in CD-CHO and ProCHOTM4, optimal
PEI concentration was significantly lower for cultures in ProCHO5. To reach an
optimal protein titre, less DNA was required when ProCHO4 was used (5.7µg mL-
1) compared to CD-CHO and ProCHO5 (9 and 9.9µg mL-1 respectively). Culture
medium also proved to significantly affect maximal protein titres as only 5.13mg
L-1 could be achieved using ProCHO4 whereas titres were 29% and 33% higher us-
ing CD-CHO and ProCHO5 respectively. At the conditions that maximised protein
titres, culture viability after 5 days was higher when cells were transfected and culti-
vated in CD-CHO (71.4% after 5 days) while being the lowest in ProCHO4 (46.8%).
Overall, transfecting and cultivating cells in CD-CHO proved to be most desirable
option. Another transfection protocol was also investigated. Called ”DA” for ”di-
rect addition protocol”, this protocol was characterised by the fact that the plasmid
DNA and DNA vehicle were added directly to a concentrated pool of cells. Prior to
transfection, cells were spun down (200g, 10min) and re-suspended at a concentra-
tion of 20.00E+06 cells mL-1 in CD-CHO supplemented with 8mM of L-glutamine
in CultiFlasks. Desired quantities of DNA, then DNA vehicle, were directly added
to the cells and the CultiFlasks placed at 37°C in the incubator. One hour post-
transfection, transfected cultures were diluted down to 5.00E+06 cells mL-1 with
fresh CD-CHO supplemented with 8mM Glutamine and the cultures allowed to
grow for 5 days. Transfecting cells using the DA protocol resulted in 57% higher
titre than using the CF protocol. However cell viability was significantly lower reach-
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ing 33.4% after 5 days in culture despite a lower optimal PEI concentration (12.4
rather than 17.54 µg mL-1). The process also seemed more robust to variation in
concentrations of basal continuous factors as shown by the relatively high 95% confi-
dence interval around predictions. Using FreeStyle reagent resulted in lower protein
titres than with PEI at the time the cultures were stopped. However culture viabil-
ities were higher suggesting that cultures could be maintained for a longer period of
time and potentially lead to better yields. Moreover, optimal DNA concentration at
transfection was three times lower: around 3µg mL-1 using FreeStyle reagent rather
than 9µg mL-1 using PEI. With respect to these results, it appears that transient
production process performances are intrinsically linked to the combination of the
basal discrete variables chosen. Introducing or changing a basal discrete variable
justifies a complete process re-optimisation.
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Table 3.1: Basal discrete and continuous factors combinations that maximised reporter protein titres.
Medium Carrier Reporter protein Protocol 
Protein 
(mg L-1) 
Culture 
Viability 
(%) 
Carrier 
(mg L-1) 
Cell 
(10-6 mL-1) 
DNA 
(mg L-1) 
CD-CHO PEI SEAP CF 7.26±0.68 71.4±3.6 17.54±0.82 2.5 9.01±1.06 
ProCHO4 PEI SEAP CF 5.13±0.21 46.8±1.9 17.22±2.03 2.26±0.43 5.7±0.98 
ProCHO5 PEI SEAP CF 7.62±0.54 62.1±3.1 12.09±0.36 2.1±0.49 9.94±0.6 
CD-CHO PEI SEAP DA 12.68±0.73 33.4±3.8 12.4±1.75 20±1 7.96±1.72 
CD-CHO PEI IgG CF 6.71±0.83 55.4±9.8 16.82±1.34 2.02±0.45 9.5±1.23 
CD-CHO PEI IgG DA 13.06±0.66 26±6.5 13.5±1.92 NA 8±1.55 
CD-CHO FR IgG CF 3.08±0.24 87.2±3.5 3.43±2 1±0.5 2.82±0.41 
CD-CHO FR IgG DA 6.30±0.46 84.5±2.1 4.59±1.15 1.5±0.7 3±2 
CF: Complex formation pre transfection; DA: Direct addition; FR: FreeStyle reagent
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3.3.4 Process performance could be further enhanced by control-
ling the culture environment post transfection
Despite resulting in higher protein yields, the DA transfection protocol induced a
premature cell death and therefore significantly reduced the protein expression phase
to a maximum of 5 days. Moreover the lysis of cells leads to the release of hydrolytic
enzymes in the culture and can affect product quantity and quality as well as com-
plicating the subsequent purification steps. By controlling the culture environment
it should be possible to maintain the culture alive for longer, as well as protecting
the DNA transcription machinery, to significantly increase protein titres. Data in
literature showed that the addition of specific active factors in the medium such
as growth factors or histone deacetylase inhibitors, as well as lowering the culture
temperature (mild-hypothermia), could result in higher culture viability and protein
titres (77, 80). Using a 25-1 fractional factorial design, the effect of mildhypother-
mia (32°C culture temperature) as well as the addition of Valproic acid (VPA),
LONG R3 Insulin-like growth factor I (LR3IGF), Dimethyl Sulfoxide (DMSO) and
Ethylenediaminetetraacetic acid (EDTA) on the process performances was evalu-
ated. Compared to a full 25 factorial design, only a half of the total possible factor
combination was performed. This resulted in significantly shorter development time
to the expense of aliasing. In other words, it was assumed that the effect of high
order factors interactions (3,4,5 factors) were not significant. Transfections were
performed in CD-CHO using the DA protocol. One hour post transfection, and
following the plan of experience, different combinations of chemicals were added to
the cultures, and for some of them, the incubation temperature was decreased to to
32°C. The titres of a reporter IgG, as well as the culture’s viability were assessed 5
days post transfection. Results were analysed using half normal probability plots.
These plots show the magnitude of the effect of the tested factors, and their inter-
actions, ordered in an increasing magnitude. The Standardised Effect for a factor
corresponds to the difference of the average process response over ”high” factor lev-
els, minus the average response over the ”low” factor levels. The values on the
y-axis are given by the idealised expected values for this number of effects, ranked
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by increasing value. A significant effect is characterised graphically as an outlier
with respect to the ”line of chance” (Figure 3.4).
In Figure 3.4 A, the effect of factors D and E, EDTA and 37°C temperature re-
spectively, fall in the top right hand corner, away from the ”line of chance”. There-
fore, both these factors had a significant effect on cell viability. Individual factor
plots revealed that EDTA was highly cytotoxic whereas mild-hypothermia resulted
in higher cell viabilities compared to cultures placed at 37°C. Figure 3.4 C shows
that factors C (DMSO) and D (EDTA), as well as numerous two factor interactions
significantly affected IgG titres. While DMSO had a positive effect, the presence of
EDTA in culture always resulted in lower IgG titres, most probably because EDTA
proved to be cytotoxic, leading to a lower amount of viable producing cells, and
lower product titres by the end of the culture. While factor A (VPA) was found to
not have a significant effect alone (p-value of 0.13), it positively counteracted the
negative effect of EDTA, suggesting that under stressed conditions VPA somehow
enhanced transgene expression levels. In other words, it is probable that VPA could
have a significant positive effect on transgene expression near the end of the culture.
Overall, incubating the culture at 32°C instead of 37°C resulted in 32% higher cul-
ture viabilities 5 days post transfection. Interestingly, despite a higher proportion of
living cells, mild hypothermia alone did not result in significantly higher IgG titres
in culture. However, combined with DMSO the final IgG titres were 25% higher
than when the cultures were incubated at 37°C. This suggest a synergistic positive
effect of DMSO and mild-hypothermia on the culture performances.
To confirm the positive effect of VPA, DMSO on IgG titres and culture viability,
two CHO cell cultures were transfected using the DA protocol. One hour post
transfection, one culture was supplemented with VPA and DMSO at 0.75mM and
1% (v/v) respectively, while the other served as control. The culture vessels were
placed at 32°C. IgG titres and culture viability were assessed every two days. The
results presented in Figure 3.5 confirmed the benefit of supplementing the culture
with VPA and DMSO. Indeed, the cells were viable for a longer period of time. At
day 6 post transfection, the culture viability was maintained above 65%, while in
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Figure 3.4: Identification of the variables that increased process performances
using a fractional factorial design. Half normal probability plots show the magnitude of
the effect of the tested factors, and their interactions, ordered in an increasing magnitude.
The Standardised Effect for a factor corresponds to the difference of the average process
response over ”high” factor levels, minus the average response over the ”low” factor levels.
The values on the y-axis are given by the idealised, expected values for this number of
effects, ranked by increasing value. Here, half normal probability plots were used to screen
for the variables significantly affecting Culture viability (A) or IgG titres (C). The (B) and
(D) figures show the evolution of the mean in culture viability and IgG titres respectively,
with respect to a variation of one single variable.
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Figure 3.5: Identification of the variables that increased process performances
using a fractional factorial design. CHO-S cultures were transfected at basal continuous
variables optima using the direct addition protocol. Half of the cultures were supplemented
with DMSO and VPA one hour post transfection and the culture vessels placed at 32°C
(square symbols). The other half served as controls (circle symbols). Cell viability (closed
symbols) and IgG titres (open symbols) were assessed every two days. Cultures were run in
triplicates.
comparison, the viability of the control culture reached 25%.
In the presence of DMSO and VPA, protein titres reached 48mg L-1 10 days post
transfection, which represented an increase of 161% over the control. In the presence
of chemical supplements, volumetric productivity gradually increased from day 0 to
day 6 reaching a maximum of 10.5mg L-1 d-1 between day 4 and day 6 compared to
1.75L-1 d-1 for the control culture over the same period. More importantly, protein
titres of 26mg L-1 after 5 days were higher than any of the titres associated with
the experiments of the fractional factorial design, confirming the predicted beneficial
synergistic effect of the addition of VPA and DMSO agents and mild hypothermia
on volumetric productivity.
To further investigate the effect of concentrations of VPA and DMSO on IgG
production, an augmented factorial design was performed. VPA concentration was
varied from 0.5 to 10mM and DMSO concentration from 0.5 to 1.5%(v/v final cul-
ture). IgG titres were assessed 10 days post transfection. However, these factors did
not significantly affect the IgG titres in culture (flat response surface, not shown).
As a result, the effect of VPA and DMSO was concentration independent within the
ranges tested.
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3.3.5 Production phase could be increased further using a simple
fed-batch strategy
The amount of recombinant protein achievable in vitro was limited by the ability
of the cells to remain viable over an extended period of time. This was probably
caused by the exhaustion of a key component in the culture medium and by the
accumulation of toxic products that result in lower cell metabolic activity (138).
Moreover, the high quantities of PEI required for transfection showed to promote
cell death and subsequently shorten production phase duration. To overcome those
issues a simple fed-batch strategy was developed. It was thought that the addition
of medium in the culture would dilute toxic components while providing additional
nutrients to sustain metabolic activity for longer. The effect of three different feed
solutions (Feed A, Feed B and a 50/50 (v/v) mix of FeedA/Feed B) as well as 4
different feeding strategies (single addition at day 0 or day 5, or semi continuous ad-
dition starting at day 0 or day 2 post transfection) on culture viability and product
titres was investigated. To do so, cultures of CHO-S cells were transfected using the
DA protocol. One hour post transfection, cultures were supplemented with DMSO
and VPA and incubated at 32°C. Feeding was started one hour post transfection
following a general factorial plan of experiment (13 individual experiments repli-
cated two times). A total of four feeding solutions were investigated. For half of the
cultures, a unique addition of feed media ( 50% of the initial culture volume) was
performed either immediately after transfection, or at day 5 post transfection. For
the other half, the feeding was done semi-continuously, with four additions (12.5%
of the initial culture volume each time) every two days. The semi continuous feed-
ing was started either immediately after transfection or at day 2 post transfection.
Culture viability and total cell concentration were measured 10 days after trans-
fection by trypan blue exclusion, and samples from the culture were taken for IgG
quantification. Results are presented in Figure 3.6.
The type of feed used (A, B or a mix of A and B) did not significantly affect pro-
cess performance (Fisher-Snedecor test). Data for a 50/50 (v/v) mix of FeedA/Feed
B are presented in Figure 3.6. In all cases feeding cultures enhanced process perfor-
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Figure 3.6: Screening of the effect of feed additions conditions on protein titres
and culture viability 10 days post transfection. CHO-S cells were transfected using
the DA protocol then supplemented with DMSO and VPA and placed at 32°C in 5mL
volume. Cultures were subsequently fed with a 50/50 (v/v) mix of FeedA/Feed B. Four
different feeding strategies were screened with a unique addition of 2.5mL at day 0 or day
5, or a semi-continuous fed-batch strategy with four additions of 0.625mL starting at day 0
or day 2. Cultures were run in duplicate.
mance. When fed, culture viabilities ranged from 59% (unique addition at day 5)
to 72% (continuous addition from d0) after 10 days. This represented an improve-
ment of 96.7% and 140% respectively over the batch culture that served as a control.
Interestingly, culture viabilities were higher when cultures were supplemented imme-
diately after transfection compared to later during the process, supporting previous
observations that PEI cytotoxicity is concentration dependent (73), and that by di-
luting it early in the culture, higher culture viabilities could be obtained. Compared
to the control, higher cell densities were obtained in fed cultures with the exception
of the culture fed at day 5 post transfection. This result showed that when realised
early, the supplementation post transfection also promoted cell growth. Compared
to a batch process, a unique addition at mid-culture resulted in a doubling of titres
by the end of the culture. As the final total cell densities are not significantly dif-
ferent, this effect can be solely attributed to the extended maintenance of living
cells in culture and/or higher expression activity. A continuous addition starting at
day 0 resulted in similar IgG titres, but also contributed to cell proliferation and
lower cell specific productivity. However, the culture viability of 78% at day 10 post
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transfection suggested that the culture could be maintained for a few more days and
that higher titres were achievable.
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3.4 Discussion
This data demonstrates the potential of an integrated DOE approach for the quick
and cost-effective development of transient production processes in CHO cells. The
basis of the approach is to only perform the experiments that will contribute to
the understanding of the process. The fact that central composite designs can be
constructed in a modular way (axial points added to an augmented factorial design),
proved to be decisive for the quick characterisation, then optimisation of the process.
The experimental design can therefore be constructed step by step, by increasing
its complexity, and therefore the number of experiments to perform, with respect to
the type of information required. Simple factor screening could be performed using
fractional factorial design, while augmented factorial design was required to model
the linear effect of factors on one or several process responses. Central composite
designs allowed for data modelling where curvature was present in the response.
(Figure 3.7). Using augmented factorial designs, it was possible to test early for the
presence of curvature in the process response, and sequentially augment the design
to a central composite design when necessary, which saved both time and number of
experiments to perform. Using central composite designs, it was possible to identify
a simple maximum in process response and the combinations of basal continuous
factors that led to it. More importantly, by identification of ranges of confidence
on basal factors, as well as combining process response contour plots, it is possible
to assess how a variation in process factors will affect the process as a whole, and
define a zone of control for guaranteed process performance (Figure 3.8). This is of
critical importance in the development of production platforms to generate consis-
tent material in terms of both quantity and quality. For example, it is known that
the lysis of cells can affect protein titres and quality by the release of proteases and
glycosidases as well as seriously complicating the purification of the product (139).
Therefore, maintaining culture viability above a given threshold can be desirable in
some applications. This approach to process development tends to become a stan-
dard in a “Quality by Design” and it is believed that it will be generalised in the
future.
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Figure 3.7: Integrated DOE approach to experimentation. The level of complexity
of the experimental design is adjusted with respect to the purpose of the experiment. Frac-
tional factorial designs are ideal for the screening of numerous factors but lack the ability to
accurately model a process response. Augmented factorial designs are ideal for process char-
acterisation: the presence of the centre point allows for the test of curvature in the response.
Additional experiments allow for the linear modelling of process responses. However those
designs are inadequate to estimate quadratic factors. By adding axial points, the design can
be augmented to a composite design with which the curvature in response can be accurately
modelled.
Using fractional factorial design it was possible to screen for the effect of 5 differ-
ent factors, and their interactions, on protein titres and culture viability. By adding
the highly cytotoxic EDTA chemical to the cultures, it was possible to generate a
stressed culture environment, with a high proportion of cells dying rapidly. This
enabled identification of the factors that beneficially impacted cell viability or pro-
tein titres after only 5 days in culture. Using this approach, the time dedicated to
experimentation could be significantly reduced and it was possible to identify the
factors that would not appear significant in non-stressed cultures.
By distributing the variables that impacted process performance into different
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Figure 3.8: Operational design space for desirable process performance. Culture
viability and IgG titres response contour plots were combined to identify a zone (represented
by the grey area) for which IgG titres were above 5mg mL-1 and culture viability above 70%.
layers, it was possible to rationally and quickly develop a PEI-mediated transfection
process. Compared to a non-optimised process, the optimisation of basal continu-
ous variables resulted in a significantly higher yield (13.1mg L-1 of a reporter IgG
5 days in culture post transfection) to the expense of a drop in culture viability.
The DA transfection protocol proved to promote cell death more quickly than the
original protocol. Mechanical damage to the cells during the concentration step pre
transfection, the culture medium exchange, as well as the transfection of a highly
concentrated pool of cells with higher concentrations of PEI are reasons that may
have contributed to this observation. It has been proved in the past that condi-
tioned medium could prevent cell apoptosis and therefore result in higher culture
viability (140). However, transfecting cells in conditioned medium proved to limit
protein expression yields by somehow reducing transfection efficiency (141). In our
protocol however, cells are re-suspended one hour post transfection. In this case,
re-suspending the cells after transfection in a medium containing a defined per-
centage of conditioned medium could potentially limit the early death of cells post
transfection, without inhibiting the transfection process itself.
Following the optimisation of the basal continuous factors it was decided to
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further enhance protein titres by maintaining biomass in a productive state for
longer. In other words, (i) maintain transcriptional and translational activity of the
trangene and (ii) maintain cells viable. In this study, mild hypothermia, DMSO and
VPA proved to synergistically enhance culture survivability and/or protein titres by
3-fold (Figure 3.9). Mild hypothermia alone correlated with higher culture viabili-
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Figure 3.9: Evolution of process performances throughout the optimisation. The
optimisation of the first layer consisted in identifying the optimal combination of basal con-
tinuous factors that maximised protein titres. Mild hypothermia coupled with the addition
of VPA and DMSO to the culture medium, resulted in higher culture viabilities that allowed
for the extension of the culture to 10 days. IgG titres and culture viability could be doubled
by the end of the culture by adopting a simple fed-batch solution.
ties. The effect of mild hypothermia on CHO cell culture is today well documented
(78, 142, 143). Reduced culture temperature would arrest cells in G1 phase of the
cell cycle as well as increasing the stability of cellular messenger RNAs. As a result,
the lifespan of RNAs in the cell is extended, yielding to an extension of the cell
lifetime but also higher cell productivity. In this study however, mild hypother-
mia induced lower specific cell productivity, probably by reducing protein synthetic
rates. This result contrasts with previous published studies on transient expression,
for which an increase in specific productivity (qP) was observed (77). The effect of
mild hypothermia is therefore more than likely to be cell line specific and further
optimisations with respect to the culture temperature should be conducted.
The presence of DMSO in the culture medium significantly increased protein
titres. The mechanisms of action remains unclear. DMSO is well known for per-
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meabilizing cell membranes and has therefore been used in the past to increase
transfection efficiency using electroporation or calcium phosphate (144, 145). How-
ever, recent studies showed than a HSPG mediated endocytosis was primarily in-
volved in the transportation of transgenes through the cell membrane of CHO-S
cells (73). Moreover, the passage through the cell membrane is thought to happen
within minutes after introduction of DNA and PEI in the medium (65). In this
study, DMSO has been added one hour post transfection. Therefore, the effect of
DMSO on transfection efficiency is more than likely to be negligible here. DMSO
has also been found to increase CHO cell-specific productivity. However its mode
of action remains unclear. Ye et al.. proved that maintenance of transcriptionally
active DNA was critical in obtaining high protein expression levels and they suggest
that DMSO could help maintain DNA integrity within the cell (146). The effect
of valproic acid on cell culture is also well documented and it is used routinely by
some companies to increase their transient protein titres (147). Acting as a histone
deacetylases inhibitor, VPA prevents DNA condensation, extending the lifespan of
viable cells (DNA condensation is known to be involved in apoptotic mechanisms)
but also maintaining the accessibility of transgene to RNA polymerases for longer.
VPA is also known to block cell proliferation, preventing the gradual loss of trans-
gene through cell divisions. This effect however could not be specifically identified
during this study. Interestingly, the addition of LR3IGF to the cultures did not
result in higher titres or culture viability which is in disagreement with the results
reported by Galbraith et al. (77). As Galbraith utilised the CHO K1SV cell line, a
possible explanation to this observation would be that the effect of LR3IGF is cell-
line specific. Feeding the cultures post transfection contributed to further extend the
culture lifespan and increase protein titres. Since the composition of the feed tested
was unknown it is difficult to explain in details the mechanisms responsible for these
observations. However our results suggest that higher culture viabilities were due
to the dilution of toxic-free PEI molecules, but also a possible nutrient depletion
during the original batch culture. It is also possible that some components in the
feed such as amino acids, may have enhanced protection against apoptosis (148).
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In conclusion, a rational development of a PEI-mediated transient production
platform in CHO-S cells could be developed in less than 5 weeks with minimal
experimentation, yielding up to 90mg L-1 and 82mg L-1 of a reporter IgG2 and
IgG1 respectively, in 10 days of culture. It is important to note that commercially
available chemically defined culture media, as well as a non optimised DNA vector
were used in this study. Screening for more culture medium at the early stage of
development could enable much higher titres to be reached. Modified DNA vectors,
with the introduction of specific intron sequences, also showed promising results
(149). More importantly, the method presented here is the first example to our
knowledge of a rational and holistic approach towards transient transfection process
optimisation. The method relies on the sequential screening and/or optimisation of
process variables at different levels: the transfection process, the protein expression
modulation via the control of the cell environment, and the cell culture process. It
allows for greater flexibility as the development can be extended to different process
variables and responses. The use of an integrated set of DOE tools minimise the
number of irrelevant experiments that generally extend development times, and
considerably strengthens the characterisation of the process. Indeed, the effect of
process factor variations on process performances can be explored and then rationally
controlled for the production of product of high consistency.
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Chapter 4
Development of a cation
exchange chromatography
platform using a Quality by
Design approach.
This Chapter presents the development of a cation exchange chromatography step
as an intermediate purification platform for the processing of monoclonal
antibodies. Using a rational Quality by Design approach, it was possible to evaluate
the effect of a variation of operational process parameters on different process
responses, and compare the performances of three different sorbents over a
relatively wide design space.
4.1 Introduction
Since no single chromatography step can achieve the product purity required for
biopharmaceuticals, a two or three process step is generally adopted. Due to its
ability to remove host cell proteins (HCP), DNA and protein aggregates, cation
exchange chromatography (CEX) is today routinely used as an intermediate or pol-
ishing purification step (95, 150). As opposed to protein A, several cation exchange
ligands are available on the market. This, coupled with a diversity of base matrix
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and manufacturer’s specific grafting techniques, contribute to create a large library
of sorbents, exhibiting different characteristics. Ghose et al. (99) cite no less than
twelve different sorbents commonly used for antibody late purification stages. The
efficacy of a CEX step is generally measured by three criteria: (i) the level of clear-
ance of contaminants such as HCP for example, (ii) the dynamic binding capacity
as binding a large quantity of protein in one go is generally desirable and (iii) the
process yield and duration. The performance of a ion exchange chromatography
sorbent are highly dependent on the mobile phases pH and ionic strength. As a re-
sult, the implementation of a CEX step requires some optimization. Moreover, the
production of monoclonal antibodies, introduced new considerations into the devel-
opment. The formation of product variants is frequent for this class of molecule. As
those variants can alter the product safety and efficacy, it became of primary im-
portance to monitor them throughout the process. The integration of the CEX step
within the overall manufacturing process should also be taken into account in the
development, the ideal being to limit the number of operations required to adjust
the feed material between different processing steps.
The work presented in this Chapter describes the development of a CEX platform
for the intermediate purification of a monoclonal antibodies using a Quality by
Design (QbD) approach. This work also provides a comparative analysis on the
performance of three sorbents: S HyperCel (Pall Life Sciences), CaptoTM S and
SP HP (GE Healthcare), and a methodology framework for future development
with other sorbents or other molecules. In this study, process performance was
established in terms of integration with pre and post CEX step: Protein A capture
step and anion exchange (AEX) polishing step (Table 4.1) as well as product quality
attributes (Table 4.2) and process attributes (maximise yield, minimise processing
time).
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Table 4.1: Process linkages
Integration
criteria
Elution
from
Protein A
CEX loading CEX elution
AEX
Loading
mAb
solution
6mg mL-1
in
20mM
citrate
buffer
No buffer
exchange
Processing
time
<4hours
Maximise yield
Elute in 20mM
phosphate
buffer
5-20mg mL-1
pH 3.75±0.1
Identical to
ProA elution
pool if
possible
Identical to
AEX loading
elution pool
if possible
6.5-8.5
Conductivity
(mS cm-1)
1.6±0.1
Identical to
ProA elution
pool if
possible
Identical to
AEX loading
if possible
<10
Table 4.2: Product quality attributes involved in CEX
Product variants
Aggregates Less than 5%
Charged variants Equal or inferior to input feed
Purity
HCP Reduction
DNA Reduction
Product attributes pH 0.5 unit lower than product pI
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4.2 Material and methods
Feed material The feed material consisted of 10g of a recombinant IgG1 puri-
fied from a CHO-S cell culture supernatant (stable cell clone) on an AxiChromTM
70/300 column containing 900mL of MabSelect Sure and connected to an A¨KTA
PilotTM system (GE Healthcare, Uppsala, Sweden). The material was aliquoted
and stored at-20°C in Protein A elution buffer (20mM citrate, pH 3.75±0.1, conduc-
tivity 1.6±0.1mS cm-1) at a concentration of 6mg mL-1. This particular mAb has a
pI of 8.8.
Chromatography sorbents and buffers Lab scale experiments were performed
on 1mL prepacked columns with three different types of sorbent: S HyperCel (Pall
Life Sciences, Portsmouth, UK), HiTrapTM Capto S 1mL and HiTrap SP Sepharose
HP (GE Healthcare). Columns were connected to an A¨KTA Explorer 100 chro-
matography system (GE Healthcare). Operating buffers consisted of 10mM citrate
for the equilibration and wash steps, 10mM citrate/ 1M NaCl for the strip step,
20mM sodium phosphate for the elution step and 0.5M NaOH for sanitizing the
sorbents. Buffers were titrated by the addition of 1M hydrochloric acid/ 1M sodium
hydroxide (Sigma-Aldrich, St Louis, MI) as required. Buffers ionic strength were
adjusted by adjusting the conductivity in solution with buffers of the same com-
position and pH, but supplemented with 1M NaCl. At large scale, a LRC column
10/80-200 (Pall) packed with 11mL of S HyperCel sorbent (Pall), also connected to
an A¨kta Explorer 100, was used.
Quality control Desired samples were analysed for their mAb concentration and
aggregates content by protein A and size exclusion chromatography (SEC) respec-
tively using an HPLC (Shimadzu, Milton Keynes, UK). Quantification of HCP was
performed using the CHO Host Cell proteins 3rd generation ELISA by Cygnus Tech-
nologies (Southport, NC). Quantification of DNA was performed using a qPCR CHO
residual DNA quantification assay (Invitrogen, Paysley, UK). All the quality con-
trols assays were performed by the QC team, Pall Life Sciences, Portsmouth. DOE
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generated experimental designs were analysed using Design-Expert (Stat-ease, Min-
neapolis, MN) and the algorithm described in Chapter 2.
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4.3 Results
4.3.1 A risk management approach guided the characterization stud-
ies to perform
An initial literature review, coupled with in-house experience, served to establish
a list of the critical process parameters i.e. the parameters whose variability may
have an impact on a product quality attribute, affect a process attributes or process
integration. This was done through a risk assessment in which the likelihood of an
existing effect was ranked from high (known to affect) to low (no data, or ratio-
nale, supporting the idea of the existence of the effect assessed) through medium
(may affect). The likelihood of a product or process attribute to be affected by a
combination of process parameters guided the nature of the method of experimenta-
tion to perform. Indeed, the process parameters known to interact with each other
to affect a process response were incorporated into a DOE-guided characterization
study. The impact of independent parameters on the process were measured using
conventional one factor at a time experimentation. The risk matrix for this CEX
step is presented in Table 4.3.
Three product quality attributes (Aggregation, HCP, and charged variants con-
tamination in the eluted product), two process attributes (yield and processing time)
as well as process integration with subsequent AEX step were considered. Aggre-
gation is a major concern during manufacturing as a relatively high percentage of
aggregates can potentially enhance immunogenicity and/or weaker binding to the
molecular target than mAb monomers (151). Moreover, as aggregation can be pro-
moted by numerous factors such as the contact with chromatography sorbents, a
change in the chemistry of the solution, or the concentration of the mAb in solution,
it was necessary to monitor it through the purification process (152). CEX is a
commonly used method for clearance of HCP. Indeed most of HCP being charged
it is theoretically possible to isolate them from the product during throughout the
purification steps by adjusting the mobile phase pH and conductivity. As a re-
sult, mobile phase pH and conductivity during loading, the wash and elution were
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likely to affect the proportion of HCPs in the eluate. MAbs, like many proteins,
have naturally charge heterogeneity that optimises the balance of gaining favorable
electrostatic interactions and determines their structure, stability, binding affinity,
chemical properties and therefore their biological reactivity. Charge heterogene-
ity can however be promoted by process of production and purification by sudden
changes in mobile phase chemistry, electrostatic contact with different charged sup-
port and temperature among others (153, 154). As a result it was estimated that
a CEX purification scheme, that encompasses numerous changes in mobile phase
pH could promote the formation of charged variants. Maximizing the binding as
well as minimizing loss during following wash and elution step was considered of
primary importance to yield an economic chromatography process. The binding/e-
lution of the charged antibodies depending mainly on mobile phase chemistry, it
was of primal importance to control mobile phase pH and conductivity to maximise
the binding during loading, minimise the loss during the wash step, and maximise
the recovery during elution. Processing time was also chosen a marker of process
performance. Indeed, it was critical for this project to be able to complete the pu-
rification run in less than a working day i.e. 8 hours. Yet, processing time could be
affected by several operational parameters such as the flowrate and residence time
during the loading, wash and elution steps, or even the nature of the sorbent of chro-
matography. Indeed, different sorbents are prone to exhibit different mass transfer
properties. The mobile phase chemistry can potentially affect the rate of desorption
of the product from the column, in a sorbent specific manner, and therefore shorten
or lengthen the required processing time to achieve an acceptable product recovery
or contaminants removal. Finally, with respect to integration with the subsequent
AEX process, the pH and conductivity of the mobile phase during elution should, if
possible, be adjusted to be compatible with a direct load on an AEX system.
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Table 4.3: Risk assessment matrix for CEX step
Step Process parameters Aggregates HCP
Charged
variants
Yield
Processing
time
Integration
with AEX
Risk mitiga-
tion
Loading
sorbent High Medium Low Univariate
pH DOE
Conductivity DOE
Residence time DOE
Wash
sorbent Univariate
pH DOE
Conductivity DOE
Flowrate DOE
Elution
sorbent Univariate
pH DOE
Conductivity DOE
Flowrate DOE
Elution stop Univariate
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4.3.2 Characterization and optimization of the product binding
4.3.2.1 Optimal binding capacity conditions were sorbent specific.
Optimal binding capacity was detrmined using the dynamic binding capacity at
10% indicator. The dynamic binding capacity of a media is the amount of protein
that can bind to the media before significant breakthrough of unbound proteins
occurs. The dynamic binding capacity at 10% breakthrough was determined for
the three sorbents tested in this study at various pH, conductivity and residence
time combinations. The pH and conductivity of the feed material were adjusted
prior to loading on the column by addition of acid/base and salt. Sorbents were
equilibrated prior to loading with 10 column volumes (CV) of 10mM citrate buffer
at pH and conductivity values identical to the feed material. Experiments were
carried out in a random order following a DOE designed plan of experiment. The
design assess the effects of various residence time, mobile phase pH and conductivity
on the DBC. The design space boundaries were chosen according to data available
in literature and experience in house (85, 155–157). The initial tested pH range
for S HyperCel sorbent was lower (3.75 to 5.25) than the one tested for Capto S
and SP HP sorbents (4.5 to 6). Tested ranges of conductivity (3 to 9mS cm-1) and
residence time (2 to 8min) were however identical for the three sorbents. Sample was
loaded at the desired flowrate on the column until the UV280nm signal increased
and reached a plateau. A 10% breakthrough corresponded at the quantity of mAb
loaded on the column for which the UV signal was equal to 10% of the UV signal
of the plateau. Dynamic binding capacity response was mapped across the design
space as a two dimensional (contour plots) representation of the model equation that
links significant variables (at 95%) to the response (Figure 4.1).These maps present
a rising ridge type of surface for both S HyperCel and SP HP sorbents whereas a
Saddle type can be observed for Capto S sorbent.
For the three sorbents, the effect of pH and conductivity on DBC was highly
significant. Where low pH and conductivity seemed to result in high DBC for both
S HyperCel and SP HP, a maximum in DBC was obtained at a significantly higher
pH when using Capto S sorbent. The effect of the interaction between pH and
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Figure 4.1: Dynamic binding capacity mapping on the initial design space.
Recorded DBC at 10% breakthrough at various pH and conductivity for Capto S (A), SP
HP (B) and S HyperCel (C) sorbents was mapped across the initial design space. Residence
time was set at 5 minutes. The response surface took the form of a rising ridge for both
S HyperCel and SPHP sorbent whereas a saddle form was detected for Capto S sorbent.
Black arrows indicate the direction where binding conditions should result in higher DBC.
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conductivity was also highly significant. When Using Capto S, a relatively high
DBC could be achieved at various pH/conductivity ratios in what seems to be a
kind of trade off between the two factors. For both S HyperCel and SPHP, DBC
was not affected by the residence time of the feed material. However, for Capto S
sorbent, increasing the residence time from 2 to 8 minutes resulted in higher DBC.
4.3.2.2 A peak in DBC was located outside of operational space
Figure 4.1 shows that higher DBC were predicted outside the initial design space
indicating that experimental design space should be adjusted. In this case, the
design space was simply extended by adding experiments. However, the range of
experiments to perform was limited by the composition of the feed material. Indeed,
the feed material used in this study had a pH of 3.75 and a conductivity of 1.6mS
cm-1. Titration of the feed material using acid/base automatically resulted in an
increase of the feed solution conductivity. For example, it was practically impossible
to get closer from the theoretical maximal DBC using Capto S sorbent as raising
the pH of the material to 5.3 resulted in an increase of the feed conductivity from
1.6 to 3mS cm-1. In other words, this co dependence between pH titration and
solution conductivity resulted in constraints on the factors settings, defining an
“impracticality zone” conflicting with the use of conventional RSM designs (BBK
and CCD). This zone is represented by the hatched area in Figure 4.2. Extending the
design space to the new irregular experimental region could be done using a specific
type of DOE-RSM designs called D-optimal designs. D-optimal designs are computer
generated design that establish the set of experimental runs to perform that will
minimise the generalised variance of the estimates of the model parameter. Using the
Design Expert software and the constraint equation specified by the impracticality
zone, it was possible to generate a plan of experiment including the runs already
performed. Theoretically, for a D-optimal design involving two factors A and B the
constraint equation is:
1 ≤ A− LLA
CPA− LLA +
HLB −B
HLB − CPB (4.1)
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where LL, HL and CP stand for “low level”, “high level” and “centre point” respec-
tively. In this study, The main difference with conventional RSM-DOE design lies
in the fact that the nature of the model (linear, interactions, quadratic) should be
specified before hand. In this particular study, the model chosen was a full quadratic
for two factors.
D-optimal designs were run for both S HyperCel and SP HP sorbents only.
Data showed that DBC could be significantly increased by loading a feed at low
conductivity. Indeed, for SP HP sorbent, a 20% increase in DBC could be achieved,
reaching 130mg mL-1 at pH 4.5, conductivity 1.6mS cm-1. For S HyperCel sorbent
a 10% increase in DBC could be achieved, reaching 160mg mL-1 by lowering the
conductivity at 1.6mS cm-1 as well. Lowering the pH below 4 generally resulted
in lower DBC. For both sorbents however the response surface took the form of a
rising ridge, meaning that operating boundaries were hit before reaching a peak in
response.
Overall, Capto S sorbent allows the binding of more mAb (165mg mL-1) than
SP HP (130mg mL-1) or S HyperCel (160mg mL-1) sorbents. However, obtaining
high DBC on Capto S required fine adjustments of the feed pH and conductivity
prior to loading whereas the protein A eluate could immediately be loaded onto a S
HyperCel sorbent.
4.3.3 Optimization of the elution step
The influence of the pH, conductivity and buffer flow velocity on the process and
product quality attributes was investigated using a DOE approach. Design spaces
were chosen according to literature and previous experience in house. Therefore,
despite testing the same range of pH (7 to 8.5) and flow velocity (61 to 306 cm h-1)
for the three sorbents, the conductivity range on Capto S sorbent was adjusted to
3 to 9mS cm-1, instead of 9 to 18mS cm-1 for both SP HP and S HyperCel. Elution
was performed over a number of CV for which, assuming 100% recovery, the final
product concentration in the eluate would be 5mg mL-1. For each condition, the
concentration of monoclonal antibody in the eluate, the percentage of aggregates as
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Figure 4.2: Extended dynamic binding capacity response mapping. The initial
design space was extended to an irregular experimental design using D-optimal designs. The
specificity of this type of design is to integrate operational constraints in its construction
to design experiments at the edge of the impracticality zone. Experimental points are
represented by the blue squares. Further characterization of DBC was performed for S
HyperCel (C) and SP HP (B) only. As the theoretical maximum DBC when using Capto S
resin was located in the impracticability zone (A), no further charcaterisation was performed.
Residence time factor was fixed at 5 minutes.
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well as concentration of HCP for every fraction was determined.
4.3.3.1 The conditions maximizing process yields were sorbent specific.
During elution experiments, fractions during sample load, wash, elution, and strip
were collected. Those fractions were analysed for their content in mAb. The overall
step recovery was then calculated using mass balance calculations. The step re-
covery gradually increased with increases in the elution buffer pH and conductivity
(Figure 4.3). The effect of an increase in pH alone resulted in an increase in re-
covery up to a certain extent for S HyperCel and SP HP sorbents. Indeed, past a
buffer conductivity of approximately 16mS cm-1, the effect of an increase in pH did
not result in an increase in recovery anymore. An increase in buffer conductivity
however always resulted in an increase in recovery. However, the decreasing slope
of the response surfaces seem to indicate that this effect was less pronounced as the
conductivity increased, and that a plateau in response will be achieved by increasing
the buffer conductivity further. The effect of pH/conductivity interaction was found
highly significant for the Capto S and S HyperCel (associated p-values of 0.0001 and
0.0006 respectively), and significant at 94% for SP HP. In this study, the simulta-
neous effect of an increase in the elution buffer pH and conductivity resulted in a
significant increase in recovery in a rising ridge type of response surface.
Reducing the elution buffer flow velocity had a significant positive effect on
recovery for S HyperCel (p-value of 0.0034) (Figure 4.3, D). The effect of flow velocity
was however not significant when the Capto S and SP HP sorbents were used.
The pH/flow velocity and conductivity/flow velocity interactions effects were not
significant, showing that the mass transfers variations due to the elution buffer flow
velocity were not influenced by variations in the elution buffer chemical properties.
Within the design space explored, the maximum product recoveries at optimal
elution conditions were sorbent specific, with the highest recovery being 99% for
Capto S, the lowest being 83% for SP HP while 91% product recovery was achievable
with S HyperCel type of sorbent. Data presented in Figure 4.3, A shows that a high
recovery was possible with Capto S at relatively low conductivity (below 10mS cm-1).
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Figure 4.3: Product recovery for the three sorbents tested. All sorbents were loaded
at 80% of the maximal DBC identified previously. sorbents were subsequently washed with
10CV of loading buffer, and then eluted with approximately 25CV of elution buffer (20mM
sodium phosphate) at various pH, conductivity and flow velocity. Percentage recovery re-
sponse was mapped for Capto S (A), SP HP (B) and S HyperCel (C) with respect to pH
and conductivity factors (flow velocity of 61cm h-1). Percentage recovery for S HyperCel
with respect to elution flow velocity is presented in D.
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Therefore material eluted from Capto S could be loaded directly on an AEX system
without prior dilution. Data also suggest that eluting product from S HyperCel or
SP HP sorbent with a buffer at higher conductivity than 18mS cm-1 would improve
recovery further. However the slope of the response surface is relatively low which
suggest that significantly higher conductivity will be required for a relatively low gain
in recovery. Figure 4.3, D suggests that eluting the product at lower flowrate from
S HyperCel sorbent could significantly improve the percentage recovery. However,
because of the minimal flowrate achievable imposed by the AKTA operating system
this option could not be validated at small scale.
The observation of differences in product recoveries can be correlated to the pro-
files of the chromatograms during the product elution and the strip and sanitization
of the column. As shown in Figure 4.4, B and C, a significantly higher quantity
of material was removed from the sorbent during the strip and sanitization steps
when SP HP was used compared to Capto S or S HyperCel. Profiles presented in
Figure 4.4, A show significant peak tailing during elution, the tailing being the less
important with Capto S while being much broader for SP HP. Interestingly, in all
cases, the strip test, performed with a buffer at high conductivity (1M NaCl, greater
than 90mS cm-1 conductivity) did not suffice to remove all the material bound to
the sorbents.
4.3.3.2 The CEX step promoted reversible aggregation in a sorbent spe-
cific manner
Preliminary aggregation study showed that samples post CEX exhibited higher per-
centage of aggregates than the feed material, and this for the three sorbents tested.
Full ANOVA analysis showed that none of the three operating factors tested in the
elution (pH, conductivity and elution flow velocity) significantly affected aggrega-
tion. Therefore, aggregation that occurred during the process was therefore not
caused by the variations in mobile phases during elution. The means and standard
deviations of monomer percentages recorded for each sorbent were then computed.
Results are presented in Table 4.4.
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Figure 4.4: UV chromatograms for the elution, strip and sanitization steps for
the three sorbents tested. Sorbents were loaded at 80% of the maximal DBC identified
previously then washed with 10CV of loading buffer. UV 280nm signal was recorded during
the three steps following the wash: elution, strip and sanitization. Elution: the product was
eluted with 25CV of 20mM phosphate buffers at the pH and conductivity that maximised
product recovery (A). Stripping: the sorbents were then stripped with 20CV of a 10mM
citrate/1M NaCl buffer pH 7 (B). Sanitization: finally, all the three sorbents werecleaned of
any residues still bound using 10CV of 0.5M sodium hydroxide at flowrates allowing 10min
of residence time (C).
Legend: Capto S, S-HyperCel, SP HP.
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Table 4.4: Comparison of the percentage of aggregates in eluate for the three sorbents
tested.
Sample source Mean of percentage of aggregates 
Feed material 1.37±0.02 
Capto S 3.68±1.48 
SP HP 18.30±8.72 
S HyperCel 10.88±5.56 
The percentage of aggregates in the eluate for every single experiment conducted was quanti-
fied by HPLC-SEC. The mean and standard deviation of this percentage across the different
sorbents tested was calculated and compared with the feed material.
A Tukeys multiple comparison test identified significant difference in means be-
tween all pairs of sorbents: SP HP and S HyperCel, SP HP and Capto S as well
as Capto S and S HyperCel. As slow loading flow velocity significantly increased
the processing time, and therefore the time the feed material was left at room tem-
perature before being loaded on the column, a further assay aimed at assessing the
stability of the feed material at room temperature was performed. It consisted in
measuring the aggregate content in the feed material right after thawing, and after 2
days left at room temperature. No significant differences were observed with 1.38%
and 1.36% of aggregates respectively. As all experiments were conducted with the
same feed material, and special care was taken to freeze down the samples down to
-20°C right after elution it was concluded that the CEX step promoted aggregation
in a sorbent specific manner. Samples purified from SP HP exhibited the highest
percentage of aggregates while samples purified on Capto S exhibited the least.
However, these observations could not be repeated afterwards. The percentage of
aggregates in the eluate using S HyperCel sorbent was constantly maintained below
4% during further screening experiments. After investigations, it appeared that the
percentage of aggregates in solution was proportional to the time the eluate was
left at room temperature before performing the quantification of aggregates assay.
In other words, aggregation that occurred during the purification on the column
was mostly reversible, and that a relatively high percentage of monomers could be
recovered when the eluate was incubated at room temperature for 3 hours before
performing the quantification assay.
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4.3.3.3 HCP clearance efficiency was sorbent specific
The HCP concentration in the column eluates was then quantified. The effect of
the pH, conductivity and the elution buffer flow velocity on the final relative HCP
quantities in the eluate (ng HCP per mg mAb) were then statistically quantified
for the Capto S and S HyperCel sorbent. Using Capto S, none of the experimental
parameters were found to affect the relative amount of HCP in the eluate meaning
that elution of HCP follows the same dynamic than the mAb product. Using S
HyperCel however, a significant cross over effect could be observed for the interaction
of the buffer pH and conductivity (p value¡0.001). The interaction plot is presented in
Figure 4.5. When conductivity was maintained to its low level (9mS cm-1, increasing
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Figure 4.5: The effect of the elution buffer pH-conductivity interaction on the
relative amount of HCP eluted from S HyperCel sorbent.
Legend: ( ) low conductivity; ( ): high conductivity. Error bars represent 95%
predicted confidence intervals.
the pH of the elution buffer resulted in a higher proportion of HCP in the eluate.
When elution buffer conductivity was at its high level however, increasing the pH
resulted in a lower relative HCP amount. These observations underlined the fact
that a significant amount of bound HCP had a lower pI than the mAb and eluted
from the sorbent at lower pH/conductivity combinations than the mAb product. At
high pH and conductivity the elution pool was enriched with mAb product, driving
the HCP relative amount down. Interestingly the effect of flow velocity on the
relative ratio was not estimated significant. In other words, the amount of HCP in
the eluate pool followed the same dynamic that the mAb product with respect to
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the flow velocity.
HCP clearance (ratio between loaded HCP amount on the column and amount
of HCP in the eluate) was more effective with Capto S with which a 84.7% reduc-
tion was possible whereas only a 36.8% and 8.9% reduction were achievable with
S HyperCel and SP HP respectively. A Tukeys multiple comparison test across
the three sorbents tested, revealed significant differences in the means of relative
HCP amounts (ppm) in the eluate. Compared to Capto S, HCP relative amount
were 4.1 and 6 times greater when eluted from S HyperCel and SP HP respectively
(Figure 4.6).
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Figure 4.6: Comparison of the HCP amounts (ppm) in eluate across the three
sorbents tested.The histograms represent the mean of the HCP amounts of all the exper-
iments performed for a given sorbent. Error bar is the representation of a 95% confidence
interval calculated on all the experiments performed for a given sorbent.
4.3.3.4 HCP clearance with S HyperCel could be increased by optimiz-
ing the wash step
Conductivity factor was thought being critical for an efficient washing step. In-
deed, theoretically high conductivity will weaken the electrostatic interaction be-
tween molecules and the resin binding sites, allowing the clearance of weakly bound
HCP. However, increasing the buffer conductivity can also result in a loss of product
and therefore a lower recovery. Theoretically, the optimal wash buffer conductivity
should be as close as possible as the one at which the product of interest will start
to elute, allowing all the molecules with lower pI than the product to desorb from
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the resin. To identify the optimal wash buffer conductivity, Capto S, SP HP and
S HyperCel sorbents were loaded at 80% of the maximal DBC and at the optimal
pH/conductivity conditions identified previously. The sorbents were washed with
10CV of 10mM citrate buffer at a pH and conductivity identical to the feed. A 50%
gradient elution over 20CV using 10mM citrate/1M NaCl buffer was then performed
and the UV280 signal monitored. The conductivities at which the signal started to
increase, and at which the signal reached 10% of the maximum were qualified as
”minimal wash conductivity” and ”maximal wash conductivity” respectively. Ex-
periments were run in duplicate. Results are reported in Table 4.5.
Table 4.5: Wash buffer conductivities boundaries for the three sorbents tested
sorbent
Conductivity
Loading
(mS cm-1)
Minimal wash
conductivity
(mS cm-1)
Maximal wash
conductivity
(mS cm-1)
Capto S 3±0.1 4.49±0.26 7.71±0.2
S HyperCel 1.6±0.1 3.02±1.27 12.62±1
SP HP 1.6±0.1 3.49±0.08 -
Capto S, SP HP and S HyperCel sorbents were loaded at 80% of the maximal DBC and at the
optimal pH/conductivity conditions identified previously. The sorbents were washed with
10CV of 10mM citrate buffer at the same pH and conductivity than the feed material. A 50%
gradient elution over 20CV using 10mM citrate/1M NaCl buffer at a pH identical to the feed
material was then performed and the UV280 signal monitored. The conductivities at which
the signal started to increase, and at which the signal reached 10% of the maximum were
qualified as ”minimal wash conductivity” and ”maximal wash conductivity” respectively.
Experiments were run in duplicate.
The minimal conductivities of the wash buffers were relatively close from the
loading conductivity for the three sorbents tested. The maximal washing conductiv-
ities were significantly higher than the minimal conductivities. S HyperCel is more
robust to variations in buffer conductivity than Capto S as shown by the smaller
difference between the minimal and maximal conductivity identified for Capto S.
Maximal conductivities for SP HP could not be established as the UV signal varied
with respect to a gradual increase in buffer taking the form of three confounded
peaks.
In order to minimise the amount of HCP in the eluate using S HyperCel, the
sorbent was washed for 10CV with a buffer at pH 1.6 and conductivity of 10mS
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cm-1 (80% of the maximal washing conductivity) and a flow velocity of 61cm/h.
The mAb product was eluted at the optimal elution conditions identified previously
and the final amount of HCP quantified by ELISA. Results showed a reduction of
36.8% of the relative HCP amount (397.36ppm) bringing the HCP clearance from
36.8% to 55.9%. The step recovery was 90.3%.
4.3.3.5 The percentage of charged variants was not affected by the pu-
rification step
The analysis of HPLC-IEX assay revealed that the percentage of charged variants in
the eluates where not significantly different between all the elution conditions tested.
Therefore the pH and conductivity of the mobile phase, as well as the flow velocity
during elution, did not promote charge modifications of the product. Moreover, the
percentage of charged variants was highly comparable to the feed material (56.23%
and 55.1% respectively) with a comparable percentage of acidic and basic variants.
As a result, it is believed the whole CEX purification step did not affect the amount
of product charged variants.
4.3.4 Ten fold scale-up
The chromatography process developed on S HyperCel sorbent was then scaled-up
to allow the binding of around 1g of antibody. It was decided to scale up the process
by keeping constant the residence time during loading and the column aspect ratio
between width and length. The elution flow velocity was however decrease from
61 to 52cm h-1 as, assuming a continuity in prediction accuracy outside the design
space, the small scale model predicted an increase in yield with a lower elution flow
velocity. This hypothesis was confirmed. Indeed the UV chromatograms during
elution, presented in Figure 4.7, shows that less CV were required to elute more
than 90% of the bound product. A recovery of 96% could be achieved at large scale.
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Figure 4.7: Comparison of the elution related UV chromatograms between the
small and large scale run using S HyperCel sorbent. The process developed with
S HyperCel was scaled-up 10 fold. Flow velocity during elution was decreased from 61 to
52cm h-1 to improve the step recovery. Legend: ( ): large scale; ( ): small scale.
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4.4 Discussion
Data presented in this chapter demonstrate that the three sorbents tested differed
substantially in their abilities to bind and elute product, as well as separate HCP.
Despite similar operating mode, the factors combination for optimal binding and
elution proved to be sorbent specific. Those differences can partially be explained
by differences in (i) ion exchange equilibrium capacities and (ii) mass transfer both
in and outside the resin beads.
Maximal DBC strongly depended on the combination of mobile phase pH and
conductivity during loading. Theoretically, at low pH and conductivity, electrostatic
bond energies between molecules and binding sites of any CEX sorbent are stronger.
However, for Capto S sorbent, DBC could be maximised at relatively high mobile
phase pH, at which cations have a global lower positive charge, and are supposed to
establish weaker bonds with the sorbent. As a result, it seems that maximal DBC
did not only depend on the ability of cation molecules to bind to the sorbent, but
also on the accessibility for those sites within the sorbent pores. Indeed, at low
pH, accessibility could have been limited (i) steric hindrance i.e. strongly bound
molecules at the pore surface prevent passage of cations inside the bead and (ii)
local charge repulsion between the bound and free cation at the surface of the beads.
The smaller the pores, and/or the bigger the molecules, the stronger the effects. At
higher pH however, mass transfer could be improved and resulted in higher DBC. It
is interesting to note that, in the case of Capto S, the detrimental effect of low pH
on DBC can be counteracted by a high mobile phase conductivity. This parameter
interaction is not a surprise as both pH and conductivity of the mobile phase impact
sorbent capacity, and cation overall positive charge.
The differences in product recovery observed, as well as peak broadening during
elution are thought to be principally due to differences in mass transfer throughout
the different sorbents. Resistance to mass transfer can be caused by two mecha-
nisms. The first one concerns narrow and deep beads pores that can slow down the
diffusion of large molecules inside the beads. The SP HP sorbent main characteristic
is precisely its relatively small beads and pores diameters. Despite increased resolu-
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tion, this characteristic may have resulted in peak broadening. In other words, the
use of SP HP sorbent over Capto S or S HyperCel would potentially be justified in
cases where a high resolution is required, i.e. the product of interest needs to be sep-
arated from contaminants having a close net global charge. The second mechanism
concerns the kinetics of adsorption/desorption of the molecules to the binding sites.
Indeed it takes a certain amount of time for a cation molecule to equilibrate between
stationary and mobile phase. In other words, molecules in the mobile phase move
ahead of the stationary phase. At constant desorption rate, as the displacement of
molecules within the bead pores relies only on a diffusive mode, higher flow velocity
will therefore result in accentuated band broadening (158). This effect is highly
significant with S HyperCel as shown by the increase in yield when the velocity of
the mobile phase during elution was decreased. Removal of contaminants during
sorbent washes and sanitisation steps was also logically affected by sorbent mass
transfer steps. Those steps needed to be performed at low velocity when using S
HyperCel which considerably lengthen the overall process. To save buffer, an al-
ternative could consist in marking a pause during the elution/wash/sanitisation to
allow complete desorption of product/contaminants within the sorbent beads pores,
before restarting the flow again. The two mechanisms presented could also explain
the differences observed in HCP clearance. Because of better mass transfers, HCP
clearance is more effective using Capto S than S HyperCel or SP HP sorbents. How-
ever, the improved clearance of HCP after optimizing the conductivity of the wash
buffer when using the S HyperCel sorbent, showed that a significant amount of HCP
with a lower pI than the mAb product, also bound to the resin. Because the loading
must be performed at higher pH when using Capto S, it is possible that HCP that
bound to the S HyperCel sorbent, did not to a Capto S sorbent.
For S HyperCel and SP HP, the first round of small scale experiments revealed a
high percentage of aggregates in the eluate, regardless of the column or the feedstock
lot used. This result however could not be replicated, the large scale run giving a
reasonably low amount of aggregates. Stability of the sample post elution was there-
fore investigated by performing aggregate assays right after elution up to 30 days
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post elution. Results showed that 10 to 25% of aggregates was present in the eluates
regardless of the pH and conductivity of the solution. However, these percentages
dropped to less than 5% after few hours only (data generated by John Welsh, Pall
Life Sciences, not shown). Therefore, the aggregation that occurred during the pu-
rification was mostly reversible. As aggregation can take several forms and depends
on numerous factors, it remains a phenomenon hard to foreseen (159) and it is dif-
ficult to know with exactitude at what stage of the phenomenon happened. One
possible explanation is that the maintained low pH during the loading and washing
steps, as well as the close proximity of bound molecules on the sorbent could have
both promoted oligomerisation. Aggregation being product specific, the processing
of other mAbs using this developed platform should be carefully controlled to ensure
less than 5% of aggregates in the final product.
The integration of the CEX step with the previous Protein A and post AEX
runs was considered key in this development. S HyperCel sorbent presents here an
advantage over Capto S as the feed material from Protein A could directly be loaded
on the column without any prior titration. In other words the Protein A elution
buffer and CEX equilibration buffer were identical. However, due to the relatively
high concentration in salts, the eluate will need to be diluted before being loaded
onto an AEX system. Finally, as opposed to Capto S, the amount of protein binding
on S HyperCel sorbent was less dependent on the mobile phase pH and conductivity.
In other words, a process using S HyperCel sorbent will be more robust to varia-
tions in mobile phase chemistry. This will represent a clear advantage for a process
designed to be run in a lab with simple, non automated equipment. It is believed
that the use of a rational approach towards the development of this CEX platform
significantly reduced development times. The outcome for this thesis project was to
develop a process based on S Hypercel resin. However, the work presented in this
Chapter could also be used as a methodology guide for future characterization of
chromatography resins and/or the development of chromatographic step.
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Table 4.6: Tested conditions and performance summary
Capto S SP HP S HyperCel
DBC
Initial
screening
pH range 4.5-6 4.5-6 3.75-5.25
Conductivity range (mS cm-1) 3-9 3-9 3-9
Residence time (min) 2-8 2-8 2-8
Extended
screening
pH range NA 3-4.5 3-4.5
Conductivity range (mS cm-1) NA 1.6-6 1.6-6
Residence time (min) NA NA NA
Optimal
conditions
Max DBC 165 130 160
pH 5.3 4.1 4.3
Residence time (min) 5 2 2
Conductivity (mS cm-1) 3 1.6 1.6
Elution
Initial
screening
pH range 7-8.5 7-8.5 7-8.5
Conductivity range (mS cm-1) 3-9 9-18 9-18
Flow velocity (cm h-1) 61-306 61-306 61-306
Optimal
conditions
pH 7 7 7
Conductivity (mS cm-1) 9 18 18
Flow velocity (cm h-1) 184 61 61
Wash
Optimal
conditions
Conductivity (mS cm-1) 7.71±0.1 NA 12.62±1
Flow velocity (cm h-1) 184 61 61
Performance
Recovery (%) 99 81 96
HCP clearance (%) 84.7 8.9 55.9
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Chapter 5
Development of an integrated
processing platform
This Chapter focuses on the scale-up and integration of the developed processing
steps to yield a global production platform. The economic aspects of the production
of one gram of mAb using this platform are presented, and compared with those
associated with the development of a platform using a stable producing cell line.
5.1 Introduction
The adoption of templated production-purification schemes by industry would con-
siderably shorten development time-lines and raw material inventory through the
utilisation of common components. The use of process platforms, early in the devel-
opment of a biopharmaceutical, would also result in streamlined documentation and
facilitated transfer to manufacturing. Taking advantage of the biochemical proper-
ties shared among all the variety of mAbs, such platforms would be of real value as
theoretically, any mAb could be processed through it. While being more frequently
used at large scale, such platforms are not yet generalised to the production then
purification of relatively low quantities of proteins (100 to 1000mg). Yet, recent
studies underlined the fact that production method should be revisited to develop
high-throughput platforms able to deliver the quantities of a multitude of therapeu-
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tic candidates to support preclinical trials (160). In this context, such platforms
would be of real value.
The main challenge of platform development lies in having a holistic approach
to process development (161). In other words, the development of a platform should
focus on developing a succession of processing steps, able altogether to comply with
the wanted product quality attributes, while taking into account factors such as ca-
pacity and connectivity as well as cost of production. Currently, the long and tedious
development of stable producing cell lines is still a prerequisite to the production of
enough quantities of a therapeutic candidates. This development leads to a process
dedicated to the expression of only one molecule, and is therefore not compatible
with the notion of platform of production. Transient gene expression (TGE) tech-
nology however allows for the production of milligrams of recombinant proteins in
few weeks only, regardless of the nature of the protein. Moreover, if the development
of a TGE platform is often a prerequisite to the expression of a candidate in enough
quantities (see Chapter 3), the platform could then be used generically to express
protein candidates of the same class, such as different mAbs for example. The fol-
lowing purification platform should therefore accommodate with low protein titres in
cell supernatant, characteristic of current transient gene expression processes. Using
Protein A sorbent in the initial capture step represents an attractive solution due to
its high selectivity (162). Most mAbs have basic isoelectric points that facilitate the
use of cation exchange media in a bind-and-elute mode as well as anion exchange in
flow-through mode. Combined together, those technologies generally allow for the
reduction of contaminants such as HCP and DNA to an acceptable level. Factors
such as feed pH and conductivity are critical throughout the platform as they can
considerably affect process performance. For example, maintaining mAb in low pH
solutions is known to promote aggregation and should be avoided (163). However,
low pH solutions is a prerequisite to efficient binding on CEX S HyperCel sorbent.
It appears clearly that these factors need to be adjusted throughout the purification
process (Figure 5.1).
This chapter describes the development of an integrated platform for the produc-
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tion of mAbs in CHO-S cells to sustain preclinical assays. The platform specifications
include the production of 0.5 to 1g of protein, the reduction of contaminants such as
HCP to hundreds of parts per million (ppm) and DNA to less than 100ppm. Main-
taining the percentage of aggregation to less than 5% also represented an objective.
The platform was based on an upstream transient expression process coupled to a
three stages purification scheme and a final ultrafiltration/diafiltration process. The
overall production using this platform allowed for significant time reduction and
savings compared to conventional production system.
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Figure 5.1: Integrated platform for the production of recombinant mAbs. The
column on the right presents the upstream processing options retained for the platform.
The parameters taken into account for the integration of each step are shown in italic. The
upstream cell culture process is performed at 5L (pilot scale) and 20L (production scale).
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5.2 Material and methods
DNA production Two different plasmids were used in this study. The first one
encoded the recombinant chimeric IgG4 mAb cB72.3 and was provided by Lonza
Biologics (Slough, UK). The second one, encoding the recombinant humanised Her-
ceptin IgG1 Her mAb, was provided by Cobra Biologics (Keele, UK). Plasmids were
transformed in DH5αTM competent cells from Life Technologies (Paisley, UK). The
seed cultures were started from glycerol stocks inoculated into LB medium (Sigma-
Aldrich, St-Louis, MI) plus 100µg mL-1 ampicillin (Sigma-Aldrich) and grown in 1L
baﬄed vented shake flasks (Sigma-Aldrich) to an OD600 comprised between 0.8 and
1.2. The seed cultures were used to provide 1% inoculums for the fermentations. All
fermentations occurred in New Brunswick Scientific BioFlo® 310 bioreactors (New
Brunswick, Edison, NJ) containing 10L of LB media supplemented with ampicillin
at a concentration of 100µg mL-1. Cultures were maintained at 37°C. The pH was
controlled at 7.0±0.1 using a 2M Sulphuric acid and 20% Ammonium hydroxide so-
lutions. The dissolved oxygen probe was calibrated to 0% by disconnecting it from
the system and 100% with air saturation. The vessel was aerated at one volume
of gas per volume of medium per minute and dissolved oxygen was maintained at
40% by proportional-integral control of agitation. Culture were stopped 16 hours
post inoculation. DNA plasmids were purified using Giga DNA purification kits
either from Sigma-Aldrich or QIAGEN (Crawley, UK). Purified plasmids DNA were
re-suspended in endotoxin free water, and stored at -20°C. A fraction of the purified
DNA plasmid was plated on an agar plate incubated at 37°C for quality control.
Pilot scale transient production - 5L scale in Wave CHO-S cells (Life Tech-
nologies) were routinely cultured in roller bottles (Corning, Surrey, UK) in CD-CHO
medium (Life Technologies) supplemented with L-glutamine (Lonza) at a concentra-
tion of 8mM at 37°C in 5% (v/v) CO2 and rotated at 2rpm. Cells were re-suspended
in fresh medium every 3-4 days at a concentration of 2.00E+05 cells mL-1. Cell con-
centration and viability were routinely measured using an hematocytometer and the
Trypan Blue exclusion assay. The passage no. 5 was used to start the preculture by
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inoculating an AppliFlex 10L wave-motioned bioreactor (Applikon Biotechnology,
Tewkesbury, UK) containing 5L of CD-CHO and 8mM of L-glutamine, at a con-
centration of 2.00E+05 cells mL-1. Cells were grown until mid-exponential phase
then harvested in 1L centrifuge bottles. Cells were spun down at 200g for 20min,
the spent media discarded, and the cells re-suspended at 20.00E+06 cells mL-1 with
0.83L of fresh medium. The re-suspended culture was transferred into two 2L roller
bottles. Re-suspended cells were transfected by adding 15mg of pB72.3 DNA plas-
mid (Lonza,) then 20mL of a 1mg L-1 solution of PEI in each bottle (Polysciences,
Warrington, USA). The transfected cultures were incubated for one hour at 32°C
in 5% (v/v) CO2 in roller bottles rotated at 2rpm. The cultures were then supple-
mented with 0.75mM of valproic acid and 1% v/v of liquid DMSO (Sigma-Aldrich).
In the mean time, a volume of 2.5L of fresh medium was pumped back into the
bioreactor and warmed up to 32°C. After incubation, the transfected cultures were
pumped back into the bioreactor and agitated at 25rpm and a rocking angle of 8°.
The culture was fed with a 0.42L mix of 50% (v/v) of FeedA/FeedB (Life Technolo-
gies) every two days, starting at day 2 post transfection (Figure 5.2).
Routine passage
Pre culture
Harvest
Concentration
Resuspension
Transfection
Incubation
Culture:
Fed-batch started at
day 2 post transfection
Harvest
Bioreactor
Bioreactor
Day 0
Day -10
Transfection step
Day 10
Day 0 to
day 10
Day -5
Figure 5.2: Pilot scale transient upstream production process flowchart. The
whole process duration lasted for 20 days. The preculture and the culture post transfection
were carried out in the same disposable bioreactor. Prior to transfecting cells, the culture
was harvested then concentrated down using a centrifugation operation. The cells were
incubated for one hour post transfection in an off line incubator before being transferred
back into the bioreactor.
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Large scale transient production - 20L scale in XRS The procedure was
identical to the one used at the pilot scale with the exception of some minor modi-
fications detailed below:
• A plasmid coding for a humanised IgG1 Her was used.
• CHO-S cells were routinely cultivated in shake flasks instead of roller bottles.
• The concentration/re-suspension step took 1hr instead of 30min
• The preculture was re-supended in 6 bottles. A total of 6 individual identical
transfections were performed within those bottles.
• All the quantities were multiplied by 4.
Capture by Protein A Two pre-packed HiTrap MabSelect Sure 5mL columns
(GE Healthcare, Upssala, Sweden) were connected in series to an A¨KTA Explorer
100 (GE Healthcare). The columns were equilibrated with 10CV of 20mM sodium
phosphate buffer pH 6.8 at 5mL min-1. After loading the sample, columns were
washed with 5CV citrate buffer pH 5 at 5mL min-1. The product was then eluted
with 3CV of 20mM citrate buffer pH3.5 at a flowrate of 5mL min-1. Columns were
stripped with 20mM citrate buffer pH2.5 then re-equilibrated. Columns were sani-
tised with 10CV of 0.1M sodium hydroxide at 5mL min-1 every three runs.
Cation exchange purification A LRC column 10/80-200 (Pall Life Sciences,
Portsmouth, UK) was packed wth 11mL of S HyperCel sorbent (Pall Life Sciences)
and connected to an A¨KTA explorer 100 (GE). The column was equilibrated with
10CV of 10mM citrate buffer pH 3.75, conductivity 1.6mS cm-1. Protein A eluate
was then loaded on the column in one go at a velocity of 14.3cm min-1. The column
was washed with 5CV of 10mM citrate buffer, pH 3.75, conductivity 10mS cm-1.
Bound mAb was eluted with 6CV of 20mM phosphate buffer pH7, conductivity
18mS cm-1. The wash and elution buffers were pumped at a flow velocity of 52cm
h-1. The column was then stripped with 10CV of 20mM sodium phosphate/1M
sodium chloride pH 7 and sanitised with 5CV of 1M sodium hydroxide before being
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re-equilibrated.
Anion exchange purification Small scale development experiments were con-
ducted using the AcroPrepTM Advance Mustang Q 96 well plates (Pall Life Sciences).
The eluates collected during the development of the cation exchange chromatogra-
phy step served as feed material (refer to Chapter 4). Those eluates were first
diluted 15 times with 1400µL of 10mM sodium phosphate/sodium chloride buffer
at the same pH and conductivity as the corresponding eluate solution. A volume
of 250µL of each of the diluted eluate solutions was then pipetted into the wells of
the plate. The volume inside each well was first reduced to 100µL before adding
150µL of sodium phosphate/sodium chloride buffer. This step was repeated three
times. For each well, the mAb concentration as well as the percentage of aggregation
were quantified using HPLC-Protein A and HPLC-Size exclusion chromatography
respectively.
Production scale purification was performed using Mustang Q coin mounted into
an appropriate stainless steel housing (Pall Life Sciences). The set-up was connected
to an A¨KTA Explorer 100 (GE Healthcare).
Concentration/buffer exchange Concentration/buffer exchange was performed
using a 30kDa T-series Centramate cassette, 0.02m2 filtration area (Pall Life Sci-
ences). The cassette was mounted in a specific holder and washed as specified by the
manufacturer’s instructions. The system was then equilibrated by pumping 300mL
of a 2.4mM L-histidine/50mM D(+)-trehalose formulation buffer. The flowthrough
of the anion exchange purification step was first reduced to reach a concentration
of approximately 50mg mL-1 of mAb in solution (15 times concentration). Then
the buffer was exchanged with the formulation buffer using diafiltration mode by
maintaining constant volume throughout the system.
Quality control Desired samples were analysed for their mAb concentration and
aggregates content by Protein A and SEC respectively using an HPLC (Shimadzu,
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Milton Keynes, UK). Quantification of HCP was performed using the CHO Host Cell
proteins 3rd generation ELISA by Cygnus Technologies (Southport, NC). Quantifi-
cation of DNA was performed using a qPCR CHO residual DNA quantification assay
(Life Technologies). All the quality controls assays were performed by the QC team,
Pall Life Sciences, Portsmouth.
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5.3 Results
5.3.1 The scale-up of the TGE process proved to be challenging
The optimised transient transfection process described in Chapter 3 was then scaled-
up from 10mL culture in CultiFlasks to a 5L culture in a Wave bag. The seed culture
grown in roller bottles was used to inoculate a 5L preculture in Wave bag. The cells
proved to adapt with difficulty to the culture in Wave bag. Indeed, the culture
viability at the end of the preculture was only 90.2%. As a comparison, the cell
viability of the preculture in the shake flasks used for the small scale experiment
could be maintained above 98% prior to transfection.
The 5L preculture was then harvested, the cells concentrated, transfected and
finally transferred back in the Wave bag as described in the Material and Methods
section. IgG titres and culture viability were assessed throughout the culture and
the results compared with data from small scale experiment (Figure 5.3). Both the
small scale and pilot scale cultures were marked by an increase in productivity 4
days post transfection. This increase was correlated with a doubling in viable cell
density between day 2 and day 4 for the small scale experiment, and an increase of
29% between day 2 and day 4 for the pilot scale culture. Indeed at day 4, viable cell
density was estimated at 9.63E+06 cells mL-1 in small scale culture and 6.46E+06
cells mL-1 at pilot scale. As a result, it is most probable that the transfected plasmid
DNA was diluted during the first cell divisions. As cell division resulted in an
increase in overall productivity, it is probable that the transfected cells protein
expression machinery was saturated by an excess of plasmid DNA. Compared to the
small scale experiment, the culture in Wave bag was characterised by a lower cell
productivity between day 4 and day 10 (5.8 mg L-1 d-1 compared to 11.2 mg L-1 d-1).
Moreover, cell productivity declined significantly after day 8 with the production of
only 1.48mg L-1 d-1 over the last two days in culture. In comparison, productivity
at small scale remained constant throughout the culture. Cell specific productivity
were comparable with 17 and 14 pg cell-1 day-1 between day 4 and day 8 for the
small and pilot scale respectively. Because of the lower amount of viable cells, IgG
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Figure 5.3: Evaluation of the transient expression process scalability. Square
symbols: 5L Wave; circle symbols: 10mL culture in CultiFlasks. The TGE process developed
in 50mL CultiFlasks was scaled-up to a 5L scale in Wave bag. A 10L Wave bag containing
5L of media was first inoculated at 2.00E+05 cells mL-1 with cells routinely grown in roller
bottles. After 5 days, the culture was harvested in centrifuge bottles. Cells were pelleted
down and the conditioned medium discarded. Cells were then re-suspended at 20.00E+06
cells mL-1 in 0.83L of fresh medium and transfected by adding DNA then PEI before being
incubated at 32°C. In the mean time, 2.6L of fresh medium were pumped back in the Wave
bag and warmed-up to 32°C. One hour post transfection, the Wave bag was inoculated with
the transfected culture to reach a concentration of 5.00E+06 cells mL-1. Culture was fed
every two days, starting at day 2 post transfection, with 1.67L of Feed A/FeedB (50% v/v).
Square symbols: 5L Wave; circle symbols: 10mL culture in CultiFlasks.
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titres were significantly lower in the Wave bag after day 6, reaching a maximum
of 53mg L-1 at day 10, 40% less than at small scale. Culture viability was lower
in the Wave bag throughout the culture and started to drop significantly after day
4. This drop in viability was also observable at small scale, but only occurred at
day 6. In other words, the culture started to die earlier at 5L scale. This effect
may be attributed to the starting viability post transfection, which was significantly
lower at 5L scale than at small scale (89.6% and 98% respectively), which in return,
was the consequence of a relatively low viability at the end of the initial preculture
carried out in the Wave bag. This effect could be attributed to the agitation in
roller bottles which was limited by the maximal operating rotation speed of the
incubator. This agitation proved to be insufficient to maintain the totality of the
culture in suspension and prevent early cell clumping and cell death compared to a
culture in shake flask.
The process was then scaled-up in a XRS bioreactor to a scale of 20L. Here,
the cells routinely cultivated in shake flasks proved to adapt well in the bioreactor.
Indeed, cells could be cultivated until mid exponential phase in 4.5 days while main-
taining the preculture viability above 98%. The concentration step post preculture
proved to be relatively complex due to the volume of culture. Indeed the culture had
to be split up in 16 individual 1L centrifuge bottles. A total of three concentration
steps by centrifugation and 16 individual re-suspensions were performed. Yet, the
cells did not seem affected by the process as a culture viability of 98.5% could be
measured in the bag post transfection could be measured. Data acquired until day
4 showed that the transfection process could be performed successfully. Indeed at
day 3, the culture viability was at 95.8% and IgG titre in culture at 21.6mg L-1.
However, a bacterial growth occurred between day 3 and 4, that compromised the
culture.
As the 20L XRS transient culture was compromised by the presence of bacteria,
it was decided to generate a simulant, as close as possible as what the original
transient culture (yields of 100mg L-1) would have been. To do so, 20L of feed
material from a stable CHO batch culture containing the IgG1 Her at 1.2g L-1 was
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purified by Protein A using 900mL of MabSelect Sure sorbent, an A¨KTA pilot and
an Axichrom 70/300 column (GE Healthcare). The Protein A sorbent captured the
mAb in solution, and the process generated a flowthrough with levels of IgG under
the detection threshold of 10mg L-1. As the eluate of the column was relatively pure
of contaminants, it is believed that most of these contaminants such as HCP and
DNA were present in the flowthrough. Purified IgG was subsequently spiked in the
flowthrough to generate a feed at a concentration of 100mg L-1. The concentration
was checked by HPLC-Protein A and estimated at 102mg L-1. This simulant served
as feed material to test the purification platform.
5.3.2 Development of a Protein A sorbent based capture step
Preliminary experiments consisted in evaluating the relation between the mAb con-
centration in solution, the residence time within the column of chromatography and
the quantity of mAb that can be bound to 1mL of MabSelect Sure Protein A sor-
bent. Feed material containing the IgG1 Her at concentration ranging from 0.5 to
6.5mg mL-1 were generated by spiking the protein into CHO-S cell culture super-
natants. Residence time within the column was varied from 1 to 5min. For each
combination of residence time and IgG concentration, fractions of the flowthrough
were taken during the loading, and mAb concentrations in each fractions quantified
by HPLC-Protein A. The total mass of mAb which was bound before breakthrough
occurred was calculated by multiplying the concentration of mAb in the feedstock
by the total volume loaded up to a 10% breakthrough point. Results showed that
the DBC was affected by the feed residence time. Indeed, the DBC got closer to the
theoretical sorbent capacity with an increase in residence time (Figure 5.4). The
effect of mAb concentration in solution on DBC however, was not found significant
at 95%. In other words, the amount of mAb that can be bound to Protein A before
breakthrough can be increased by increasing the residence time within the column,
up to the point where the actual capacity of the column is achieved. The quantifica-
tion of mAb quantities in the fraction collected during the DBC study showed that
breakthrough occurred relatively suddenly after a given amount of mAb was bound
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Figure 5.4: MabSelect Sure DBC study. Feed material containing the IgG1 Her at
concentration ranging from 0.5 to 6.5mg mL-1 were generated by spiking the protein into
CHO-S cell culture supernatants. Residence time within the column was varied from 1 to
5min. Fractions of the flowthrough were taken during the loading and mAb concentrations
in each fractions quantified by HPLC-Protein A. The total mass of mAb which was bound
before breakthrough occurred was calculated by multiplying the concentration of mAb in
the feedstock by the total volume loaded up to a 10% breakthrough point. Courtesy of Nigel
Jackson, Pall Life Sciences.
to the sorbent.
It is common practice to apply the sample to a final load of 80% of the DBC,
10% breakthrough (164). Therefore, at a 5min residence time, it could be established
that 1mL of MabSelect Sure could bind 36.5mg of mAb. As a result, binding 1g of
mAb in one attempt would require 27.4mL of sorbent. However, as transient feeds
are characterised by low concentration of mAb, loading the feed on the column while
respecting a 5min residence time would represent a rather long process. For example,
with a feed at 100mg L-1, the loading would take more than 30 hours on a single
column. As culture feed was rich in nutrients and sterility was not maintained
during cell harvest operation, the feed was prone to bacteria contamination and
growth within few hours. Therefore, it was decided to reduce the time of loading
to less than 4 hours and to scale out the capture process instead of scaling it up.
Residence time was decreased to 2 minutes, and the volume of sorbent set to 10mL
by connecting two 5mL prepacked columns in series. The column was loaded with
only 115mg of mAb in one go (1150mL of feed). A series of 10 runs was performed by
stripping and re-equilibrating the column between each run. The average yield was
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95.9%± 0.3% giving a total of 1103mg purified mAb. This yield was comparable to
the yields obtained during the development of the capture step performed in house
from a CHO supernatant containing a stably expressed mAb at a concentration of
1.2g L-1 (data provided by Nigel Jackson, Pall Life Sciences).
5.3.3 A membrane-based AEX process allowed for a fast and effi-
cient polishing step.
The eluate of a cation exchange chromatography step was then used as feed mate-
rial to develop an AEX process. The effect of the pH and conductivity of this feed
material on AEX process performances (yield and product aggregation) was exper-
imentally assessed at small scale using a 2 factors CCD design. The material pH
values ranged from 6 to 8 while material conductivity ranged from 3 to 9mS cm-1.
Data showed that in the ranges tested, neither the pH or conductivity were impact-
ing the process performances, with p-values of 0.18 and 0.33. The process yield
was above 95% for all the experiments conducted while the percentage of monomers
exceeded 97%. Analysis conducted on one sample (pH7, conductivity 6mS cm-1)
showed a Log reduction of 2.57 in DNA and a three times reduction in HCP.
The process was then scaled from the 96 well plate to a Mustang Q coin to process
hundreds of millilitres. The feed material issued from a large scale cation exchange
purification step was firstly diluted down using a 20mM sodium phosphate buffer
pH7 to bring the conductivity down from 18 to 6mS cm-1. The feed was loaded on
the system at 3.5mL min-1 then washed for 5 minutes with 20mM Sodium Phosphate
buffer pH7, conductivity 6mS cm-1. The process showed to be scalable as a yield
of 95.7% could be achieved while the aggregate content was maintained at its level
pre-purification. The overall process could be completed in 125min with 100min for
the sample loading only.
5.3.4 Step by step performance of the platform
Along the purification of the reporter mAb from the simulant feed, samples were
taken at each processing step to determine the step yield, the percentage of monomers
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Table 5.1: Platform performances step by step.
mAb 
 
IgG Monomers 
Charged 
variants 
Step
yield  HCP 
 
DNA  
 
(g/L) (%) (%) (%) (mg) (ng mg-1) (ng mg-1) 
Small scale 
Transient 0.08 99.2 36.2 - - - - 
Simulant 0.1 99.1 54.6 - 1150.00   
Capture 8.09 99.2 55 95.9 1102.85 813.6 32129.39 
Intermediate 19.35 97.8 55.1 95.8 1056.53 307.6 112.4 
Polishing 3.02 98.4 54.2 95.7 1011.10 102.4 0.3 
UF/DF 50.23 98.4 -  98.9 999.98 80.7 0.44 
Time 
 
20d 
- 
5d 
4hr 
2hr 
2hr 
Samples were taken along the production and purification of the reporter mAb. The percent-
age of monomers were quantified by size exclusion chromatography, while the percentages of
charged variants were obtained by HPLC-Ion exchange chromatography. MAb concentra-
tions were determined by manual UV280nm spectrophotometry excepted for the cell culture
small scale transient and simulant materials which were quantified using an HPLC-Protein
A assay. Individual step yields were maintained above 95% leading to an overall efficiency
of 86.9% from the expression of the mAb to the final UFDF step. The amount of HCP
and DNA were quantified during the development of the platform at small scale with a feed
material originated from a CHO-S supernantant containing a stably expressed IgG1 at 1.2g
L-1.
and correctly charged molecules. Results are reported in Table 5.1. Aggregation was
mostly not affected by the different processing steps as the percentage of monomers
was kept above 97.8% throughout the purification. Data on the cation exchange
step showed however than significant aggregation could occur during the process
(see Chapter 4). However the phenomenon proved to be reversible and therefore
did not affect the quality of the final product. The percentage of charged variants
was on average maintained at 55% throughout the purification. Therefore it is more
than likely that molecules were altered during the cell culture step and not during
the purification. The percentage of charged variants in a transient supernatant was
1.5 times lower than in a culture where the same mAb was stably transfected. In
other words, transient gene expression led to better product quality than stable ex-
pression. The yields of all the processing steps were above 95% and the overall yield
across the platform was 86.9%. While the upstream transient expression process
took 20 days to perform, the purification of the mAb could be carried out relatively
quickly.
The amount of HCP and DNA that figure in the table were quantified during the
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development of the platform at small scale with an original supernatant containing
a stably expressed mAb at 1.2g L -1. Using this platform, it was possible to obtain
a 10 times reduction of the relative amount of HCP (ng of HCP per mg of mAb)
and a 4.9Log reduction in the relative amount of DNA.
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5.4 Discussion
The scale-up of the transient gene expression process from 10mL scale to 20L proved
to be particularly challenging. The main difficulty lied in maintaining sterility while
harvesting the preculture in centrifuge bottles, centrifuging down litres of broth, then
re-suspending the cells in fresh media. If these steps were successfully performed at
the 5L scale, a contamination occurred at the 20L scale. It is difficult to identify the
stage at which the contamination occurred. However, after a little investigation, the
integrity of the seal in the lid of some centrifuge bottles showed to be compromised
and it is more than likely that culture got contaminated when in contact with the lid
of some bottles. It appears now of primal importance to be able to concentrate the
cells in-line, i.e., maintain the cells within the culture bag while removing culture
media. This would significantly mitigate the risk of contamination but would also
speed up the overall process. Concentration in-line could be performed by using a
TFF micro filtration module connected to the culture bag. In house data showed
that it was possible to concentrate a high density CHO cell broth (14E+06 cells mL-1
25 times in 20 minutes while maintaining a high cell viability (Woodgate J., data
not shown). Therefore this technology could be used to perform the concentration
step prior to transfection. (Figure 5.5).
The costs of the platform were driven by the cost of consumables required for the
DNA production and culture media for the transient gene expression step. There-
fore, primary efforts in the future should focus on improving the transient titres
up to 600mg L-1. Preventing early cell death post transfection also represented
a challenge. From a process design point of view, a perfusion culture system in
which conditioned media is constantly replaced by fresh media would represent an
interesting alternative to the fed-batch process presented here. Indeed, culture by
products but also toxic molecules are known to infer with cell productivity. The key
parameter for a conventional perfusion system is the retention of cells in the biore-
actor. This is generally performed by the use of filters through which cells cannot
pass. However in this particular case, because transient titres were relatively low
compared to cultures of stable producing clone, it would be of primal importance to
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Figure 5.5: In line concentration of a cell culture using a Kleenpak TFF mi-
crofiltration module. By coupling a TFF module top the XRS bioreactor it should be
possible to concentrate down the preculture relatively quickly while maintaining cells alive.
The concentration factor could be calculated in real time by performing a mass balance
between the volume of media in the bag, and the media collected on the balance. SciPres®
pressure sensors (SciLog, Inc, Middleton, WI) can be sterilised by autoclaving and could
easily be integrated to the system to apply a desired trans-membrane pressure. XRS culture
bag figure is a courtesy of John M. Woodgate.
also retain the expressed product. In the case of mAbs, an ultrafiltration filter with
a pore size of 30kDa could represent a viable solution. However, filters are subject
to fouling. Wave Biotech published a few years ago the development of a floating
perfusion filter at the surface of the culture liquid. The tangential movement of the
filter during the rocking of the bioreactor platform would provide enough shearing
to prevent filter fouling (107). Another solution could consist in designing a double
bag bioreactor or a bag with an external layer. The inner face of the layer would be
porous to allow nutrient exchange through the whole surface of the culture bag. Yet,
by enhancing productivity titres to 0.5g L-1, it would also become possible to per-
form the transient culture in smaller bioreactors such as shake flasks or even vented
bottles. In this case, the bioreactor could be divided into two compartments sepa-
rated by a porous layer. The bottom compartment would contain the cell culture,
the top serving as manual exchange of fresh/conditioned media at regular intervals
during the culture to mimic a semi continuous perfusion mode.
The purification of 1g of mAb could be performed relatively quickly in an effi-
cient manner. The main difficulty being the capture of a feed lowly concentrated
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in mAb. Working with an excess of Protein A sorbent allowed the experimenter to
decrease the residence time and therefore speed up the process while maintaining a
high step yield. Moreover, due to the cost of Protein A sorbent, significant savings
could be made by scaling the process out, instead of scaling it up. The further DSP
applications were relatively easy to implement and integrate as processing platforms.
The Protein A eluate was normalised in terms of concentration, pH and conductiv-
ity. Therefore, the nature of the protein expressed, or the upstream culture process,
would have a limited impact on the late purification steps performances. The tran-
sition between the Protein A capture step and the subsequent cation exchange step
did not require any adjustment of the feed material. Indeed, the Protein A elution
buffer and S HyperCel equilibration buffer were identical. Therefore, the eluate from
Protein A could directly be loaded on the cation exchange chromatography column.
This characteristic could in the future be employed to design a more continuous
process with no interruption between the capture and the intermediate purification
step. Using membrane based chromatography technology instead of sorbent beads
proved to be advantageous when the volume of feed to process was relatively high.
In this study, membrane chromatography was used for the late polishing purification
step. At this stage, diluting the salts in the cation exchange eluate was a prerequisite
before performing the final purification step. As a result, a relatively large volume
of material needed to be processed. Because AEX chromatographic membranes can
be loaded at high flowrate, the purification of 350mL could be performed in less
than 3 hours. At that scale, the disposable membrane modules serving for the sep-
aration are relatively inexpensive. Therefore the stainless steel membrane housing
system represented the main cost of the step. However, this cost represented only
4% of the overall production platform costs and can be amortised with the produc-
tion of bigger quantities or different mAbs. Yet, a significant improvement to the
step would be to design a disposable plastic capsule for the purification membrane.
Chromatographic steps do not require any automation as simple peristaltic pumps
could be used to load, wash and eluate the material at the desired flowrates.
Despite the contamination that occurred at the 20L scale transient culture, the
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developed platform is thought to be capable of generating 1g of pure mAb. The in-
tegration of the different processing options simplified the overall process of produc-
tion by limiting the intervention of the experimenter between the different processing
steps. The platform was made of disposable/reusable components to minimise the
use of stainless steel. Each processing step can, however, be presented as a dispos-
able solution to prevent product cross contamination or eliminate a non negligible
volume of buffers. Yet, some components of the platform such as the sorbents of
chromatography or the cassette of filtration, could be reused to minimise the cost
of the platform.
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General discussion and future
directions
This Chapter summarises the contribution of my research, and attempt to inscribe
it within the current state and needs of biopharma industry towards the
development of new biopharmaceuticals. Directions for future work are also
considered.
The core problem of today’s biopharmaceutical companies is the lack of productivity
in the early stages of drug development. The industry spends far more on R&D and
produces far fewer new molecules than it did 20 years ago. It is not the modes
of production that changed, but the market (165). If blockbuster medicines have
helped large populations to face generic health disorders or illnesses, their efficacy
varies from one patient to another. Yet, the demand for more effective medicines is
rising, and as the population ages, new medical needs emerge. In other words, the
market moves towards personalised medicine i.e. more effective drugs designed for
much smaller numbers of patients. In this context, it becomes necessary to amplify
the relevance of early molecules testing by bringing more molecules into testing while
decreasing the costs of early production. At the moment, production systems rely
on long, tedious and product specific developments. If those are a prerequisite to
a large scale production, they are incompatible with the quick and cost effective
production of numerous molecules to support preclinical development.
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6.1 The development of a transient production platform
This thesis aimed to develop a platform for the production of milligrams to gram
of recombinant protein. The idea was that the platform should accommodate the
flexibility required for the quick and cost effective production of multi-products. In
theory, transient expression technology represented the ideal expression platform as
it allows for the conversion of recombinant gene into protein products in days. How-
ever, transient expression processes utilises functionally heterogeneous parental cell
populations, whose intrinsic genetic heterogeneity has not been exploited to derive a
host cell clone intrinsically suited to the expression of the product. As a result tran-
sient production processes are generally low yielding (73). Moreover, the processes
are relatively complex with numerous interdependent variables underpinning the
overall process efficiency. A sub-project within this thesis was therefore to take into
account the intrinsic complexity associated with transient production processes to
develop a transient expression platform in CHO-S cells. This development was done
rationally by sequentially optimizing three groups of variables involved either in the
early transfection process, the transgene expression and cell maintenance, and/or
culture process design. Using an integrated set of DOE tools, the whole platform
could be developed in 45 days and the process yield be improved by more than 200
fold, yielding approximately 88 and 82mg L-1 of an IgG2 and an IgG1 respectively
in 10 days. Product quality attributes such as charged variants and percentage of
monomers were also checked. Interestingly, compared to a stably expressed prod-
uct, a transiently expressed mAb showed a larger proportion of correctly charged
molecules.
The process developed at small scale was scaled up to 5, then 20L. The scale-up
proved to be particularly challenging as simple operations at lab scale were difficult
to reproduce at large scale. Furthermore, mammalian cell culture can be charac-
terised as very demanding processes where a single mistake can rapidly be associated
with disastrous consequences on the process at large scale. At 5L, the non adapted
routine passage method resulted in significantly lower yields than the ones achieved
at lab scale. At the 20L scale, the limited capacity of the centrifuge used for the cell
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concentration step resulted in the multiplication of the operations and the eventual
contamination of the cultures. First days post transfection showed that the trans-
fection process succesfully occurred and that the cells were expressing the reporter
protein in the ranges observed at lab scale. This event stressed the need of including
scalability as a parameter during the development of a process at lab scale, and
the need for testing the protocol with a simulant at large scale prior to running the
definitive process.
6.2 The development and integration of a purification
platform
It was necessary at this stage to also evaluate the potential of integration of an ap-
propriate purification platform with the upstream transient cell culture. The major
challenge brought by transient culture is the relatively low concentration of product
within the cell culture supernatant. If the high selectivity of Protein A guaranteed
the capture of the majority of the product on a chromatography column, loading the
whole supernatant in one go could not be accomplished without significantly long
loading time, and eventually the contamination of the feed. Moreover, the efficiency
of the capture on Protein A strongly depended on the residence time within the
chromatography column, the capacity of the overall system tending to the maximal
capacity with longer residence and therefore loading times. A solution to the prob-
lem required (i) increasing the volume of Protein A sorbent so the column could be
loaded at high flowrates without losing product and (ii) scaling out the process. An
advantage of this solution is its flexibility. Protein A sorbent based capture process
are relatively robust for cell culture supernatant variations. Although providing ex-
cellent purification performance, some host cell proteins, as well as nucleic acids can
co-elute with the product. By combining a cation exchange, followed by an anion
exchange step, it was possible to considerably reduce these contaminants to an ac-
ceptable level. The cation exchange step was performed using S HyperCel sorbent
as it was possible to load the Protein A eluate straight onto the column without the
158
Chapter 6. General discussion and future directions
need to titrate the Protein A eluate first. In this work, the Protein A capture and
the CEX steps were performed in series. However, an improved version could be
to develop a continuous process by eluting the product from Protein A directly on
the S HyperCel sorbent. Final polishing purification and ultrafiltration/diafiltration
steps using membrane chromatography and TFF respectively could be performed
easily and relatively quickly.
The purification platform presented here was developed for monoclonal antibod-
ies as they represent the current major class of biopharmaceuticals. It is clear that
some changes should be introduced for the purification of other classes of recombi-
nant proteins as the capture by Protein A sorbent is specific to mAbs. However,
this work also provides a methodology framework that could be used in the future
to develop new capture processes and subsequently adapt the platform as needed.
6.3 Economical considerations related to the use of the
platform
For each processing step, a cost of goods analysis was carried out. Parameters such as
consumables, the hours of labour (estimated at £10 hr-1) and the specific investment
in equipment required to generate 1g of purified mAb were taken into account.
General equipment routinely used in cell line development such as bioreactor units,
or cell culture incubators however, were not taken into account in the analysis.
Capital charges such as energy costs and footprint area in the building were not
taken into account as they vary strongly across different companies and are usually
not communicated to the public. Results are presented in Figure 6.1.
DNA production costs were driven at 60% by the costs of the single-use DNA
purification kits. This step also represented a labour intensive process as 43 hours
of work in total was required to generate the amount of DNA required. The devel-
opment of the transient gene expression process was the most labour-intensive step
in the overall process with a total of 50 hours of work required. The transient gene
expression process costs were driven by the cost of basal media (48%) as well as the
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Figure 6.1: Breakdown of COG for performing each processing step once. The
relative costs of consumables, specific materials and hours of labour for each processing
step are represented. While consumables and labour were driving the costs of upstream
processing steps, investment in specific equipment.material represented the main cost of the
downstream processing applications.
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feed media (18%). The cost of DNA also represented a significant part in the overall
cost of this step. The costs of the downstream applications were on the contrary
driven by the specific investment in reusable equipment. S HyperCel sorbent being
relatively inexpensive, the relative costs of buffers and labour required for the in-
termediate purification steps were higher compared to the capture step. Indeed the
chromatographic sorbents MabSelect Sure Protein A and S HyperCel accounted for
79% and 45% of the overall costs of the capture and intermediate purification steps
respectively. The polishing purification and UF/DF steps costs were driven by the
investment in the specific coin holder, and cassette housing, respectively.
The breakdown of the COG for the production of 1g of one mAb is detailed in
Figure 6.2, A. The transient gene expression process represented the most costly
operation at 33% of the overall costs. Despite the relatively high cost of Protein
A sorbent, the capture step only represented 10% of the costs. The UF/DF step
however accounted for more than a quarter of the overall costs. This is primarily
due to the investment in a cassette holder. In fact, the investment in equipment and
other reusable components represented 39.9% of the overall costs for the production
of one mAb. The relative cost of consumables, labour and investment required
to produce 1g of 10 different mAbs, or 10g of one mAb, were then summed-up
with respect to each processing step, and compared with the costs associated with
the production of one gram of only one mAb. As shown in Figure 6.2, the steps
that required significant initial investment in equipment and/or labour now only
represent a relatively low part of the overall costs (14%). In fact it appeared clearly
that the costs of production were now mostly driven by the consumables necessary
to perform the DNA production (21%) and the transient gene expression processes
(57%). In other words, transient expression titres represented a major bottleneck in
the platform and increasing titres would result in significant savings in the amount
of consumables required to generate 1g of protein.
A simulation of what the cost of the production will be with respect to an in-
crease in titres has been performed and the results are presented in Figure 6.3.
Doubling transient titres would result in 22.4% reduction of the overall production
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Figure 6.2: Breakdown of COG for the production of one mAb and 10 mAbs. The
relative cost of consumables, labour and investment required to produce 1g of 10 different
mAbs, or 10g of one mAb (B), were then summed-up with respect to each processing step,
and compared with the costs associated with the production of one gram of only one mAb
(A).
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Figure 6.3: Cost benefits provided by an increase in transient expression titres.
Consumables required in the DNA production step and transient gene expression process
represented 36.7% of the overall production costs. By increasing transient titres, the amount
of consumables, and therefore the costs to generate 1g of mAb could be significantly reduced.
cost. Increasing titres to 600mg L-1 would result in 43.4% savings. However increas-
ing transient titres above 600mg L-1 would not result in significant savings anymore.
At this stage, production costs become incompressible and the cost of production is
mainly driven by downstream applications.
Finally the resources required to generate 1g of protein using the development of
a stable producing clone, or the transient expression process, were compared (Fig-
ure 6.4). Genmab B.V. company evaluates at 13 months and 1.4 full time equivalent
salary (28,000£) the resources required to manually develop a stable cell clone (166).
Following the detailed protocol presented by Lundgren et. al, it was possible to es-
timate the resources required to develop a producing stable cell clone to £30,737
and 12 months (167). The details of this estimation are presented in Appendices.
In comparison, developing a TGE platform and generating 1g of mAb was 5.7 times
cheaper and could be achieved 4.24 times quicker (Figure 6.4). Moreover, previous
data showed that once developed, a TGE platform can be reused to express other
mAbs with no, to minor tweaking of the process. Therefore, it becomes possible
to generate the required quantities of mAb in 34 days which reduces the overall
production time by 59.5%.
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Figure 6.4: Comparison of the resources required to generate 1g of mAb using
the developed transient production platform or a stable producing clone. For
each step of a protocol detailing the development of a stable producing clone, an estimation
of the required consumables and labour was performed (167). The associated costs and time
of development were summed up and are presented here. Those numbers correlated with
the numbers presented by Gerritsen et al. (166). The production of 1g of mAb once the
production platform has been developed could be reduced from 84 to 34 days
6.4 Future improvement should focus on the upstream
transient expression process
Cost analysis revealed that the obtaining 1g of protein using the developed TGE
expression platform was much cheaper than having to generate a stable expressing
clone. However the breakdown of COGs also revealed that the costs of the overall
platform were driven by the price of consumables required at large scale. The costs
associated with the DNA production are hardly compressible as the step is limited
not by the bacteria host productivity, but the capacity of the disposable purifica-
tion kits limited to 15mg. Therefore, further direct improvement should focus on
increasing transient titres up to 600mg L-1. This could be done by several means.
Firstly, the screening of initial basal discrete variables, such as the culture medium,
should be intensified. Indeed, a recent study showed that the nature of culture
medium used at transfection could impact transient production titres by more than
400 fold (168). Secondly, the development of a DNA vector with a specific sequence
aimed at (i) improving the half life of the vector within the cell, (ii) promoting
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the vector transportation into the cell nucleus with, for example, a greater affinity
for nuclear import sequences, (iii) introducing a stronger promoter than the actual
CMV, (iv) including the genes coding for growth factors favouring the long term
cell survival such as p21 or p28 and (v) including sequences coding for regulatory
elements. Lastly, the development of new DNA vehicles less cytotoxic than PEI
would aid production of higher titres.
At this stage of the development, the platform is characterised by a shift in
scale between the upstream transient expression system, and the purification plat-
form. Indeed, transient cultures are relatively low yielding. As a result, litres of
culture need to be run to achieve 1g of protein. However this work shows that 1g of
mAb could efficiently be purified using 10mL chromatography columns. Therefore,
compared to the costs of consumables required in cell culture, the downstream pro-
cessing material is relatively inexpensive. Moreover, initial equipment investment in
cassette or AEX membrane holder can be reused to such a large extent (stainless
steel) that their cost can be amortised.
6.5 Towards a fully disposable platform?
The current trend towards disposable manufacturing reflects the pressure on compa-
nies to increase their flexibility without exposure to excessive investment risk. Using
disposable processing material allows companies to shift resources from upfront cap-
ital investment into variables costs of consumables spread over time. However, if the
advantages of disposable over stainless steel and in cell culture processes are today
widely accepted, the benefits of disposable manufacturing over reusable equipment
for downstream applications still remains to be proven. The main advantage of dis-
posable is to eliminate the need for cleaning in place then validation steps that are
required with reusable equipment. However, the cost of some material is so high
that using it as a disposable component is not economically viable. Moreover, the
single-use-then-disposal of equipment capable of being reused highlights some ethi-
cal problems. With respect to mAb processing, the cost of downstream processing
are generally driven by the cost of the Protein A sorbent. In this case, it is clear
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that cleaning and validating the system between uses is cheaper than buying more
sorbent. Interestingly, from both a practical and economical point of view, a so-
lution would be to use both properties and introduce continuous processes. Using
the Protein A example, performing several cycles of capture and elution throughout
the culture would require a limited amount of sorbent while ensuring to use it as its
maximum potential before disposal.
6.6 The place of DOE driven experimentation in data
and knowledge management
With respect to the complexity of current pharmaceutical processes, managing ex-
perimentation and the treatment of data are of primary importance to avoid an
information overload and gain maximum knowledge on the product and/or the pro-
cess from less data. The difficulty shifts from not being able to produce enough
material to quickly developing a process able to perform the task. According to
Davenport and Pruzak, knowledge is located at the apex of a three levels pyramid
(169). The first level consists of the generation of data by experimentation. Efforts
conducted during experimentation can be converted to information after proper data
analysis. Finally, the information gained allows the scientist to get knowledge on
the product and/or process. Current regulatory context shows that it becomes of
utmost importance to characterise a production process and the influence of ba-
sic operational parameters on the product and process quality attributes. In other
words, providing a methodology framework for experimentation and development is
now of primary importance. The traditional paradigm of optimizing processes by
varying one factor at a time can only result in long, challenging development. More-
over, the limited gain in information and knowledge on the product/process leads
to the biased estimation of the potential of a molecule to reach the market later on.
Finally, this approach leads to the development of ”locked” processes, unadapted to
the inherent variability associated with the current biological systems in use. QbD
is clearly aimed at addressing this situation by introducing a rational, cost effective
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method of development. The approach is to develop as early as possible an under-
standing of the relationships between the input material, the process parameters
and the resultant products quality attributes. This method leads to a more strin-
gent screening of the potential of a molecule to reach the market. By using QbD,
that encompasses the use of DOE, the development of a process can be conducted
relatively quickly. More importantly, the gain in information is far superior than
with traditional methods of experimentation thanks to a thorough and rational sta-
tistical analysis of data. The knowledge gained during the development can then
be used during the manufacturing to adjust in real time the process parameters to
constantly meet the product specifications (Figure 6.5).
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Figure 6.5: Traditional versus future paradigm for the development of biophar-
maceutical processes. The traditional paradigm for process development leads to the de-
velopment of locked processes for which any variability in input material will be transferred
to the product. Compared to traditional development, the use of DOE driven experimen-
tation allows the scientist to increase the amount of knowledge construct a design space
within which the effect of the variations of input material and critical process parameters
on the process/product is known. It is believed that in a near future, it will be possible to
continuously adjust the process parameters to compensate for input material variability and
constantly produce high quality product. Adapted from (88).
It appears that the democratisation of DOE in process development is one of
the first steps to address the current challenges the biopharm industry is facing.
However, the method is relatively complex and the knowledge of statistics required
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for the use of DOE represents a major barrier to its generalisation within the in-
dustry. Available statistical packages are too generic and unintuitive. The industry
will certainly gain from a dedicated software, or more integration with the current
platform of development. It is believed that the method could be almost entirely
generalised and automated. The integrated DOE set of tools used in Chapter 3 to
develop a TGE platform represents an example of what a generic DOE approach
to process optimisation could be. The algorithm, presented in Chapter 2 proves
that even complex tasks such as the selection and validation of an empirical model
from a set of data could be automated. Moreover, the past few years have seen the
arrival on the market of small scale platforms for the expanded throughput of early
screening of process conditions such as the Micro-24 MicroBioReactor from Pall Life
Sciences. This is the perfect opportunity to democratise the use of DOE during
process development. It is believed that the integration of a DOE module to the
control software could be of real value.
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Appendix A
Statistical modules library
All the modules have been written in Mathematica as “packages” that the experi-
menter calls within the software.
A.1 Mother file - Algorithm
SetDi r ec to ry [
Input [ ” Please i n s e r t the path o f the d i r e c t o r y that
conta in s the \
e x c e l f i l e o f your data . The format o f the path has to be \
’ ’C : / . . . ’ ’ ” ] ] data =
Import [ Input [
” Please i n s e r t the name o f the f i l e from which you would
l i k e to \
ana lyze the data . The format o f the name has to be \
’ ’ f i l ename . x l s ’ ’ ” ] ] Needs [ ” ModelsGenerator ‘ ” ]
Candidates = ModelsGenerator [ data ] ;
Needs [ ” ModelsEqGenerator ‘ ” ]
ModelsEqGenerator [ data ] ;
Needs [ ” ShapiroWilkTest ‘ ” ]
Needs [ ” BoxCoxTransformation ‘ ” ]
Needs [ ” DataTransformation ‘ ” ]
TableFullNormalResModels = Table [
NormalResModel = Candidates [ [ n ] ] ;
NormalResModelEq = ModelsEqGenerator [ data ] [ [ n ] ] ;
I f [ ShapiroWilkTest [ NormalResModel ] == ”Yes ” ,
(
BoxCoxTest =
BoxCoxTransformation [ NormalResModel , NormalResModelEq
] ;
NeedTransformation = I f [ BoxCoxTest [ [ 1 , 2 , 1 ] ] == 1 , ”No
” , ”Yes ” ] ;
TModelResNormal = I f [ NeedTransformation == ”Yes ” ,
(
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Tdata = DataTransformation [ data , BoxCoxTest [ [ 1 , 2 ,
1 ] ] ] ;
l = NormalResModel [ ” BestFitParameters ” ] ;
L i stParameters = Table [ l [ [ n , 1 ] ] , {n , Length [ l ] } ] ;
L i s tFac to r s =
Array [ Subsc r ip t [
Global ‘ x , #] &, {Length [ Global ‘ data [ [ 1 , 1 , 1
; ; ] ] ] − 1 } ] ;
TModel =
Nonl inearModelFit [ Tdata , NormalResModelEq ,
ListParameters ,
L i s tFac to r s ] ;
ShapiroWilkTest [ TModel ]
) , ” Nul l ”
] ;
I f [ TModelResNormal == ”No” , TModel ]
) ,
NormalResModel ] , {n , Length [ Candidates ] } ] ;
TableNormalResModels = Cases [ TableFullNormalResModels ,
Except [ Nul l ] ] ;
Needs [ ” Mode lS ign i f i cance ‘ ” ]
Tab l eS ign i f i cantMode l s =
Cases [ Table [
I f [ Mode lS i gn i f i cance [ TableNormalResModels [ [ n ] ] ] == ”Yes
” ,
TableNormalResModels [ [ n ] ] ]
, {n , Length [ TableNormalResModels ]}
] ,
Except [ Nul l ]
] ;
Needs [ ” ModelOver f i t t ing ‘ ” ]
GoodFittingModels =
Cases [
Table [ I f [
Mode lOver f i t t ing [ Tab l eS ign i f i cantMode l s [ [ n ] ] ] ==
”Not o v e r f i t t e d ” , Tab l eS ign i f i cantMode l s [ [ n ] ] ] , {n ,
Length [ Tab l eS ign i f i cantMode l s ] } ] ,
Except [ Nul l ]
] ;
Needs [ ” Mode lS ta t i s t i c s ‘ ” ]
Potent ia lMode l s =
Cases [ Table [
I f [ M o d e l S t a t i s t i c s [ GoodFittingModels [ [ n ] ] ] [ [ 1 , 2 , 4 ] ] <
0 . 2 ,
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GoodFittingModels [ [ n ] ] ] ,
{n , Length [ GoodFittingModels ] } ] ,
Except [ Nul l ] ] ;
PosModelEq =
Flat ten [ Table [
Po s i t i on [ TableFullNormalResModels , Potent ia lMode l s [ [ n
] ] ] , {n ,
Length [ Potent ia lMode l s ] } ] ] ;
ModelFullEq =
Table [ ModelsEqGenerator [ data ] [ [ PosModelEq [ [ n ] ] ] ] , {n ,
Length [ Potent ia lMode l s ] } ] ;
Needs [ ” ModelOptimums ‘ ” ]
Needs [ ” ModelContourPlots ‘ ” ]
Needs [ ” Mode lS ta t i s t i c s ‘ ” ]
Needs [ ” ModelResAnalysis ‘ ” ]
Needs [ ” BoxCoxTransformation ‘ ” ]
Table [ Grid [{{ Sty l e [ ” Model” n , Bold , Large ]} , { Sty l e [ ”
ModelOptimums ” ,
Bold , Large ]} , {ModelOptimums [ ModelFullEq [ [ n ] ] ,
Potent ia lMode l s [ [ n ] ] ] } , { Sty l e [ ” Model S t a t i s t i c s ” , Bold
,
Large ]} , {M o d e l S t a t i s t i c s [ Potent ia lMode l s [ [ n ] ] ] } , {
Sty l e [
”Model Equation ” , Bold , Large ] ,
”( caut ion , model may be transformed , s ee below the box−
cox \
r e s u l t s ) ”} , {Normal [ Potent ia lMode l s [ [ n ] ] ] } ,
{ Sty l e [ ” Box−Cox r e s u l t s ” , Bold , Large ]} , {
BoxCoxTransformation [
Potent ia lMode l s [ [ n ] ] , ModelFullEq [ [ n ] ] ] } , {
ModelResAnalysis [
Potent ia lMode l s [ [ n ] ] ] } ,
{ Sty l e [ ” Contour p l o t s ” , Large , Bold ]} , {ModelContourPlots
[
Potent ia lMode l s [ [ n ] ] ] } } , Alignment −> Left , Frame −>
All ,
FrameStyle −> Thick ] , {n , Length [ Potent ia lMode l s ] } ]
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A.2 ModelsGenerator
BeginPackage [ ” ModelsGenerator ‘ ” ]
ModelsGenerator : : usage=”ModelsGenerator gene ra t e s a t ab l e o f
r e g r e s s i o n models . ”
Begin [ ” Private ‘ ” ]
ModelsGenerator [ data ] :=( Length [ data [ [ 1 , 1 , 1 ; ; ] ] ] ;
lmf=Array [ Subsc r ip t [ Global ‘ x ,#]& ,{Length [ data
[ [ 1 , 1 , 1 ; ; ] ] ] − 1 } ] ;
l o f a=De l e t eDup l i ca t e s [ F lat ten [ Table [ Subsc r ip t [ Global ‘ x , i ]
lmf ,{ i , Length [ lmf ] } ] ] ] ;
lp=Take [{Global ‘ a , Global ‘ b , Global ‘ c , Global ‘ d , Global ‘ e , Global
‘ f , Global ‘ g , Global ‘ h , Global ‘ i , Global ‘ j , Global ‘ k , Global ‘ l ,
Global ‘m, Global ‘ n , Global ‘ o , Global ‘ p , Global ‘ q , Global ‘ r ,
Global ‘ s , Global ‘ t , Global ‘ u , Global ‘ v , Global ‘w} , Length [ lmf
]+Length [ l o f a ] + 1 ] ;
lmp=Take [{Global ‘ a , Global ‘ b , Global ‘ c , Global ‘ d , Global ‘ e ,
Global ‘ f , Global ‘ g , Global ‘ h , Global ‘ i , Global ‘ j , Global ‘ k ,
Global ‘ l , Global ‘m, Global ‘ n , Global ‘ o , Global ‘ p , Global ‘ q ,
Global ‘ r , Global ‘ s , Global ‘ t , Global ‘ u , Global ‘ v , Global ‘w} ,
Length [ lmf ] + 1 ] ; l s p=Drop [ lp , Length [ lmp ] ] ;
MfM=Total [ lmp∗Prepend [ lmf , 1 ] ] ;
MatM=l o f a ∗ l s p ∗Transpose [ Tuples [{1 , 0} , Length [ l o f a ] ] ] ;
L isteModele=Table [ Total [MatM [ [ 1 ; ; , i ] ] ] +MfM,{ i , Length [ Tuples
[{1 , 0} , Length [ l o f a ] ] ] } ] ;
PreTableModele=Table [ Nonl inearModelFit [ data [ [ 1 , 1 ; ; ] ] ,
L isteModele [ [ n ] ] , lp , lmf ] ,{n , Length [ ListeModele ] } ] / /
MatrixForm ;
Table [ l=Chop [ PreTableModele [ [ 1 , n ] ] [ ” BestFitParameters ” ] ] ;
L i s tp=Cases [ Table [ I f [ ( n / . l ) !=0 ,n ] ,{n , F lat ten [{ lmp , l s p } ] } ] ,
Except [ Nul l ] ] ;
PModel=Nonl inearModelFit [ data [ [ 1 , 1 ; ; ] ] , L isteModele [ [ n ] ] ,
L i s tp [ [ A l l ] ] , lmf ] ,{n , Length [ ListeModele ] } ]
)
End [ ]
EndPackage [ ]
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A.3 ModelsEqGenerator
BeginPackage [ ” ModelsEqGenerator ‘ ” ]
ModelsEqGenerator : : usage=”ModelsEqGenerator gene ra t e s a l i s t
o f a l l the p o s s i b l e r e g r e s s i o n models formal equat ion
f o r a s e t o f data . ”
Begin [ ” Private ‘ ” ]
ModelsEqGenerator [ data ] :=( Length [ data [ [ 1 , 1 , 1 ; ; ] ] ] ;
lmf=Array [ Subsc r ip t [ Global ‘ x ,#]& ,{Length [ data
[ [ 1 , 1 , 1 ; ; ] ] ] − 1 } ] ;
l o f a=De l e t eDup l i ca t e s [ F lat ten [ Table [ Subsc r ip t [ Global ‘ x , i ]
lmf ,{ i , Length [ lmf ] } ] ] ] ;
lp=Take [{Global ‘ a , Global ‘ b , Global ‘ c , Global ‘ d , Global ‘ e , Global
‘ f , Global ‘ g , Global ‘ h , Global ‘ i , Global ‘ j , Global ‘ k , Global ‘ l ,
Global ‘m, Global ‘ n , Global ‘ o , Global ‘ p , Global ‘ q , Global ‘ r ,
Global ‘ s , Global ‘ t , Global ‘ u , Global ‘ v , Global ‘w} , Length [ lmf
]+Length [ l o f a ] + 1 ] ;
lmp=Take [{Global ‘ a , Global ‘ b , Global ‘ c , Global ‘ d , Global ‘ e ,
Global ‘ f , Global ‘ g , Global ‘ h , Global ‘ i , Global ‘ j , Global ‘ k ,
Global ‘ l , Global ‘m, Global ‘ n , Global ‘ o , Global ‘ p , Global ‘ q ,
Global ‘ r , Global ‘ s , Global ‘ t , Global ‘ u , Global ‘ v , Global ‘w} ,
Length [ lmf ] + 1 ] ; l s p=Drop [ lp , Length [ lmp ] ] ;
MfM=Total [ lmp∗Prepend [ lmf , 1 ] ] ;
MatM=l o f a ∗ l s p ∗Transpose [ Tuples [{1 , 0} , Length [ l o f a ] ] ] ;
Table [ Total [MatM [ [ 1 ; ; , i ] ] ] +MfM,{ i , Length [ Tuples [{1 , 0} , Length
[ l o f a ] ] ] } ] )
End [ ]
EndPackage [ ]
A.4 DataTransformation
BeginPackage [ ” DataTransformation ‘ ” ]
DataTransformation : : usage=”Transform a s e t o f data with a
power t rans fo rmat ion ”
Begin [ ” Private ‘ ” ]
DataTransformation [ data , RecommendedTransformation ] :=(
I f [ RecommendedTransformation==0, NewResponse=Log [ Global ‘ data
[ [ 1 , 1 ; ; , Length [ Global ‘ data [ [ 1 , 1 , 1 ; ; ] ] ] ] ] ] , NewResponse=
Global ‘ data [ [ 1 , 1 ; ; , Length [ Global ‘ data [ [ 1 , 1 , 1 ; ; ] ] ] ] ] ˆ
RecommendedTransformation ] ;
Newdata=P a r t i t i o n [ F lat ten [ R i f f l e [ Global ‘ data [ [ 1 , 1 ; ; , 1 ; ;
Length [ Global ‘ data [ [ 1 , 1 , 1 ; ; ] ] ] − 1 ] ] , NewResponse ] ] , Length [
Global ‘ data [ [ 1 , 1 , 1 ; ; ] ] ] ]
)
End [ ]
EndPackage [ ]
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A.5 BoxCoxTransformation
BeginPackage [ ” BoxCoxTransformation ‘ ” ]
BoxCoxTransformation : : usage=”Performs a BoxCox
trans fo rmat ion i . e . t e s t i f data should be transformed ”
Begin [ ” Private ‘ ” ]
BoxCoxTransformation [ ModelFullEquation , ModelFormalEquation
] :=(
l=ModelFullEquation [ ” BestFitParameters ” ] ;
Listparam=Table [ l [ [ n , 1 ] ] , { n , Length [ l ] } ] ;
GM=Exp [ ( \ ! \ (
\∗Underoverscr iptBox [ \ ( \ [ Sum] \ ) , \(p = 1\) , \( Length [ Global ‘
data [ \ ( [ 1 , \ (\ (1\ ) \ ( ; ; \ ) \) ] \ ) ] ] \ ) ] \ ( Log [ Global ‘ data [ \ ( [ 1 ,
p , Length [ Global ‘ data [ \ ( [ 1 , 1 ]\ ) ] ] ] \ ) ] ] \ ) \) ) /Length [
Global ‘ data [ [ 1 , 1 ; ; ] ] ] ] ;
s [ x , w ] : = ( ( xˆw)−1)/(w∗GMˆ(w−1) ) ;
TTableneg=Table [ s [ Global ‘ data [ [ 1 , 1 ; ; , Length [ Global ‘ data
[ [ 1 , 1 ] ] ] ] ] , n ] ,{n , −3 , −0 .1 ,0 .2} ] ;
TTablepos=Table [ s [ Global ‘ data [ [ 1 , 1 ; ; , Length [ Global ‘ data
[ [ 1 , 1 ] ] ] ] ] , n ] ,{n , 0 . 1 , 3 , 0 . 2 } ] ;
TTable=Join [ TTableneg , TTablepos ] ;
lmf=Array [ Subsc r ip t [ Global ‘ x ,#]& ,{Length [ Global ‘ data
[ [ 1 , 1 , 1 ; ; ] ] ] − 1 } ] ;
tdata=P a r t i t i o n [ F lat ten [ R i f f l e [ Global ‘ data [ [ 1 , 1 ; ; , 1 ; ; Length [
Global ‘ data [ [ 1 , 1 ] ] ] − 1 ] ] , TTable [ [ 2 , ; ; ] ] ] ] , Length [ Global ‘
data [ [ 1 , 1 ] ] ] ] ;
ListeLogSSRes=Table [ tdata=P a r t i t i o n [ F lat ten [ R i f f l e [ Global ‘
data [ [ 1 , 1 ; ; , 1 ; ; Length [ Global ‘ data [ [ 1 , 1 ] ] ] − 1 ] ] , TTable [ [ n
, ; ; ] ] ] ] , Length [ Global ‘ data [ [ 1 , 1 ] ] ] ] ;
TModel=Nonl inearModelFit [ tdata , ModelFormalEquation , Listparam
, lmf ] ;
Log [ TModel [ ”ANOVATable ” ] [ [ 1 , 1 , 3 , 3 ] ] ] , { n , Length [ TTable
[ [ 1 ; ; , 1 ] ] ] } ] ;
ListeLambda=Join [ Chop [ Range [ −3 , −0 .1 , 0 . 2 ] ] , Chop [ Range
[ 0 . 1 , 3 , 0 . 2 ] ] ] ;
L i s t e r e s=P a r t i t i o n [ R i f f l e [ ListeLambda , ListeLogSSRes ] , 2 ] ;
Lambda=Cases [ Table [ I f [ L i s t e r e s [ [ n ,2] ]==Min [ ListeLogSSRes ] ,
L i s t e r e s [ [ n , 1 ] ] ] , { n , Length [ L i s t e r e s [ [ 1 ; ; , 1 ] ] ] } ] , Except [
Nul l ] ] ;
BestTransformedResp=s [ Global ‘ data [ [ 1 , 1 ; ; , Length [ Global ‘ data
[ [ 1 , 1 ] ] ] ] ] , Lambda [ [ 1 ] ] ] ;
TransformedData=P a r t i t i o n [ F lat ten [ R i f f l e [ Global ‘ data
[ [ 1 , 1 ; ; , 1 ; ; Length [ Global ‘ data [ [ 1 , 1 ] ] ] − 1 ] ] ,
BestTransformedResp ] ] , Length [ Global ‘ data [ [ 1 , 1 ] ] ] ] ;
BestTransformedModel=Nonl inearModelFit [ TransformedData ,
ModelFormalEquation , Listparam , lmf ] ;
AnovaBTM=BestTransformedModel [ ”ANOVATable ” ] ; SSStar=AnovaBTM
[ [ 1 , 1 , 3 , 3 ] ] ∗ ( 1 + ( Quant i le [ StudentTDistr ibut ion [ DofResidual
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] , 0 . 9 5 ] ) ˆ2/ DofResidual ) ;
SSStar=AnovaBTM[ [ 1 , 1 , 3 , 3 ] ] ∗ ( 1 + ( Quant i le [ StudentTDistr ibut ion
[ DofResidual ] , 0 . 9 5 ] ) ˆ2/ DofResidual ) ;
DofModel=Length [ Normal [ ModelFullEquation ] ] −1 ;
DofResidual=ModelFullEquation [ ”ANOVATable” ] [ [ 1 , 1 , 5 , 2 ] ] −
DofModel ;
IFun=I n t e r p o l a t i o n [ L i s t e r e s ] ;
HighCI=x / . Quiet [ FindRoot [ IFun [ x]== Log [ SSStar ] ,{ x , 3 } ] ] ;
LowCI=x / . Quiet [ FindRoot [ IFun [ x]== Log [ SSStar ] ,{ x , −3} ] ] ;
I f [ ( LowCI<=1)==True&&(HighCI>=1)==True ,
RecommendedTransformation={1} ,RecommendedTransformation=
Nearest [{ −1 ,−0.5 ,0 ,0 .5} ,Lambda ] ] ;
BoxCoxTransformationGrid=Grid [{{” RecommendedTransformation ” ,
”Lambda” , ”LowCI” , ”HighCI ”} ,{RecommendedTransformation
[ [ 1 ] ] , Lambda [ [ 1 ] ] , LowCI , HighCI }} ,Frame−>Al l ]
)
End [ ]
EndPackage [ ]
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A.6 ModelSignificance
BeginPackage [ ” Mode lS ign i f i cance ‘ ” ]
Mode lS ign i f i cance : : usage=”Test i f a model i s s i g n i f i c a n t at
95% us ing an ANOVA t e s t . ”
Begin [ ” Private ‘ ” ]
Mode lS ign i f i cance [ ModelFul lEquation ] :=( t e s t=
ModelFullEquation [ ”ANOVATable ” ] ;
DofModel=Length [ Normal [ ModelFullEquation ] ] −1 ;
SSModel=t e s t [ [ 1 , 1 , 5 , 3 ] ] − t e s t [ [ 1 , 1 , 3 , 3 ] ] ; MSModel=SSModel/
DofModel ;
DofResidual=t e s t [ [ 1 , 1 , 5 , 2 ] ] −DofModel ;
MSResidual=t e s t [ [ 1 , 1 , 3 , 3 ] ] / DofResidual ;
F i s h e r s t a t i s t i c=S e t P r e c i s i o n [ MSModel/MSResidual , 4 ] ; Maxi=
FindMaximum [{PDF[ FRat ioDi s t r ibut ion [ DofModel , DofResidual
] , x ] , x>0} ,{x } ] ; Needs [ ” Hypothes isTest ing ‘ ” ] ; I f [
F i s h e r s t a t i s t i c <x / . Maxi [ [ 2 ] ] , va l eur=CDF[
FRat ioDi s t r ibut ion [ DofModel , DofResidual ] , F i s h e r s t a t i s t i c
] , va l eur=1−CDF[ FRat ioDi s t r ibut ion [ DofModel , DofResidual ] ,
F i s h e r s t a t i s t i c ] ] ;
I f [ va leur<= 0.05 , ”Yes ” ,”No ” ] )
End [ ]
EndPackage [ ]
A.7 ModelOverfitting
BeginPackage [ ” ModelOver f i t t ing ‘ ” ]
Mode lOver f i t t ing : : usage=”Test i f the model i s o v e r f i t t e d or
not by check ing pvalues o f model eq f a c t o r s at 10%.”
Begin [ ” Private ‘ ” ]
Mode lOver f i t t ing [ ModelFul lEquation ] :=(
I f [ S e l e c t [ Drop [ ModelFullEquation [ ” ParameterPValues ” ] , Length [
Global ‘ data [ [ 1 , 1 ] ] ] ] , # > 0.10&]!={} ,” Ove r f i t t ed ” ,” Not
o v e r f i t t e d ” ] )
End [ ]
EndPackage [ ]
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A.8 ModelOptimums
BeginPackage [ ” ModelOptimums ‘ ” ]
ModelOptimums : : usage=”Generates a g r id with the optimal
s u t i e d response as we l l as the f a c t o r s l e ad ing to i t and
t h e i r a s s o c i a t e d con f idence i n t e r v a l s ”
Needs [ ” M u l t i v a r i a t e S t a t i s t i c s ‘ ” ] ;
Begin [ ” Private ‘ ” ]
ModelOptimums [ ModelFormalEquation , ModelFul lEquation ] :=(
CovM=Chop [ ModelFullEquation [ ” CovarianceMatrix ” ] ] ;
CovM2=S e t P r e c i s i o n [CovM, 5 ] ;
mnd=Quiet [ Mul t inormalDi s t r ibut ion [ ModelFullEquation [ ”
BestFitParameters ” ] [ [ All , 2 ] ] , CovM2 ] ] ;
l=ModelFullEquation [ ” BestFitParameters ” ] ;
Listparam=Table [ l [ [ n , 1 ] ] , { n , Length [ l ] } ] ;
f g t=Function [##,Evaluate [ ModelFormalEquation ] ]&@@ {Listparam
} ;
f g t 2=Apply [ fgt , RandomReal [mnd ] ] ;
lmf=Array [ Subsc r ip t [ Global ‘ x ,#]& ,{Length [ Global ‘ data
[ [ 1 , 1 , 1 ; ; ] ] ] − 1 } ] ;
S ta t s=Table [ Maximize [{Apply [ fgt , RandomReal [mnd ] ] , Table [ Min [
Global ‘ data [ [ 1 , All , n ]]]<= lmf [ [ n]]<=Max[ Global ‘ data [ [ 1 , All
, n ] ] ] , { n , 1 , Length [ lmf ] } ] } , lmf ] , { 1 0 } ] ;
MeanOptResp=Through [{Mean , StandardDeviat ion } [ S ta t s [ [ All
, 1 ] ] ] ] ;
MeanOptFactors=Through [{Mean , StandardDeviat ion } [ S ta t s [ [ All
, 2 , All , 2 ] ] ] ] ;
Zut=Table [ lmf [ [ n ] ] , { n , Length [ lmf ] } ] ;
Zut2=Table [ MeanOptFactors [ [ 1 , n ] ] , { n , Length [ lmf ] } ] ;
Zut3=Table [ MeanOptFactors [ [ 2 , n ] ] , { n , Length [ lmf ] } ] ;
PL=Flat ten [ Join [{” ”} ,{” Response ”} ,{Zut } ] ] ;
DL=Flat ten [ Join [{”Optimum”} ,{MeanOptResp [ [ 1 ] ] } , Zut2 ] ] ;
TL=Flat ten [ Join [{”95% C. I . ”} ,{MeanOptResp [ [ 2 ] ] } , Zut3 ] ] ;
Grid [{PL,DL,TL} ,Frame−>Al l ]
)
End [ ]
EndPackage [ ]
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A.9 ModelStatistics
BeginPackage [ ” Mode lS ta t i s t i c s ‘ ” ]
M o d e l S t a t i s t i c s : : usage=”Generate a t a b l e with the ba s i c
s t a t i s t i c s a s s o c i a t e d with a non l i n e a r model f i t . ”
Begin [ ” Private ‘ ” ]
M o d e l S t a t i s t i c s [ ModelFul lEquation ] :=(PRESS=Total [ Table [ (
ModelFullEquation [ ” F i tRes idua l s ” ] [ [m] ]/(1−
ModelFullEquation [ ” HatDiagonal ” ] [ [m] ] ) ) ˆ2 ,{m, 1 , Length [
Global ‘ data [ [ 1 , 1 ; ; ] ] ] } ] ] ; t e s t=ModelFullEquation [ ”
ANOVATable ” ] ; SSModel=t e s t [ [ 1 , 1 , 5 , 3 ] ] − t e s t [ [ 1 , 1 , 3 , 3 ] ] ;
RSqM=SSModel/ t e s t [ [ 1 , 1 , 5 , 3 ] ] ;
s ample s i z e=Length [ Global ‘ data [ [ 1 , A l l ] ] ] ;
RSqAdjM=1−(( samples i ze −1)/( samples i ze−Length [ Normal [
ModelFullEquation ] ] ) )∗(1−RSqM) ; RSqPredM=1−(PRESS/ t e s t
[ [ 1 , 1 , 5 , 3 ] ] ) ; D i f f=RSqAdjM−RSqPredM ;
Grid [{{”RSq” ,” Ajusted RSq” ,” Pred RSq” ,” Adj RSq − Pred RSq
”} ,{RSqM, RSqAdjM, RSqPredM , RSqAdjM−RSqPredM}} ,Frame−>Al l ] )
End [ ]
EndPackage [ ]
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A.10 ModelResAnalysis
BeginPackage [ ” ModelResAnalysis ‘ ” ]
ModelResAnalysis : : usage=”Perform r e s i d u a l a n a l y s i s on a
s p e c i f i e d model”
Begin [ ” Private ‘ ” ]
ModelResAnalysis [ Model ] :=(
PR=Model [ ” PredictedResponse ” ] ;
SR=Model [ ” Student i z edRes idua l s ” ] ;
CD=Table [{PR [ [ n ] ] , SR [ [ n ] ] } , { n , Length [PR ] } ] ;
TableF=Table [ Global ‘ data [ [ 1 , 1 ; ; , n ] ] , { n , Length [ Global ‘ data
[ [ 1 , 1 ] ] ] − 1 } ] ;
Coordinates=Table [ P a r t i t i o n [ R i f f l e [ TableF [ [ n ] ] , SR ] , 2 ] , { n ,
Length [ Global ‘ data [ [ 1 , 1 ] ] ] − 1 } ] ;
lmf=Array [ Subsc r ip t [ Global ‘ x ,#]& ,{Length [ Global ‘ data
[ [ 1 , 1 , 1 ; ; ] ] ] − 1 } ] ;
HLPlot=L i s t P l o t [CD, PlotSty le−>{PointSize−>Large } ,Frame−>True
, PlotRange−>{−4 ,4}];
FLPlots=Table [ L i s t P l o t [ Coordinates [ [ i , 1 ; ; ] ] , PlotRange−>{{Min
[ Coordinates [ [ i , 1 ; ; , 1 ] ] ] − 1 ,Max [ Coordinates [ [ i
, 1 ; ; , 1 ] ] ] + 1} ,{ −4 , 4}} , AxesOrigin−>{Min [ Coordinates [ [ i
, 1 ; ; , 1 ] ] ] − 1 , 0 } , Frame−>True , P lotSty l e−>{PointSize−>Large } ,
FrameLabel−>{lmf [ [ i ] ] , ” Student ized Res idua l s ”} ] ,{ i , Length
[ TableF ] } ] ;
Grid [{{ Sty l e [ ” Res idua l s Ana lys i s ” , Bold , Large ]} ,{Grid [{{ Sty l e
[ ” I n f l u e n c e o f i n d i v i d u a l f a c t o r s on the re sponse ” , Bold
]} ,{ FLPlots } ,{” Points in the char t s above should
d i s t r i b u t e around the 0 l i n e in a random pattern .”} } ,
Frame−>Al l ]} ,{Grid [{{ Sty l e [ ” Homoscedast ic i ty and
l i n e a r i t y o f the r e s i d u a l s ” , Bold ]} ,{HLPlot } ,{” Points in
the graph above should ( i ) d i s t r i b u t e randomly around the
0 l i n e in ( i i ) a random pattern . I f the se c o n d i t i o n s are
not v e r i f i e d i t i s advised to not use t h i s model ”}} ,
Frame−>Al l ]}} , Frame−>All , Alignment−>Le f t ]
)
End [ ]
EndPackage [ ]
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A.11 ModelContourPlots
BeginPackage [ ” ModelContourPlots ‘ ” ]
ModelContourPlots : : usage ”hh”
Begin [ ” Private ‘ ” ]
ModelContourPlots [ ModelFul lEquation ] :=(
r e s=Table [ ContourPlot [ ModelFullEquation [ Subsc r ip t [ Global ‘ x ,
1 ] , Subsc r ip t [ Global ‘ x , 2 ] , n ] ,{ Subsc r ip t [ Global ‘ x , 1 ] , Min [
Global ‘ data [ [ 1 , All , 1 ] ] ] , Max [ Global ‘ data [ [ 1 , All , 1 ] ] ] } , {
Subsc r ip t [ Global ‘ x , 2 ] , Min [ Global ‘ data [ [ 1 , All , 2 ] ] ] , Max [
Global ‘ data [ [ 1 , All , 2 ] ] ] } , ContourLabels−>True ,
ColorFunction−>”Rainbow ” , Frame−>True ,
ColorFunct ionSca l ing −>{0,n/Max[ Global ‘ data [ [ 1 , All , 3 ] ] ] } ,
BoundaryStyle−>Black ] ,{n , Min [ Global ‘ data [ [ 1 , All , 3 ] ] ] , Max [
Global ‘ data [ [ 1 , All , 3 ] ] ] , Max [ Global ‘ data [ [ 1 , All , 3 ] ] ] / 1 0 } ] ;
lmf=Array [ Subsc r ip t [ Global ‘ x ,#]& ,{Length [ Global ‘ data
[ [ 1 , 1 , 1 ; ; ] ] ] − 1 } ] ;
IP1=Grid [{{” Contourplot f o r the x1x2 i n t e r a c t i o n ”} ,{
ListAnimate [ res , ControlPlacement−>Top , AnimationRunning−>
False ]}} , Frame−>Al l ] ;
I f [ Length [ lmf ]==3,
(
r e s2=Table [ ContourPlot [ ModelFullEquation [ Subsc r ip t [ Global ‘ x ,
1 ] , n , Subsc r ip t [ Global ‘ x , 3 ] ] , { Subsc r ip t [ Global ‘ x , 1 ] , Min
[ Global ‘ data [ [ 1 , All , 1 ] ] ] , Max [ Global ‘ data [ [ 1 , All , 1 ] ] ] } , {
Subsc r ip t [ Global ‘ x , 3 ] , Min [ Global ‘ data [ [ 1 , All , 3 ] ] ] , Max [
Global ‘ data [ [ 1 , All , 3 ] ] ] } , ContourLabels−>True ,
ColorFunction−>”Rainbow ” , Frame−>True ,
ColorFunct ionSca l ing −>{0,n/Max[ Global ‘ data [ [ 1 , All , 2 ] ] ] } ,
BoundaryStyle−>Black ] ,{n , Min [ Global ‘ data [ [ 1 , All , 2 ] ] ] , Max [
Global ‘ data [ [ 1 , All , 2 ] ] ] , Max [ Global ‘ data [ [ 1 , All , 2 ] ] ] / 1 0 } ] ;
IP2=
IP2=Grid [{{” Contourplot f o r the x1x3 i n t e r a c t i o n ”} ,{
ListAnimate [ res2 , ControlPlacement−>Top , AnimationRunning−>
False ]}} , Frame−>Al l ] ) ] ;
{IP1 , IP2}
)
End [ ]
EndPackage [ ]
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Cost analysis of the
development of a stable
producing clone
This cost analysis has been performed by estimating the cost of consumables and
hours of work ( 10£ hr-1) for each steps involved in the selection of a stable cell line
from 2000 clones and including one sub cloning step.
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Step Consumables Unit Price Supplier Labor (hr) Cost 
       
CHOK1 culture Flask 250mL 4 131.1 Sigma 4 40 
 CD-CHO 400mL 17.2 Invitrogen   
 Glutamine 200mM 16mL 0.32 Lonza   
       
Electroporation DNA 200ug 100 Experimenter 4 40 
       
Culture in mSX Flask 250mL 4 131.1 Sigma 8 80 
 CD-CHO 400mL 17.2 Invitrogen   
 Glutamine 200mM 16mL 0.32 Lonza   
 MSX-3 hydrate 75uM 239.1 SIGMA   
       
Dilution in 96 well plates 96 well plates 20 2976 Cole-Parmer 8 80 
 CD-CHO 192mL 8.6 Invitrogen   
 Glutamine 200mM 8mL 0.15 Lonza   
 MSX-3 hydrate 75uM 191.3 Sigma   
       
Screening for colonies and ELISA ELISA plates 12 1134  RD Biotech 16 160 
       
Expansion in 24 well plates 24 well plates 20 3288 Cole-Parmer 8 80 
 CD-CHO 2400mL 106 Invitrogen   
 Glutamine 200mM 96mL 1.92 Lonza   
 MSX-3 hydrate 75uM 2293.6 Sigma   
202
A
p
p
en
d
ix
B
.
C
ost
an
a
ly
sis
of
th
e
d
evelop
m
en
t
of
a
stab
le
p
ro
d
u
cin
g
clon
e
Screening for colonies and ELISA ELISA plates 5 472.5  RD Biotech 16 160 
       
Expansion in shake flasks Flasks 125mL 20 143.4 Sigma   
 CD-CHO 600mL 25.8 Invitrogen   
 Glutamine 200mM 24mL 0.45 Lonza   
 MSX-3 hydrate 75uM 358.65 Sigma   
       
Screening for colonies and ELISA ELISA plates 5 472.5  RD Biotech 16 160 
       
Dilution in 96 well plates 96 well plates 20 2976 Cole-Parmer 8 80 
 CD-CHO 192mL 8.6 Invitrogen   
 Glutamine 200mM 8mL 0.15 Lonza   
 MSX-3 hydrate 75uM 191.3 Sigma   
       
Screening for colonies and ELISA ELISA plates 12 1134  RD Biotech 16 160 
       
Expansion in 24 well plates 24 well plates 20 3288 Cole-Parmer 8 80 
 CD-CHO 2400mL 106 Invitrogen   
 Glutamine 200mM 96mL 1.92 Lonza   
 MSX-3 hydrate 75uM 2293.6 Sigma   
       
Screening HPLC Assay 320 1280 In house 16 160 
6  60 
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Expansion in 6 well plates 6 well plates 16 4195.2 Cole-Parmer 8 80 
 CD-CHO 480mL 21.2 Invitrogen   
 Glutamine 200mM 16mL 0.32 Lonza   
 MSX-3 hydrate 75uM 459.1 Sigma   
       
Screening HPLC Assay 80 320  6 60 
       
Expansion shake flasks Flask 250mL 20 654 Sigma 6 60 
 CD-CHO 5000mL 213.5 Invitrogen   
 Glutamine 200mM 180mL 3.6 Lonza   
       
Sum   29255.7  154 1540 
Total      30736.7 
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Case study on a Trebuchet
In RSM Simplified, the authors presented the resolution of a problem involving
a trebuchet (121). The aim of the study being to analyse the influence of the arm
length, the counterweight, and the missile weight on the distance at which the missile
could be thrown. To do so, they built up a model scale trebuchet firing racquetballs.
Then performed experimentation following a Box Behnken type of RSM design. The
results of their experimentation is presented in Table (Table C.1)
To analyse the data the authors goes through a whole procedure involving a
lack of fit tests, the analysis of various statistics and finally an ANOVA. Despite
identifying that one factor in their model is not significant, they decided to carry
on.
To assess if the algorithm developed in this thesis could be used to automati-
cally conduct the study, the experimental data was fed into the algorithm. Results
show that the algorithm successfully selected a quadratic model without the factor
identified by the authors as being insignificant. 2D plot generated by the algorithm
was very similar to the one generated by the authors. Using this plot is was possible
to identify a combination of arm length, counterweight and missile weight to reach
any desired thrown distance.
In summary, in this particular case, the algorithm allowed the user to achieve
similar results than the authors, without, however, any manual analysis to perform,
as the algorithm is automated.
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Table C.1: Results table from trebuchet experiment
Arm length Counterweight Missile weight Thrown distance
(inches) (pounds) (ounce) (yards)
4 10 2.5 33
8 10 2.5 85
4 20 2.5 86
8 20 2.5 113
4 15 2 75
8 15 2 104
4 15 3 40
8 15 3 89
6 10 2 83
6 20 2 108
6 10 3 49
6 20 3 101
6 15 2.5 88
6 15 2.5 91
6 15 2.5 91
6 15 2.5 87
6 15 2.5 91
Figure C.1: Comparison of the 2D results plot generated by the authors of RSM Simplified
book, and the algorithm developed in this thesis
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We describe a design of experiments (DoE) response surface modeling strategy to opti-
mize the concentration of basal variables underpinning polyethylenimine (PEI) mediated
transfection of different CHO-K1 derived parental cell populations in a chemically deﬁned
medium, speciﬁcally the relative concentration of linear 25 kD PEI, host CHO cells and
plasmid DNA. Using recombinant secreted alkaline phosphatase (SEAP) reporter activity as
the modeled response, a discrete simple maximum was predicted for each CHO host cell
population. Differences between the modeled optima derived from host cell speciﬁc differen-
ces in PEI cytotoxicity, such that the PEI:cell interaction effectively limited PEI-DNA poly-
plex load at a relatively constant PEI:DNA ratio. However, across the three CHO host cell
populations, SEAP reporter production was not proportional to plasmid DNA input at the
host cell speciﬁc predicted basal variable optima. A 10-fold variation in SEAP reporter out-
put per mass of plasmid DNA delivered was observed. To determine the cellular basis of
this difference in transient productivity, host CHO cells were transfected with ﬂuorescently
labeled polyplexes followed by ﬂow cytometric analysis. Each CHO host cell population
exhibited a distinct functional phenotype, varying in the extent of PEI-DNA polyplex binding
to the cell surface and degree of polyplex internalization. SEAP production was directly pro-
portional to the level of polyplex internalization and heparan sulfate proteoglycan level.
Taken together, these data show that choice of host CHO cell line is a critical parameter,
which should rationally precede cell line speciﬁc transient production platform design using
DoE methodology. VC 2011 American Institute of Chemical Engineers Biotechnol. Prog., 28:
179–187, 2012
Keywords: Chinese hamster ovary cells, design of experiments, transient transfection,
polyethylenimine
Introduction
Chinese hamster ovary (CHO) cells remain the most com-
monly used mammalian cell type for biopharmaceutical
manufacture.1,2 In all cases, to generate a CHO cell based
production system capable of generating sufﬁcient product
for preliminary clinical trials and toxicology testing it has
been necessary to use a cell line development process based
on stable transfection of a parental host CHO cell popula-
tion, followed by intensive cell clone isolation and screening
operations.3 This process identiﬁes cell clones that not only
have transcriptionally active recombinant genes, but a variety
of other functional capabilities that permit high-level manu-
facture of the protein product.4–6 The CHO cell clone factory
background itself has to be ‘‘permissive’’ to the required
function (e.g., Condon et al.7), where substantial variation in
functional capability between individual CHO cell lines is
frequently observed,8 deriving from acquired genetic hetero-
geneity within the host cell population.6 Despite this, cell
line functional variability has not been harnessed in the
development of alternative transient production processes,
which have the potential advantage of a relatively rapid con-
version of recombinant gene into protein product. In combi-
nation with new disposable processing technology for
mammalian cell based production processes,9 there is a real
opportunity for transient production systems to routinely pro-
vide early stage product for the clinic and toxicology labora-
tory rapidly and inexpensively. Indeed, for early process
development applications, the use of a transient expression
Correspondence concerning this article should be addressed to D. C.
James at d.c.james@shefﬁeld.ac.uk..
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system to predict reliably key manufacturability attributes
(e.g., yield, post-translational modiﬁcations, aggregation, etc)
is highly desirable in itself. In fact, the key difference
between transient production systems and stable cell line
development procedures is the general lack of cell clone
functional screening/isolation technology (that underpins sta-
ble cell line generation) applied to the former. A typical
transient production process uses functionally heterogeneous
parental cell populations, whose intrinsic genetic/functional
heterogeneity has not been exploited at all to derive a host
cell line intrinsically suited to the task. Moreover, there are
very few examples of gene expression technology speciﬁ-
cally designed for transient production (e.g., Liao and Sun-
strom, 200610).
Therefore, scalable transient production processes based
on CHO cells are generally low yielding, with maximum
reported titers of recombinant proteins in the range 80–100
mg L1,11,12 and typically complex with respect to optimiza-
tion of the numerous factors that have been shown to inﬂu-
ence transient process yield (Figure 1). These include
discrete, process-speciﬁc choices (e.g., base medium type
and gene delivery vehicle) and a range of interacting process
design variables or effectors that can potentially inﬂuence
the quantity and quality of the recombinant product.12–14
Development of a productive transient process therefore
represents a signiﬁcant parameter optimization problem,
where the use of design tools to reduce the complexity and
time taken to generate a production process would be of real
value. To achieve this design of experiments (DoE) method-
ologies represent an attractive solution, although few reports
describe the application of DoE methods for mammalian
cell based bioprocess design. DoE methods are preferable
to relatively slow and cumbersome one-factor-at-a-time
(OFAT) approaches as they avoid experimental bias and
quasi-optima with a reduced number of experiments re-
quired.15 A key advantage of DoE methods is their ability to
identify reliably dependency or interactions between varia-
bles affecting the process outputs, which is not possible via
OFAT optimization.
In this study, we provide a DoE based strategy that uses
response surface methodology to rapidly optimize the basal
continuous variables underpinning polyethylenimine (PEI)-
mediated transfection of different CHO host cell lines in a
chemically deﬁned medium. Based on this, we demonstrate
for the ﬁrst time that there is substantial inherent variability
between CHO cell lines with respect to their ability to be
transfected by this method, and that this variation is primar-
ily a consequence of cell line speciﬁc differences in binding
and internalization of PEI polyplexes.
Materials and Methods
Cell culture
CHO-K1 derived suspension adapted CHO host cell lines,
CHO-S (Invitrogen, Paisley, UK), CHO-L (CHOK1SVTM,
Lonza Biologics, Slough, UK) and CHO-M (MedImmune,
Cambridge, UK) were routinely cultured in vented Ehrlen-
meyer shake ﬂasks (Corning, Surrey, UK) in CD-CHO
medium (Invitrogen, Paisley, UK) supplemented with L-glu-
tamine (Sigma-Aldrich, St. Louis; 6 mM CHO-L and CHO-
M, 8 mM CHO-S) at 37C in 5% (v/v) CO2 with orbital
shaking at 140 rpm. Cells were resuspended in fresh medium
every 3–4 days at a concentration of 2  105 cells mL1.
Cell concentration and viability were routinely measured by
an automated Trypan Blue exclusion assay using a Vi-Cell
counter (Beckman-Coulter, High Wycombe, UK) according
to manufacturer’s instructions.
Reporter plasmid preparation
The plasmid used in this study was based on pSEAP2-
Control (Clontech, Mountain View, CA) backbone. The
SV40 enhancer of pSEAP2-Control was deleted by partial
digestion with HpaI and BamHI. After blunting the ends
with Klenow enzyme (Roche, Penzberg, Germany), the DNA
was self-ligated. CMV promoter was ampliﬁed by PCR from
pcDNA3.1/V5-His-TOPO/lacZ (Invitrogen) with primers:
CMV-a, 50-GATCAGATCTCGATGTACGGGCCAGATATA
CG-30 and CMV-bN, 50-GATCGAATTCGATCTGACGGTT
CACTAAACCAGCTCTGCTTATATAGACCTCCCAC-30 and
cloned into the BglII and EcoRI sites of pSEAP2-Control. The
sequence of all constructs was veriﬁed. Plasmid DNA was
puriﬁed using a plasmid midi puriﬁcation kit (Qiagen, Craw-
ley, UK), resuspended in a Tris-HCl buffer, pH 8.5 and stored
at 20C.
Figure 1. Interacting variables underpinning mammalian host cell based transient production process design.
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Transfection of CHO cells with PEI
Cells were cultured in shake ﬂask to mid exponential phase
prior to transfection. One hour prior to transfection, cells were
diluted to the desired concentrations in 50 mL Cultiﬂasks (Sar-
torius AG, Goettingen, Germany) in CD-CHO supplemented
with 8 mM (CHO S) or 6 mM (CHO M, CHO L) of glutamine
in a total volume of 5 mL. In separate eppendorf tubes, the
desired quantities of 25 kD linear PEI (Polysciences, Warring-
ton) and DNA were diluted with an equal volume of NaCl 300
mM. PEI and DNA were then mixed together and allow to
complex for 1 min in a total volume of 333 lL made up with
150 mM NaCl. The PEI/DNA solution was then added to the
cells. Cultiﬂasks were immediately orbitally shaken by hand
and directly placed in an incubator at 37C in 5% CO2 with or-
bital shaking at 170 rpm and an orbital throw of 50 mm. Cul-
tures were harvested after ﬁve days. Cell concentration and
viability were assessed. Samples were taken and stored at
20C for secreted alkaline phosphatase (SEAP) quantiﬁca-
tion using the Sensolyte pNPP Secreted Alkaline Phosphatase
colorimetric reporter gene assay kit (Cambridge Biosciences,
Cambridge, UK) according to manufacturer’s instructions.
Transfection of CHO cells by electroporation
At two days post subculturing, 1  107 cells were resus-
pended in 100 lL nucleofection solution and 2 lg of SEAP
plasmid DNA was added to the suspension prior to cuvette
electroporation in an Amaxa Nucleofector (Lonza, Slough,
UK) using the standard CHO cell protocol. Cells were subse-
quently resuspended in 40 mL medium and cultured in sus-
pension prior to analysis.
Flow cytometry
All ﬂow cytometric analyses were performed on a FACSCa-
liburTM instrument (BD Biosciences, Oxford, UK). Plasmid
DNA was labeled with ﬂuorescein using a ‘‘Label IT’’ kit
(Mirus, Madison, WI) at a ratio of 2:1 ﬂuorophore to DNA.
Prior to transfection this was mixed with unlabeled DNA at a
1:4 ratio (labeled:unlabeled) and transfections were carried
out using standard procedures as stated. Cells were washed
twice with PBS buffer prior to analysis. To measure polyplex
uptake post-transfection, cells were washed in PBS, resus-
pended in ‘‘CellscrubTM’’ complex removal buffer (Genlantis,
San Diego, CA), incubated for 10 min at RT and washed twice
in PBS prior to ﬂow cytometric analysis. For anti-heparan sul-
fate immunostaining, cells were washed in PBS, ﬁxed in 4%
(w/v) paraformaldehyde (PFA) on ice for 20 min then washed
twice with ice-cold PBS and stored at 4C at a concentration
of 1  106 mL1. Prior to immunostaining, ﬁxed cells were
washed with PBSB buffer, [PBS, 1% (w/v) BSA] and incu-
bated with anti-HS antibodies (Seikagaku 10E4 or HepSS1
murine monoclonals; AMSbio, Abingdon, UK) at a dilution of
1:100 for 30 min at 4C. Cells were washed twice in PBSB
and stained with anti-mouse IgM FITC-labeled secondary
antibody (Invitrogen) at a dilution of 1:500 for 30 min at 4C
followed by three washes in PBSB prior to analysis.
Results
Empirical identiﬁcation of the design space for RSM
optimization of PEI mediated transfection
The three basal continuous variables that underpin the pro-
ductivity of a non-viral transient production system are the
relative concentration of host cells, plasmid DNA encoding
the product and chemical gene delivery vehicle (Figure 1).
In this study, we are concerned with the transfection of CHO
cell lines with plasmid DNA condensed with the cationic
polymer PEI. The latter is known to be cytotoxic.16 There-
fore, despite the known modulation of PEI cytotoxicity by
DNA17,18 we considered that only the discrete interaction
between PEI and the host cell impacts signiﬁcantly on the
design space (upper) limit as it deﬁnes an inherently critical
response factor, host cell viability. The other possible inter-
actions, host cell/DNA and DNA/PEI do not directly inform
on design space boundaries. Accordingly, we ﬁrst measured
the impact of increased PEI concentration on the prolifera-
tion and viability of three suspension-adapted parental CHO
cell lines, CHO-S, CHO-L, and CHO-M, each maintained in
CD-CHO medium. Each CHO cell line was obtained from a
different commercial source: although all cell lines
were derived originally from CHO-K1 cells. As shown in
Figure 2, although each CHO cell line exhibited a similar
speciﬁc growth rate over a ﬁve-day culture period in control
conditions [average l ranging from 0.3 d1 (CHO-S) to
0.28 d1 (CHO-L), at an initial seeding density of 1.5  106
cells mL1 diluted from a 96 h mid-exponential cell culture
in each case], their response to added PEI was extremely
cell line speciﬁc. CHO-L was the most resistant to PEI,
maintaining the highest viable cell concentration as PEI
concentration increased. In contrast, CHO-M exhibited a pre-
cipitous decline in cell viability at PEI concentrations
[10 lg mL1. Based on these simple empirical
Figure 2. Empirical determination of CHO host cell responses
to PEI to identify a DoE design space critical limit.
Different CHO host cells (CHO-S n, CHO-L ~, and
CHO-M ^, each seeded at 1.5 3 106 cells mL21)
were exposed to varying concentrations of PEI (25
kDa, linear).
Viable cell concentration (A) and percent cell viability (B)
were measured after ﬁve days culture. n ¼ 3  SD.
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observations, the lower and upper bounds of PEI concentra-
tion employed were set to arbitrary, cell line speciﬁc limits,
which corresponded to a ﬁnal cell viability of 95% (upper
bound) or 70% (lower bound) after ﬁve days growth at a
given PEI concentration (Table 1). The plasmid DNA con-
centration range was set with reference to previous published
literature.19–21 For each cell line the DNA:PEI ratios used
were the same, ranging between 1:2 and 1:7 (w/w). There-
fore, for each cell line, the maximum DNA load employed
was limited by the (cell line speciﬁc) maximum set PEI con-
centration. With respect to cell concentration range, an arbi-
trary lower bound of 0.5  106 cells mL1 was employed
uniformly, and the upper limit of initial cell concentration
was also equivalent in each case, set to 2.5  106 cells
mL1, the latter representing a concentration of mid-expo-
nential cells from a diluted donor 96 h culture compatible
with the maintenance of high cell viability over a subsequent
ﬁve day transient production period under control conditions.
Sequential response surface models identify an optimal,
cell line speciﬁc combination of basal variables for
transient production
Initially, face-centered Box-Wilson (central composite)
designs were constructed using the selected basal variable
(PEI, DNA, and cells) concentration ranges as design space
boundaries using Design Expert 7 software. A Box-Wilson
design was employed initially because this method can theo-
retically generate accurate predictions of response variable
output across a broad, untested design space as it uses basal
variable combinations at the extremities of this space.22 For
each cell line SEAP reporter output after a ﬁve day produc-
tion period was measured at 15 different coordinates within
the cell line speciﬁc design space (three levels per variable),
with the mid-point assay replicated six times to determine
pure error. Calculated from SEAP reporter output, a response
surface model was used to predict an optimal combination of
basal variables for maximum SEAP reporter production for
each cell line (Figure 3A). Each model mathematically
described the relationship between SEAP response and basal
variables, a second order function of individual, basal vari-
able interaction and quadratic terms. Coefﬁcients of determi-
nation (R2 value) from the Box-Wilson design are 0.88,
0.93, and 0.76 for CHO S, L, and M, respectively, indicating
a satisfactory model ﬁt of experimental data. For example,
the model derived from the CHO-L cell line Box-Wilson
design analysis shown in Figure 3A is as follows:
Relative SEAP ¼ 194.32 þ 23.21  [PEI]  4.00 
[DNA] þ 57.31  [Cells] þ 0.54  [PEI][DNA] þ 0.69 
[PEI][Cells] þ 0.47[DNA][Cells]  0.70  [PEI]2  0.35 
[DNA]2  18.3  [Cells]2
For each cell line, a simple maximum response prediction
(SEAP volumetric titer) was identiﬁed within the design
space, associated with a cell line speciﬁc optimum combina-
tion of basal variable concentrations (Table 2). For each cal-
culated basal variable optimum, a predicted 95% conﬁdence
interval (deﬁned as the conﬁdence that another model of the
same order will predict an optimum within the given range)
was calculated using an in-house program written within
Mathematica software (Wolfram Research, Long Hanbor-
ough, U.K). These are shown in Table 2.
To validate the Box-Wilson modeled predictions of basal
variable optima for each cell line and to produce a higher re-
solution prediction of these optima, we performed a Box-
Behnken design using the Box-Wilson predicted optima as
the mid-range level for each basal variable. The Box-
Behnken design was used in sequence after the Box-Wilson
design as the former method enables a prediction of response
variable output using fewer combinations of basal variables
than the Box-Wilson design within a design space that is not
required to be tested at its extremities. For this analysis, the
high to low range of basal variable concentrations employed
was divided by two relative to the Box-Wilson design. For
each cell line, SEAP reporter output after a ﬁve day produc-
tion period was measured at 13 different coordinates within
the cell line speciﬁc design space (three levels per variable),
with the mid-point assay replicated ﬁve times to determine
pure error. As described above for the Box-Wilson analysis,
a response surface model was used to predict an optimal
combination of basal variables for maximum SEAP reporter
production for each cell line. An example of this analysis for
the CHO-L host cell line is shown in Figure 3B, and the
Box-Behnken predicted optimal basal variable concentrations
for each host cell line are listed in Table 2. Coefﬁcients of
determination (R2 values) from the Box-Behnken models
were 0.98, 0.98, and 0.97 for CHO S, L, and M, respec-
tively, indicating an excellent model ﬁt of experimental data.
Together, these data show clearly that the basal variable
optima predicted by both methods are highly comparable, all
Box-Behnken predicted optima lie within the 95% conﬁ-
dence intervals associated with the Box-Wilson predicted
optima. The 95% conﬁdence intervals associated with the
Box-Behnken predicted optima are consistently lower than
those associated with the Box-Wilson optima, likely deriving
from the more restricted design space.
The predicted optimal basal variable concentrations were
cell line speciﬁc. Most obviously, there was an apparent rela-
tionship between cell line resistance to PEI (Figure 2) and
optimum predicted PEI concentration in the rank order
CHO-L[ CHO-S[ CHO-M. As the DNA:PEI (w:w) ratio
at each optimum was relatively constant, ranging from 1:1.8
(CHO-S cells) to 1:2.4 (CHO-M cells), cell cultures more re-
sistant to PEI could be effectively ‘‘loaded’’ with more plas-
mid DNA, varying from 3.3 pg DNA cell1 (CHO-M) to 5.2
pg DNA cell1 (CHO-L).
These data suggest that at the predicted optima, whilst the
PEI:DNA interaction is unlikely to be cell line speciﬁc, the
PEI:cell interaction is cell line speciﬁc, and it is this that
limits DNA input into the culture. Justifying the DoE
approach taken here, at least one signiﬁcant (P \ 0.05,
Fisher/Snedecor test) interaction between discrete basal vari-
ables was identiﬁed across the Box-Behnken design space
for each cell line. However, the interactions identiﬁed as sig-
niﬁcant (either PEI-cell or cell-DNA or PEI-DNA) were cell
line speciﬁc. Therefore, by comparison to the DoE method,
necessarily cell line speciﬁc transient process optimization
by the OFAT approach (e.g., Boussif et al., 199523; Haldan-
kar et al. 200624) where optimal parameters are identiﬁed
sequentially (with the inherently larger number of
Table 1. Summary of Host CHO Cell Line Speciﬁc DoE Design
Space Limits for Initial Box-Wilson Experimental Design
Process variable
Host cell
CHO S CHO L CHO M
[PEI] (lg mL1) 7.520 1226 8.513
[DNA] (lg mL1) 110 1.713 16.5
[Cells] (106 cells mL1) 0.52.5 0.52.5 0.52.5
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experiments required) represents an inefﬁcient and statisti-
cally limited means to identify basal variable optima.
Comparison of transient process outputs at cell
line speciﬁc basal variable optima
The three CHO host cells clearly differed with respect to
the overall level of recombinant protein produced during
small-scale DoE optimization. To comparatively evaluate
their relative performance at each discrete basal variable op-
timum, SEAP production and host cell growth were meas-
ured after a comparable ﬁve-day transient production period.
These data are shown in Figure 4. CHO-S cells secreted
approximately eight-fold more SEAP reporter than either
CHO-L or CHO-M cells. With respect to the relative efﬁciency
of product formation per mass of DNA substrate, CHO host
cells differed substantially, where the relative ratio of SEAP
produced per mass of DNA substrate was CHO-S (1):CHO-L
(0.1):CHO-M (0.16). These data show clearly that despite
rational optimization of the transient process, the intrinsic
‘‘transfectability’’ of each host cell varied substantially. How-
ever, these data also showed that the CHO host cell lines varied
with respect to their relative rates of cell proliferation and death
during the production process. This critical process design pa-
rameter cannot be easily inferred from an empirical determina-
tion of cell response to PEI alone (Figure 2) as DNA interaction
with PEI may modulate its cytotoxicity. Cell death can be con-
sidered a critical output parameter as (i) release of hydrolytic
enzymes from dead cells can potentially affect both product
quality and quantity and (ii) potential extension of the culture
process to increase product titer requires viable cells. Although
exhibiting a higher productivity, the CHO-S based production
process negatively affected host cell viability greater than the
other host cells, with 2.5-fold more dead cells than either the
CHO-L or CHO-M cultures. The speciﬁc rate of CHO-S cell
death (0.17 d1) during transient production was two-fold
higher than that of the other host cells (þ/0.02 d1), although
the observed host cell viabilities generally concur with the DoE
predicted cell viabilities (Table 2). Importantly, we note that, it
would be possible to use both SEAP reporter output and cell vi-
ability as selection criteria for optimal process design using
‘‘Desirability’’ function within the DoE software. For example,
for a CHO-S process, with a predicted cell viability, maintained
in excess of 90%, predicted SEAP reporter output would be
80% of that observed at SEAP maximizing conditions.
Variation in cell surface polyplex binding and
internalization underpins variation in CHO host cell
transient process performance
As recent studies have shown that variation in CHO cell
surface molecular composition can affect polyplex mediated
transfection efﬁciency,25–27 we tested the hypothesis that
Figure 3. Optimization of continuous basal variables for transient transfection of CHO cells by sequential DoE response surface
modeling.
Box-Wilson (A) followed by higher resolution Box-Behnken (B) response surface designs were used to predict the optimal concentration of continu-
ous basal variables (PEI, cells, and DNA) for each CHO host cell line. The schematic boxes illustrate experimental design coordinates in each case,
and an example of a modeled response surface (Cells-PEI interaction at the predicted optimal DNA concentration) for CHO-L cells is shown. The
simple maximum predicted response for SEAP production is indicated by a star.
Table 2. Predicted CHO Host Cell Speciﬁc Basal Variable Optima
for Maximum SEAP Production Identiﬁed by Sequential DoE
Response Surface Modeling
Cell line BW RSM BB RSM
CHO S [Cells] (106 cells mL1) 2.4 (0.3) 2.5 (*)
[PEI] (lg mL1) 15 (1.3) 16.3 (0.9)
[DNA] (lg mL1) 8.3 (2.3) 9.0 (0.3)
Cell viability (%) 71.4 (3.6) 69.3 (6.4)
CHO L [Cells] (106 cells mL1) 2.1 (0.1) 2.1 (0.0)
[PEI] (lg mL1) 22.4 (0.5) 22.6 (0.1)
[DNA] (lg mL1) 11.6 (1.2) 11.2 (0.1)
Cell viability (%) 97.5 (2.4) 96.9 (þ0.2)
CHO M [Cells] (106 cells mL1) 1.7 (0.9) 1.6 (0.0)
[PEI] (lg mL1) 11.4 (1.7) 13.0 (1.0)
[DNA] (lg mL1) 4.6 (2.6) 5.4 (0.9)
Cell viability (%) 91.9 (1.1) 94.3 (0.4)
In each case, the predicted cell viability after a ﬁve day production
period is shown.
2.5  106 cells mL1 represents a practical optimum and not a
prediction.
BW, Box-Wilson design; BB, Box-Behnken design.
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CHO host cells differed in their ability to bind and internal-
ize polyplexes. For this experiment, all CHO host cells were
transfected with ﬂuorescently labeled plasmid DNA using
identical conditions (i.e., at the same concentration of basal
variables) to permit a direct comparison of polyplex particle
binding and internalization by ﬂow cytometry. The CHO-M
basal variable optima (1.6  106 cells mL1, 13 lg PEI
mL1, and 5.4 lg mL1 DNA) were used for each CHO cell
host as this modeled optimum (i) employed the least cyto-
toxic combination of basal variables at the common
PEI:DNA (w/w) optimum (approx. 2:1) and (ii) was within
the modeled design space for each host cell permitting pre-
diction of SEAP output in each case. We distinguished
between ﬂuorescent polyplexes on the cell surface and those
internalized using a proprietary reagent, CellScrubTM
designed to remove extracellular DNA complexes bound to
the cell surface by electrostatic interactions.28,29 As exempli-
ﬁed in Figure 5A, association of ﬂuorescent polyplexes with
cells was quantiﬁed by ﬂow cytometry, and treatment of
cells with CellScrub effectively removed cell surface poly-
plexes enabling quantiﬁcation of internalized particles. Pre-
liminary experiments with CHO-S cells analyzed up to 4
min post-transfection showed that[92% of total cell associ-
ated polyplex ﬂuorescence was removed using the CellScrub
procedure (data not shown). Comparative analysis of all
CHO host cells after 30 min and 4 h transfection showed
that each population differed markedly in the relative extent
of polyplex binding and internalization (Figures 5B,C).
These data show that (i) for each host cell polyplex binding
to the cell surface was saturated by 30 min; CHO-M cells
bound least polyplex at the cell surface, 75% less than CHO-
S and 82% less than CHO-L, (ii) CHO-S cells exhibited the
highest rate of polyplex internalization; [4-fold more poly-
plexes were internalized by CHO-S cells than either CHO-L
or CHO-M cells, (iii) internalization of polyplexes was not
proportional to cell surface polyplex binding; for CHO-L
cells only 8.2% of total cell associated ﬂuorescence was in-
tracellular after 4 h transfection, whereas CHO-S and CHO-
M cells internalized cell surface polyplexes more rapidly,
with 41 and 34% of total cell ﬂuorescence measured as intra-
cellular after 4 h. We note that the observed host cell spe-
ciﬁc differences in polyplex binding were not related to cell
surface area/volume ratio as each host cell population typi-
cally exhibited a similar size distribution prior to transfection
(16–18 lm diameter).
At the basal variable concentrations employed for this
analysis the predicted relative SEAP production for each cell
line from DoE response, surface modeling (Figure 5D) was
clearly proportionate to the degree of polyplex internaliza-
tion by each host cell population (Figure 5C). These data
implied that molecular interactions between polyplexes and
the host CHO cell surface and the associated endocytotic
pathway(s) used were host cell line speciﬁc. As previous
studies have shown that (i) CHO cell surface heparan sulfate
proteoglycan (HSPG) level is related to polyplex internaliza-
tion25 and (ii) cell surface polyplexes colocalize with anti-
HSPG antibodies on BS-C-1 cells,26 we tested the hypothesis
that differences in polyplex binding and/or internalization
between host CHO cells is related to their cell surface HSPG
Figure 4. Host CHO cell line speciﬁc differences in PEI-medi-
ated transient protein production.
Each CHO cell line was transfected at the predicted basal vari-
able optimum identiﬁed by response surface modeling (Table
2). SEAP reporter production (gray bars), viable cell concentra-
tion (white bars), and total cell concentration (black bars) were
measured after ﬁve days culture. n ¼ 3  SD.
Figure 5. Host CHO cells vary in PEI-DNA polyplex binding and
internalization.
Plasmid DNA was ﬂuorescently labeled with ﬂuorescein, and
host CHO cells (1.6  106 cells mL1) were transfected with
PEI-DNA polyplexes formed at a PEI:DNA (w/w) ratio of 2.4:1
with ﬁnal concentrations in culture of 13 lg mL1 PEI and 5.4
lg mL1 DNA. For each CHO host cell, cell surface and inter-
nalized PEI-DNA polyplex ﬂuorescence was measured by ﬂow
cytometry (A; CHO-L cells transfected for 30 min are shown as
an example) either before (light gray line; total polyplex ﬂuores-
cence) or after removal of extracellular polyplexes using Cell-
ScrubTM reagent (dark gray line; internalized polyplex
ﬂuorescence only). Different CHO host cells were analyzed by
ﬂow cytometry either 30 min (B) or 4 h (C) after transfection,
white bars represent total cell associated polyplex, black bars
represent internalized polyplexes. n ¼ 2  SD, geometric means
are shown in each case. For each CHO host cell, the SEAP output
predicted by response surface modeling at the basal variable con-
centrations employed is shown in Figure 5D (see Figure 3).
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content. As shown in Figure 6, CHO-S cells were more
heavily stained (approx. 4–5 fold) with anti-HSPG monoclo-
nal antibodies (10E4 and HepSS1) than either CHO-L or
CHO-M cells. These data imply that CHO cell surface
HSPG content is correlated with polyplex internalization rate
(Figure 5C) rather than polyplex binding (Figure 5B), as pre-
viously described by Wong et al.,25 and that this parameter
is genetically variable between CHO cell lines.
Lastly, to conﬁrm that the observed differences in SEAP
production via PEI mediated transfection were a conse-
quence of host cell speciﬁc variation in polyplex binding and
internalization, each host cell population was also transfected
by electroporation, a gene delivery mechanism that does not
use the endocytotic pathway. Each host cell population was
electroporated using identical conditions and SEAP produc-
tion was measured after ﬁve days. These data are shown in
Figure 7. Whilst host cell speciﬁc SEAP production was
clearly less variable than for PEI mediated transfection,
CHO-L cells demonstrated higher levels of SEAP production
than either CHO-S or CHO-M cells. Taken together, these
data indicate that host cell speciﬁc variation in PEI-mediated
transfection is primarily a function of two discrete properties
of the host cell surface, polyplex binding capacity and the
rate of endocytotic internalization of bound particles.
Discussion
Our data demonstrate that host CHO cell lines differ sub-
stantially in their relative ability to be transfected via endo-
cytosis. This is functional characteristic governs the intrinsic
suitability of a given CHO cell as a vehicle for scalable tran-
sient production of recombinant proteins. This cell line spe-
ciﬁc variation impacts transient production process design in
two fundamental and interdependent ways, (i) basic optimi-
zation of process variables has to be cell line speciﬁc and (ii)
screening or engineering of host cell populations for improved
transient production should primarily target cell surface bind-
ing and/or internalization of DNA nanoparticles. With respect
to the former, we have shown clearly that DoE response-sur-
face methodology (RSM) permits the rapid identiﬁcation of an
optimal combination of process variables. Although recombi-
nant protein productivity is highlighted in the current study,
host cell concentration and viability can also be considered
important key process outputs. Using RSM modeling permits
a ‘‘sweet spot’’ combination of responses to be achieved by
manipulation of the input variables (i.e., DNA, PEI, and cell
concentrations) using desirability functions.30 For example, an
accumulation of nonviable cells over the production process
may adversely affect product titer or quality via the release of
intracellular proteases or glycosidases.31
The main difﬁculty in response surface methodology lies in
the choice of initial design space for the subsequent response
surface optimization. Generally, using factorial designs and
method of steepest ascent, the experimenter gradually moves
towards the vicinity of the operating conditions where there is
an optimal response and where RSM optimization should be
conducted.32 This sequential approach for design space identi-
ﬁcation can be time and labor consuming. In this study, we
show that identifying the initial RSM design using empirical
cell speciﬁc cytotoxicity to free PEI in the culture medium is a
rapid and effective method.
Each CHO host cell population exhibited a distinct
functional phenotype with respect to cell surface polyplex
binding and internalization; either high binding/high internal-
ization (CHO-S), high binding/low internalization (CHO-L),
or low binding/high internalization (CHO-M). From these
data, we infer that both the molecular composition of the
cell surface and associated mechanisms of endocytosis are
host cell population speciﬁc, yielding the observed differen-
ces in ‘‘permissivity’’ to polyplex mediated transfection. In
general, this substantial phenotypic heterogeneity implies
that these aspects of CHO cell function (binding to, and
endocytosis of extracellular polymers), which may originally
have been relevant to the function of the somatic CHO cell
are now subject to neutral genetic drift in an unstable genetic
background, irrelevant to the objective function (prolifera-
tion) of CHO cells during serial subculture in a synthetic
environment. For cancer cell lines, it has been reported that
the genome can evolve during subculture to an extent that
caution should be exercised in using these cultures as models
of human cancer.33
Figure 6. Host CHO cell heparan sulfate proteoglycan level co-
varies with PEI-DNA polyplex internalization.
Host CHO cells (1  106) were ﬁxed in 4% (w/v) paraformal-
dehyde then labeled with murine anti-HSPG monoclonal anti-
bodies followed by FITC-labeled goat anti-mouse secondary
antibodies prior to analysis by ﬂow cytometry. (A) Flow cyto-
metric analysis of cell surface HSPG level. (B) Median CHO
cell surface HSPG content. In each case, values were adjusted
for the ﬂuorescence of secondary antibody stained control cells.
n ¼ 3  SD.
Figure 7. Host CHO cells exhibit, limited variation in transient
production after gene delivery by electroporation.
CHO cells (1  107) were transfected with 2 lg of plasmid
DNA then diluted to 2.5  105 cell mL1 and cultured for ﬁve
days prior to measurement of SEAP production. n ¼ 3  SD.
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More speciﬁcally, we infer that host cell speciﬁc variation in
polyplex binding may derive from differences in the relative
abundance of cell surface proteins bearing polyanionic glycos-
aminoglycans (GAG) of varying molecular composition impli-
cated in cell surface polycation binding and uptake.34 For
example, HSPG deﬁcient CHO cells have been shown to ex-
hibit reduced transfection efﬁciency mediated by polyplexes
and lipoplexes26 and more recently, FUT8 (fucosyltransferase
8) knockout CHO cells with a lower HSPG content than control
cells exhibit a reduced uptake of PEI polyplexes.25 In accord-
ance with this, ﬂow cytometric analysis of CHO-S cells with
anti-HSPG monoclonal antibodies showed that this host cell
line had a 4 to 5-fold higher cell surface HSPG content than ei-
ther CHO-L or CHO-M cells, implying that cell surface HSPG
level may be used to screen CHO cell populations for ‘‘trans-
fectable’’ genetic variants. We also note in relation to this that
variation in the cell surface content of different HSPGs may
affect polyplex transfection as described by Paris et al.35
With respect to internalization of polyplexes, mammalian
cells may use a variety of endocytotic pathways for internal-
ization of molecular cargo.36,37 Currently, there is no general
consensus on the mechanistic link between nonspeciﬁc cell
surface binding of polyplexes (or lipoplexes) by GAG mole-
cules and the discrete mechanisms of endocytosis. A situa-
tion obscured by mammalian cell line speciﬁc observations
made in a variety of studies,38–40 which may relate to varia-
tions in the relative abundance of discrete HSPGs.35 Where
CHO cells have been used speciﬁcally, the available data
suggests that polyplexes are likely to be internalized by non-
clathrin, noncaveolae dependent26 ﬂuid-phase mechanisms41
such as macropinocytosis.
In conclusion, this study shows that, as for stable produc-
tion of recombinant proteins by CHO cells, discrete CHO
host cell populations may be inherently more ﬁt-for-purpose
than others, where choice of CHO host cell is a key factor
underpinning productivity.4–6 We suggest that the optimiza-
tion of a transient production process should rationally begin
with cell clone screening operations to isolate transfection-
competent host cells, followed by rapid DoE-based design of
a clone-speciﬁc optimal production process.
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